Microbial Compositions and Their Uses

A microbial composition targeting specific bacteria with 16S nucleic acid sequences is used to treat and prevent equine colic, effectively reducing symptoms and episode frequency.

BR122026025134A2Pending Publication Date: 2026-11-10NATIVE MICROBIALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR122026025134
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-05-06
Filing Date
2020-05-06
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing treatments for equine colic, particularly those induced by microbial factors, are inadequate in addressing early-stage symptoms and preventing progression to more severe forms of the condition.

Method used

A microbial composition comprising specific bacteria with 16S nucleic acid sequences similar to SEQ ID NOs: 1-574, formulated with carriers suitable for equine administration, is administered to horses to treat and prevent colic.

Benefits of technology

The microbial composition effectively reduces symptoms of colic and decreases the frequency of colic episodes in horses, providing a targeted and preventive approach to equine health.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

1 / 159 Microbial Compositions and Their Uses Separated from BR112021022253-7, filed on 06 / 05 / 2020. Cross-reference to related orders

[001] This application claims priority over U.S. Provisional Application 62 / 843,689, filed May 6, 2019, the contents of which are incorporated herein by reference in their entirety. Statement Regarding Sequence Listing

[002] The Sequence Listing associated with this application is provided in text format rather than a paper copy and is incorporated herein by reference in the descriptive report. The name of the text file containing the sequence listing is ASBI_013_02WO_ST25.txt. The text file is 224 kb, was created on May 6, 2020, and is being submitted electronically via EFS-Web. Field of Invention

[003] This disclosure relates to isolated and biologically pure microorganisms that have applications, inter alia, in the treatment of colic in horses. The disclosed microorganisms can be used in their isolated and biologically pure states, as well as formulated in compositions. Fundamentals

[004] The equine industry is a vital economic component of our economy, producing horses for work, show, entertainment, racing, rodeo, and companionship. There are over 70 different types of equine colic. Many of these are attributed to microbes. Others are likely, but not confirmed, to be microbial, and some have no connection to microbes. Some early-stage forms of microbial colic are the precipice for many other forms of colic. This is caused by a healthy horse or other equine being induced through internal or external pressures into a colic-like state. This temporary colic may naturally correct back to a healthy state or progress to many other types of symptomatic colic. Colic induction can often occur through emotional, physical, and / or immunomodulatory stress, as well as inadequate diet. Petition 870260102095, dated 02 / 10 / 2026, page 10 / 641 2 / 159 Summary

[005] In some embodiments, the present disclosure provides a microbial composition comprising: one or more bacteria with a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from SEQ ID NOs: 1-574; and a carrier suitable for equine administration.

[006] In some embodiments, the microbial composition comprises one or more bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475. In some embodiments, the microbial composition comprises one or more bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475.In some embodiments, the microbial composition comprises one or more bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO: 476. In some embodiments, the microbial composition comprises one or more bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO: 476.

[007] In some embodiments, the microbial composition comprises two, three, four, five, or more bacteria with a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from SEQ ID NOs: 1-574. In some embodiments, the microbial composition comprises two, three, four, or five bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475. In some embodiments, the microbial composition comprises two, three, four, or five bacteria with a Petition 870260102095, dated 02 / 10 / 2026, p. 11 / 641 3 / 159 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475. In some embodiments, the microbial composition comprises two, three, four, or five bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO: 476. In some embodiments, the microbial composition comprises two, three, four, or five bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group that consists of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433 and / or SEQ ID NO: 476.

[008] In some embodiments, the present disclosure provides a microbial composition comprising: one or more bacteria selected from Clostridium spp.; Streptococcus spp.; Escherichia spp.; and Atlantibacter spp.; and a carrier suitable for equine administration.

[009] In some embodiments, the present disclosure provides a microbial composition comprising: one or more bacteria selected from a Clostridium butyricum bacterium; a Streptococcus equinis bacterium; an Escherichia coli bacterium; a Clostridium maximum bacterium; and an Atlantibacter hermannii bacterium; and a carrier suitable for equine administration.

[0010] In some embodiments, the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID NOs: 5-13; the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID NOs: 143-150; the bacterium Escherichia coli comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID NOs: 321-328; the bacterium Clostridium maximum comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID NOs: 430-437; and / or the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID Nos: 480-486. Petition 870260102095, dated 02 / 10 / 2026, p. 12 / 641 4 / 159

[0011] In some embodiments, the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 5-13; the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 143-150; the bacterium Escherichia coli comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 321-328; the bacterium Clostridium maximum comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 430-437; and / or the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 480-486.

[0012] In some embodiments, the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 5 or SEQ ID NO: 11; the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 141 or SEQ ID NO: 142; the bacterium Escherichia coli comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 319 or SEQ ID NO: 320; the bacterium Clostridium maximum comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 426 or SEQ ID NO: 433; and / or the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 475 or SEQ ID NO: 476.

[0013] In some embodiments, the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 5 or SEQ ID NO: 11; the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 141 or SEQ ID NO: 142; the bacterium Escherichia coli comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 319 or SEQ ID NO: 320; the bacterium Clostridium maximum comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 426 or SEQ ID NO: 433; and / or the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 475 or SEQ ID NO: 476.

[0014] In some modalities, one or more bacteria have a MIC score of at least about 0.2. In some modalities, the equine is an equine Petition 870260102095, dated 02 / 10 / 2026, p. 13 / 641 5 / 159 domesticated or a wild equine. In some disciplines, the equine is selected from a horse, a zebra, a mule, and a donkey.

[0015] In some embodiments, the carrier comprises a solidifying agent and a sweetening agent. In some embodiments, the solidifying agent is selected from xanthan gum, agar, and gelatin. In some embodiments, the sweetening agent is selected from corn syrup, molasses, cane molasses, brewer's yeast, and honey.

[0016] In some embodiments, the composition is formulated as a gel, a liquid, a powder, a tablet, a capsule, a pill, a feed additive, a feed ingredient, a feed supplement, a water additive, a heat-stabilized additive, a moisture-stabilized additive, a pelleted feed additive, a pre-pelleted applied feed additive, a post-pelleted applied feed additive, or a spray additive.

[0017] In some embodiments, the composition is formulated for administration by injection, direct application to the target organ, bolus administration, oral administration (as with or as part of food), fecal enema, fecal microbiota transplantation via nasogastric intubation.

[0018] In some embodiments, the microbial composition comprises one or more bacteria in an amount effective to treat one or more symptoms of colic in a horse or to reduce the frequency of colic episodes.

[0019] In some embodiments, the present disclosure provides a method for preventing and / or treating colic in a horse, comprising administering a microbial composition described in this document to a horse in need in an amount effective to prevent and / or treat colic in horses that received the microbial composition compared to a horse to which the microbial composition was not administered.

[0020] In some disciplines, the equine is either a domesticated equine or a wild equine. In some disciplines, the equine is selected from a horse, a zebra, a mule, and a donkey.

[0021] In some modalities, the microbial composition is administered daily for at least 1, 2, 3, 4, 5, 6, 7 days or more. In some modalities, the microbial composition is administered daily for at least 1 week, for Petition 870260102095, dated 02 / 10 / 2026, page 14 / 641 6 / 159 less 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, or more. In some modalities, the microbial composition is administered daily for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months or more.

[0022] In some embodiments, the microbial composition is administered to the horse with an antibiotic, a proton pump inhibitor and / or feed. In some embodiments, the microbial composition is administered to the horse after the administration of an antibiotic, a proton pump inhibitor and / or feed.

[0023] In some embodiments, administration of the microbial composition reduces one or more selected colic symptoms of abdominal pain, stomach irritation, rolling, stomach kicking, distension of the GI organs, and decreased feeding. In some embodiments, administration of the microbial composition reduces the frequency of colic episodes in a horse administered with the microbial composition compared with a horse that did not receive the microbial composition. Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Proceedings

[0024] Some microorganisms described in this application have been deposited in the United States Department of Agriculture (USDA) Agricultural Research Service (ARS) Culture Collection (NRRL®), located at 1815 N. University St., Peoria, IL 61604, USA. Some microorganisms described in this application have been deposited in the Bigelow National Center for Marine Algae and Microbiota, located at 60 Bigelow Drive, East Boothbay, Maine 04544, USA.

[0025] Deposits were made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for Purposes of Patent Procedure. The NRRL® and Bigelow National Center for Marine Algae and Microbiota accession numbers and corresponding filing dates for the microorganisms described in this application are provided in Table 1.

[0026] The strains designated in the table below have been deposited in the laboratories of Ascus Biosciences, Inc. since at least February 2019. Table 1. Microbial deposits Petition 870260102095, dated 02 / 10 / 2026, p. 15 / 641 7 / 159 BLAST Taxonomy Strain Designation SEQ ID Depository No.° de Acesso Clostridium butyricum AscusEQ_4A 6 Bigelow 202004045 Ascus EQ_4B 7 Bigelow 202004042 AscusEQ_4C 8 Bigelow 202004042 Ascus EQ_4D 9 Bigelow 202004043 Ascus EQ_4E 10 Bigelow 202004043 Ascus EQ_4F 11 Bigelow 202004043 NRRL NRRL B- 67941 Ascus EQ_4G 12 Bigelow 202004043 Ascus EQ_4H 13 Bigelow 202004044 Terrisporobacter mayombei Ascus EQ_5A 15 Bigelow 202004042 Ascus EQ_5B 16 Bigelow 202004042 Ascus EQ_5C 17 Bigelow 202004042 Ascus EQ_5D 18 Bigelow 202004044 Mogibacterium pumilum AscusEQ_7A 20 Bigelow 202004042 Ascus EQ_7B 21 Bigelow 202004043 Ascus EQ_7C 22 Bigelow 202004043 Ascus EQ_7D 23 Bigelow 202004043 Catabacter hongkongensis Ascus EQ_9A 26 Bigelow 202004043 Clostridium nitritogenes AscusEQ_12A 30 Bigelow 202004045 AscusEQ_12B 31 Bigelow 202004044 AscusEQ_12C 32 Bigelow 202004044 AscusEQ_12D 33 Bigelow 202004044 AscusEQ_12E 34 Bigelow 202004044 AscusEQ_12F 35 Bigelow 202004044 AscusEQ_12G 36 Bigelow 202004044 Oribacterium sp.AscusEQ_14A 39 Bigelow 202004043 AscusEQ_14B 40 Bigelow 202004043 Lachnospiraceae bacterium AscusEQ_15A 42 Bigelow 202004044 AscusEQ_15B 43 Bigelow 202004044 AscusEQ_15C 44 Bigelow 202004044 AscusEQ_15D 45 Bigelow 202004044 AscusEQ_15E 46 Bigelow 202004044 Lachnospiraceae bacterium AscusEQ_16A 48 Bigelow 202004043 AscusEQ_16B 49 Bigelow 202004043. Petição 870260102095, de 02 / 10 / 2026, pág. 16 / 641 8 / 159 AscusEQ_16C 50 Bigelow 202004043 AscusEQ_16D 51 Bigelow 202004043 Odoribacter splanchnicus AscusEQ_17A 53 Bigelow 202004042 AscusEQ_17B 54 Bigelow 202004043 AscusEQ_17C 55 Bigelow 202004044 AscusEQ_17D 56 Bigelow 202004044 AscusEQ_17E 57 Bigelow 202004044 AscusEQ_17F 58 Bigelow 202004044 Terrisporobacter glycolicus AscusEQ_21A 63 Bigelow 202004045 AscusEQ_21B 64 Bigelow 202004044 AscusEQ_21C 65 Bigelow 202004044 AscusEQ_21D 66 Bigelow 202004044 AscusEQ_21E 67 Bigelow 202004044 AscusEQ_21F 68 Bigelow 202004044 AscusEQ_21G 69 Bigelow 202004044 Eubacterium barkeri AscusEQ_24A 73 Bigelow 202004043 Ascus EQ_24B 74 Bigelow 202004043 AscusEQ_24C 75 Bigelow 202004043 AscusEQ_24D 76 Bigelow 202004043 Lachnospiraceae bacterium AscusEQ_32A 78 Bigelow 202004043 Cellulosilyticum ruminicola AscusEQ_31A 81 Bigelow 202004043 AscusEQ_31B 82 Bigelow 202004043 AscusEQ_31C 83 Bigelow 202004043 AscusEQ_31D 84 Bigelow 202004043 Erysipelotrichaceae bacterium AscusEQ_28A 86 Bigelow 202004043 AscusEQ_28B 87Bigelow 202004043 AscusEQ_28C 88 Bigelow 202004043 AscusEQ_28D 89 Bigelow 202004043 AscusEQ_28E 90 Bigelow 202004043 AscusEQ_28F 91 Bigelow 202004043 AscusEQ_28G 92 Bigelow 202004043 Howardella ureilytica AscusEQ_29A 94 Bigelow 202004043 AscusEQ_29B 95 Bigelow 202004043 Butyrivibrio fibrisolvens Ascus EQ_33A 98 Bigelow 202004043 Ascus EQ_33B 99 Bigelow 202004043 Ascus EQ_33C 100 Bigelow 202004043 AscusEQ_33D 101 Bigelow 202004043 Petição 870260102095, de 02 / 10 / 2026, pág. 17 / 641 9 / 159 Ascus EQ_33E 102 Bigelow 202004043 Lachnospiraceae bacterium Ascus EQ_35A 105 Bigelow 202004043 Ascus EQ_35B 106 Bigelow 202004043 Ascus EQ_35C 107 Bigelow 202004043 Ascus EQ_35D 108 Bigelow 202004043 Ascus EQ_35E 109 Bigelow 202004043 Frisingicoccus caecimuris AscusEQ_37A 112 Bigelow 202004044 Ascus EQ_37B 113 Bigelow 202004044 Ascus EQ_37C 114 Bigelow 202004044 Ascus EQ_37D 115 Bigelow 202004044 Ascus EQ_37E 116 Bigelow 202004044 Ascus EQ_37F 117 Bigelow 202004044 Ascus EQ_37G 118 Bigelow 202004044 Ascus EQ_37H 119 Bigelow 202004044 Ruminiclostridium thermocellum Ascus EQ_38A 120 Bigelow 202004043 Spiroplasma sp.Ascus EQ_39A 122 Bigelow 202004043 Algoriphagus ratkowskyi AscusEQ_130A 126 Bigelow 202004044 AscusEQ_130B 127 Bigelow 202004044 AscusEQ_130C 128 Bigelow 202004044 AscusEQ_130D 129 Bigelow 202004044 AscusEQ_130E 130 Bigelow 202004044 AscusEQ_130F 131 Bigelow 202004044 AscusEQ_130G 132 Bigelow 202004044 Prevotella copri AscusEQ_344A 134 Bigelow 202004044 Ascus EQ_344B 135 Bigelow 202004044 AscusEQ_344C 136 Bigelow 202004044 Ascus EQ_344D 137 Bigelow 202004044 Ascus EQ_344E 138 Bigelow 202004044 Ascus EQ_344F 139 Bigelow 202004044 Ascus EQ_344G 140 Bigelow 202004044 Streptococcus equinus AscusEQ_140A 142 Bigelow 202004045 NRRL NRRL B- 67943 AscusEQ_140B 143 Bigelow 202004045 AscusEQ_140C 144 Bigelow 202004044 AscusEQ_140D 145 Bigelow 202004044 AscusEQ_140E 146 Bigelow 202004044. Petição 870260102095, de 02 / 10 / 2026, pág. 18 / 641 10 / 159 AscusEQ_140F 147 Bigelow 202004044 AscusEQ_140G 148 Bigelow 202004044 Prevotella copri AscusEQ_484A 150 Bigelow 202004044 AscusEQ_484B 151 Bigelow 202004044 AscusEQ_484C 152 Bigelow 202004044 AscusEQ_484D 153 Bigelow 202004044 AscusEQ_484E 154 Bigelow 202004044 AscusEQ_484F 155 Bigelow 202004044 AscusEQ_484G 156 Bigelow 202004044 Duodenibacillus massiliensis AscusEQ_1187A 158 Bigelow 202004045 AscusEQ_1187B 159 Bigelow 202004044 AscusEQ_11870 160 Bigelow 202004044 AscusEQ_1187D 161 Bigelow 202004044 Bacteroidales bacterium AscusEQ_200A 163 Bigelow 202004042 AscusEQ_200B 164 Bigelow 202004043 AscusEQ_200C 165 Bigelow 202004043 AscusEQ_200D 166 Bigelow 202004043 AscusEQ_200E 167 Bigelow 202004043 AscusEQ_200F 168 Bigelow 202004044 AscusEQ_200G 169 Bigelow 202004044 Bacteroidia bacterium AscusEQ_183A 171 Bigelow 202004045 AscusEQ_183B 172 Bigelow 202004043 AscusEQ_183C 173 Bigelow 202004043 AscusEQ_183D 174 Bigelow 202004043 AscusEQ_183E 175 Bigelow 202004043 AscusEQ_183F 176 Bigelow202004043 AscusEQ_183G 177 Bigelow 202004044 Cecembia lonarensis AscusEQ_226A 179 Bigelow 202004042 AscusEQ_226B 180 Bigelow 202004043 AscusEQ_226C 181 Bigelow 202004043 AscusEQ_226D 182 Bigelow 202004044 AscusEQ_226E 183 Bigelow 202004044 AscusEQ_226F 184 Bigelow 202004044 AscusEQ_226G 185 Bigelow 202004044 Bacteroidia bacterium Ascus EQ_369A 187 Bigelow 202004043 Ascus EQ_369B 188 Bigelow 202004044 AscusEQ_369C 189 Bigelow 202004044 AscusEQ_369D 190 Bigelow 202004044 Petição 870260102095, de 02 / 10 / 2026, pág. 19 / 641 11 / 159 Ascus EQ_369E 191 Bigelow 202004044 Ascus EQ_369F 192 Bigelow 202004044 AscusEQ_369G 193 Bigelow 202004044 Bacteroidales bacterium AscusEQ_820A 195 Bigelow 202004042 AscusEQ_820B 196 Bigelow 202004043 AscusEQ_820C 197 Bigelow 202004044 AscusEQ_820D 198 Bigelow 202004044 AscusEQ_820E 199 Bigelow 202004044 Clostridium maximum AscusEQ_253A 201 Bigelow 202004043 AscusEQ_253B 202 Bigelow 202004043 AscusEQ_253C 203 Bigelow 202004043 AscusEQ_253D 204 Bigelow 202004043 AscusEQ_253E 205 Bigelow 202004043 AscusEQ_253F 206 Bigelow 202004044 AscusEQ_253G 207 Bigelow 202004044 Bacteroidales bacterium AscusEQ_126A 210 Bigelow 202004042 AscusEQ_126B 211 Bigelow 202004043 AscusEQ_126C 212 Bigelow 202004043 AscusEQ_126D 213 Bigelow 202004043 AscusEQ_126E 214 Bigelow 202004043 AscusEQ_126F 215 Bigelow 202004043 AscusEQ_126G 216 Bigelow 202004044 Bacteroidales bacterium AscusEQ_1029A 218 Bigelow 202004044 AscusEQ_1029B 219 Bigelow 202004044 AscusEQ_1029C 220 Bigelow 202004044 Bacteroidales bacteriumAscusEQ_980A 223 Bigelow 202004043 Ascus EQ_980B 224 Bigelow 202004043 AscusEQ_980C 225 Bigelow 202004043 Ascus EQ_980D 226 Bigelow 202004043 Ascus EQ_980E 227 Bigelow 202004043 Ascus EQ_980F 228 Bigelow 202004044 Bacteroidia bacterium AscusEQ_1166A 230 Bigelow 202004043 AscusEQ_1166B 231 Bigelow 202004043 AscusEQ_11660 232 Bigelow 202004043 AscusEQ_1166D 233 Bigelow 202004043 AscusEQ_1166E 234 Bigelow 202004043 AscusEQ_1166F 235 Bigelow 202004044 AscusEQ_1166G 236 Bigelow 202004044 Petição 870260102095, de 02 / 10 / 2026, pág. 20 / 641 12 / 159 Acidaminococcus sp. AscusEQ_105A 238 Bigelow 202004042 AscusEQ_105B 239 Bigelow 202004043 AscusEQ_105C 240 Bigelow 202004043 AscusEQ_105D 241 Bigelow 202004043 AscusEQ_105E 242 Bigelow 202004043 AscusEQ_105F 243 Bigelow 202004043 AscusEQ_105G 244 Bigelow 202004043 Bacteroidales bacterium AscusEQ_145A 246 Bigelow 202004042 AscusEQ_145B 247 Bigelow 202004043 AscusEQ_145C 248 Bigelow 202004043 Bacteroides graminisolvens Ascus EQ_669A 251 Bigelow 202004043 Ascus EQ_669B 252 Bigelow 202004043 AscusEQ_669C 253 Bigelow 202004043 AscusEQ_669D 254 Bigelow 202004043 Ascus EQ_669E 255 Bigelow 202004043 Ascus EQ_669F 256 Bigelow 202004043 AscusEQ_669G 257 Bigelow 202004043 Bacteroidales bacterium AscusEQ_703A 259 Bigelow 202004043 AscusEQ_703B 260 Bigelow 202004044 AscusEQ_703C 261 Bigelow 202004044 AscusEQ_703D 262 Bigelow 202004044 Parabacteroides distasonis AscusEQ_436A 264 Bigelow 202004042 AscusEQ_436B 265 Bigelow 202004042 AscusEQ_436C 266 Bigelow 202004042 AscusEQ_436D 267 Bigelow 202004044AscusEQ_436E 268 Bigelow 202004044 AscusEQ_436F 269 Bigelow 202004044 AscusEQ_436G 270 Bigelow 202004044 Bacteroides coprophilus AscusEQ_680A 272 Bigelow 202004043 Ascus EQ_680B 273 Bigelow 202004044 AscusEQ_680C 274 Bigelow 202004044 AscusEQ_680D 275 Bigelow 202004044 Ascus EQ_680E 276 Bigelow 202004044 Ascus EQ_680F 277 Bigelow 202004044 Bacteroidales bacterium AscusEQ_762A 280 Bigelow 202004043 Ascus EQ_762B 281 Bigelow 202004043 AscusEQ_762C 282 Bigelow 202004043 AscusEQ_762D 283 Bigelow 202004043 Petição 870260102095, de 02 / 10 / 2026, pág. 21 / 641 13 / 159 Ascus EQ_762E 284 Bigelow 202004043 Ascus EQ_762F 285 Bigelow 202004043 Ascus EQ 762G 286 Bigelow 202004043 Phascolarctobacterium sp. Ascus EQ_773A 289 Bigelow 202004044 Ascus EQ_773B 290 Bigelow 202004044 Ascus EQ_773C 291 Bigelow 202004044 AscusEQ_773D 292 Bigelow 202004044 Ascus EQ_773E 293 Bigelow 202004044 Ascus EQ_773F 294 Bigelow 202004044 AscusEQ_773G 295 Bigelow 202004044 Phascolarctobacterium sp AscusEQ_625A 298 Bigelow 202004042 AscusEQ_625B 299 Bigelow 202004043 AscusEQ_625C 300 Bigelow 202004044 AscusEQ_625D 301 Bigelow 202004044 AscusEQ_625E 302 Bigelow 202004044 AscusEQ_625F 303 Bigelow 202004044 Bacteroides graminisolvens Ascus EQ_783A 306 Bigelow 202004043 Ascus EQ_783B 307 Bigelow 202004043 Ascus EQ_783C 308 Bigelow 202004043 AscusEQ_783D 309 Bigelow 202004043 Ascus EQ_783E 310 Bigelow 202004043 Phascolarctobacterium sp.AscusEQ_1316A 312 Bigelow 202004042 AscusEQ_1316B 313 Bigelow 202004044 AscusEQ_1316C 314 Bigelow 202004044 AscusEQ_1316D 315 Bigelow 202004044 AscusEQ_1316E 316 Bigelow 202004044 AscusEQ_1316F 317 Bigelow 202004044 AscusEQ_1316G 318 Bigelow 202004044 Escherichia coli AscusEQ_61A 320 Bigelow 202004045 NRRL NRRL B- 67942 AscusEQ_61B 321 Bigelow 202004044 AscusEQ_61C 322 Bigelow 202004044 AscusEQ_61D 323 Bigelow 202004044 AscusEQ_61E 324 Bigelow 202004044 AscusEQ_61F 325 Bigelow 202004044 AscusEQ_61G 326 Bigelow 202004044 Bacteroidetes AscusEQ_1022A 328 Bigelow 202004042. Petição 870260102095, de 02 / 10 / 2026, pág. 22 / 641 14 / 159 bacterium AscusEQ_1022B 329 Bigelow 202004043 AscusEQ_1022C 330 Bigelow 202004043 AscusEQ_1022D 331 Bigelow 202004044 Phascolarctobacterium sp. AscusEQ_607A 333 Bigelow 202004045 AscusEQ_607B 334 Bigelow 202004045 AscusEQ_607C 335 Bigelow 202004043 AscusEQ_607D 336 Bigelow 202004043 AscusEQ_607E 337 Bigelow 202004043 Alloprevotella sp. AscusEQ_412A 339 Bigelow 202004042 AscusEQ_412B 340 Bigelow 202004043 AscusEQ_412C 341 Bigelow 202004043 AscusEQ_412D 342 Bigelow 202004043 AscusEQ_412E 343 Bigelow 202004044 AscusEQ_412F 344 Bigelow 202004044 AscusEQ_412G 345 Bigelow 202004044 Muribaculaceae bacterium AscusEQ_1362A 347 Bigelow 202004044 Bacteroidia bacterium Ascus EQ_696A 349 Bigelow 202004043 Ascus EQ_696B 350 Bigelow 202004043 AscusEQ_696C 351 Bigelow 202004043 AscusEQ_696D 352 Bigelow 202004043 Ascus EQ_696E 353 Bigelow 202004043 Ascus EQ_696F 354 Bigelow 202004043 Bacteroides massiliensis Ascus EQ_835A 357 Bigelow 202004043 Ascus EQ_835B 358 Bigelow 202004044 AscusEQ_835C 359Bigelow 202004044 AscusEQ_835D 360 Bigelow 202004044 Oscillibacter valericigenes Ascus EQ_595A 362 Bigelow 202004043 Ascus EQ_595B 363 Bigelow 202004044 AscusEQ_595C 364 Bigelow 202004044 AscusEQ_595D 365 Bigelow 202004044 Ascus EQ_595E 366 Bigelow 202004044 Ascus EQ_595F 367 Bigelow 202004044 AscusEQ_595G 368 Bigelow 202004044 TM7 bacterium AscusEQ_1850A 370 Bigelow 202004042 AscusEQ_1850B 371 Bigelow 202004043 AscusEQ_1850C 372 Bigelow 202004043 Phascolarctobacterium AscusEQ_298A 374 Bigelow 202004044 Petição 870260102095, de 02 / 10 / 2026, pág. 23 / 641 15 / 159 succinatutens AscusEQ_298B 375 Bigelow 202004044 AscusEQ_298C 376 Bigelow 202004044 AscusEQ_298D 377 Bigelow 202004044 AscusEQ_298E 378 Bigelow 202004044 Bacteroides graminisolvens AscusEQ_743A 380 Bigelow 202004043 AscusEQ_743B 381 Bigelow 202004043 AscusEQ_743C 382 Bigelow 202004043 AscusEQ_743D 383 Bigelow 202004043 AscusEQ_743E 384 Bigelow 202004043 Alphaproteobacteria bacterium AscusEQ_722A 386 Bigelow 202004043 Ascus EQ_722B 387 Bigelow 202004043 AscusEQ_722C 388 Bigelow 202004043 AscusEQ_722D 389 Bigelow 202004043 Ascus EQ 722E 390 Bigelow 202004044 Ascus EQ 722F 391 Bigelow 202004044 Ascus EQ 722G 392 Bigelow 202004044 Cecembia lonarensis AscusEQ_603A 395 Bigelow 202004043 AscusEQ_603B 396 Bigelow 202004043 AscusEQ_603C 397 Bigelow 202004043 AscusEQ_603D 398 Bigelow 202004044 AscusEQ_603E 399 Bigelow 202004044 AscusEQ_603F 400 Bigelow 202004044 AscusEQ_603G 401 Bigelow 202004044 Phascolarctobacterium sp.AscusEQ_1567A 404 Bigelow 202004042 AscusEQ_1567B 405 Bigelow 202004042 AscusEQ_1567C 406 Bigelow 202004042 AscusEQ_1567D 407 Bigelow 202004044 AscusEQ_1567E 408 Bigelow 202004044 AscusEQ_1567F 409 Bigelow 202004044 AscusEQ_1567G 410 Bigelow 202004044 Bacteroidia bacterium AscusEQ_1921A 412 Bigelow 202004042 AscusEQ_1921B 413 Bigelow 202004044 AscusEQ_1921C 414 Bigelow 202004044 AscusEQ_1921D 415 Bigelow 202004044 AscusEQ_1921E 416 Bigelow 202004044 AscusEQ_1921F 417 Bigelow 202004044 AscusEQ_1921G 418 Bigelow 202004044 Bacteroides AscusEQ_476A 420 Bigelow 202004043. Petição 870260102095, de 02 / 10 / 2026, pág. 24 / 641 16 / 159 graminisolvens AscusEQ_476B 421 Bigelow 202004043 AscusEQ_476C 422 Bigelow 202004043 AscusEQ_476D 423 Bigelow 202004043 AscusEQ_476E 424 Bigelow 202004043 AscusEQ_476F 425 Bigelow 202004043 Clostridium maximum AscusEQ_414A 427 Bigelow 202004043 AscusEQ_414B 428 Bigelow 202004043 AscusEQ_414C 429 Bigelow 202004043 AscusEQ_414D 430 Bigelow 202004043 AscusEQ_414E 431 Bigelow 202004043 AscusEQ_414F 432 Bigelow 202004044 AscusEQ_414G 433 Bigelow 202004044 NRRL NRRL B- 67940 Bacteroidia bacterium AscusEQ_1253A 435 Bigelow 202004043 AscusEQ_1253B 436 Bigelow 202004043 AscusEQ_1253C 437 Bigelow 202004044 Bacteroides mediterraneensis AscusEQ_324A 439 Bigelow 202004045 Ascus EQ_324B 440 Bigelow 202004045 AscusEQ_324C 441 Bigelow 202004042 AscusEQ_324D 442 Bigelow 202004043 Ascus EQ_324E 443 Bigelow 202004043 Phascolarctobacterium sp.AscusEQ_1536A 445 Bigelow 202004043 AscusEQ_1536B 446 Bigelow 202004044 AscusEQ_1536C 447 Bigelow 202004044 AscusEQ_1536D 448 Bigelow AscusEQ_1536E 449 Bigelow 202004044 AscusEQ_1536F 450 Bigelow 202004044 AscusEQ_1536G 451 Bigelow 202004044 Bacteroides massiliensis AscusEQ_971A 453 Bigelow 202004043 AscusEQ_971B 454 Bigelow 202004043 AscusEQ_971C 455 Bigelow 202004044 AscusEQ_971D 456 Bigelow 202004044 AscusEQ_971E 457 Bigelow 202004044 Algoriphagus taiwanensis AscusEQ_257A 459 Bigelow 202004044 AscusEQ_257B 460 Bigelow 202004044 AscusEQ_257C 461 Bigelow 202004044 AscusEQ_257D 462 Bigelow 202004044. Petition 870260102095, dated 02 / 10 / 2026, p. 25 / 6 17 / 1 AscusEQ_257E 463 Bigelow 202004044 AscusEQ_257F 464 Bigelow 202004044 Bacteroidales bacterium AscusEQ_452A 466 Bigelow 202004042 AscusEQ_452B 467 Bigelow 202004042 AscusEQ_452C 468 Bigelow 202004043 AscusEQ_452D 469 Bigelow 202004043 AscusEQ_452E 470 Bigelow 202004043 AscusEQ_452F 471 Bigelow 202004043 AscusEQ_452G 472 Bigelow 202004043 Atlantibacter hermannii AscusEQ_109A 476 Bigelow 202004045 NRRL NRRL B- 67944 AscusEQ_109B 477 Bigelow 202004045 AscusEQ_109C 478 Bigelow 202004045 AscusEQ_109D 479 Bigelow 202004042 AscusEQ_109E 480 Bigelow 202004044 AscusEQ_109F 481 Bigelow 202004044 AscusEQ_167A 482 Bigelow 202004045 AscusEQ_167B 483 Bigelow 202004043 AscusEQ_167C 484 Bigelow 202004043 Prevotella copri Ascus EQ_363A 486 Bigelow 202004042 Ascus EQ_363B 487 Bigelow 202004044 AscusEQ_363C 488 Bigelow 202004044 AscusEQ_363D 489 Bigelow 202004044 Ascus EQ_363E 490 Bigelow 202004044 Ascus EQ_363F 491 Bigelow 202004044 AscusEQ_363G 492 Bigelow 202004044 Bacteroidales bacterium AscusEQ_299A494 Bigelow 202004042 AscusEQ_299B 495 Bigelow 202004043 AscusEQ_299C 496 Bigelow 202004043 AscusEQ_299D 497 Bigelow 202004043 AscusEQ_299E 498 Bigelow 202004043 AscusEQ_299F 499 Bigelow 202004043 AscusEQ_299G 500 Bigelow 202004043 Prevotella oris AscusEQ_456A 502 Bigelow 202004043 AscusEQ_456B 503 Bigelow 202004043 AscusEQ_456C 504 Bigelow 202004043 AscusEQ_456D 505 Bigelow 202004043 Petição 870260102095, de 02 / 10 / 2026, pág. 26 / 641 18 / 159 AscusEQ_456E 506 Bigelow 202004043 AscusEQ_456F 507 Bigelow 202004043 Bacteroides caecicola AscusEQ_232A 509 Bigelow 202004045 AscusEQ_232B 510 Bigelow 202004043 AscusEQ_232C 511 Bigelow 202004043 Algoriphagus ratkowskyi AscusEQ_235A 513 Bigelow 202004043 AscusEQ_235B 514 Bigelow 202004044 AscusEQ_235C 515 Bigelow 202004044 AscusEQ_235D 516 Bigelow 202004044 AscusEQ_235E 517 Bigelow 202004044 AscusEQ_235F 518 Bigelow 202004044 AscusEQ_235G 519 Bigelow 202004044 Parabacteroides distasonis AscusEQ_490A 521 Bigelow 202004042 AscusEQ_490B 522 Bigelow 202004042 AscusEQ_490C 523 Bigelow 202004043 AscusEQ_490D 524 Bigelow 202004044 AscusEQ_490E 525 Bigelow 202004044 AscusEQ_490F 526 Bigelow 202004044 AscusEQ_490G 527 Bigelow 202004044 Bacteroidales bacterium Ascus EQ_588A 530 Bigelow 202004043 Ascus EQ_588B 531 Bigelow 202004043 AscusEQ_588C 532 Bigelow 202004043 AscusEQ_588D 533 Bigelow 202004043 Ascus EQ_588E 534 Bigelow 202004043 Alphaproteobacteria bacterium AscusEQ_1234A 536 Bigelow202004045 AscusEQ_1234B 537 Bigelow 202004043 AscusEQ_1234C 538 Bigelow 202004043 AscusEQ_1234D 539 Bigelow 202004043 AscusEQ_1234E 540 Bigelow 202004043 Anaerocella delicata AscusEQ_962A 542 Bigelow 202004045 Ascus EQ_962B 543 Bigelow 202004042 AscusEQ_962C 544 Bigelow 202004042 Alphaproteobacteria bacterium AscusEQ_916A 546 Bigelow 202004045 AscusEQ_916B 547 Bigelow 202004043 AscusEQ_916C 548 Bigelow 202004043 AscusEQ_916D 549 Bigelow 202004043 AscusEQ_916E 550 Bigelow 202004043 Prevotella sp. AscusEQ_1095A 552 Bigelow 202004042 Petição 870260102095, de 02 / 10 / 2026, pág. 27 / 641 19 / 159 AscusEQ_1095B 553 Bigelow 202004043 AscusEQ_1095C 554 Bigelow 202004043 AscusEQ_1095D 555 Bigelow 202004043 AscusEQ_1095E 556 Bigelow 202004043 AscusEQ_1095F 557 Bigelow 202004043 AscusEQ_1095G 558 Bigelow 202004043 Phascolarctobacterium sp. AscusEQ_614A 560 Bigelow 202004044 AscusEQ_614B 561 Bigelow 202004044 AscusEQ_614C 562 Bigelow 202004044 AscusEQ_614D 563 Bigelow 202004044 AscusEQ_614E 564 Bigelow 202004044 AscusEQ_614F 565 Bigelow 202004044 AscusEQ_614G 566 Bigelow 202004044 Bacteroidales bacterium Ascus EQ_698A 569 Bigelow 202004044 Ascus EQ_698B 570 Bigelow 202004044 AscusEQ_698C 571 Bigelow 202004044 AscusEQ_698D 572 Bigelow 202004044 Ascus EQ_698E 573 Bigelow 202004044 Ascus EQ_698F 574 Bigelow 202004044 AscusEQ_698G 575 Bigelow 202004044 Brief Description of the Figures

[0027] FIG. 1 illustrates the significant difference in beta diversity (left) and alpha diversity (right) between colic and healthy states in horses.

[0028] FIG. 2 illustrates the differences in microbial load and microbial populations (total cells / ml), as well as the taxonomic differences at the phylum level in the fecal microbiome of horses with colic vs. without colic.

[0029] FIG. 3 shows that binary classification algorithms can use the microbial composition of fecal samples to determine whether the source patient is in a state of colic or not.

[0030] FIG. 4 shows that multiclass classification algorithms can use the microbial composition of fecal samples to determine whether the source patient is in a state of symptomatic colic, asymptomatic colic, or not.

[0031] FIG. 5 shows a principal coordinate analysis of samples Petition 870260102095, dated 02 / 10 / 2026, page 28 / 641 20 / 159 classified as: colic-free / healthy; colic; temporary / transient colic (symptomatic colic); or temporary / transient colic (asymptomatic colic).

[0032] FIG. 6 shows the alpha diversity of samples classified as colic-free / healthy; colic; temporary / transient colic (colic / symptomatic); or temporary / transient colic (colic-free / asymptomatic).

[0033] FIG. 7 illustrates that the MIC scoring network and the classification based on colic are anticorrelated.

[0034] FIG. 8 shows cross-validation scores of machine learning models for accurately diagnosing microbe-mediated colic.

[0035] FIG. 9 shows heat maps of fecal microbial abundances (y-axis) in healthy states and with colic over time (x-axis).

[0036] FIG. 10 shows that principal coordinate analysis can be used to determine the effectiveness of fecal transplantation.

[0037] FIG. 11 provides heat maps of fecal microbial abundances (y-axis) between healthy and colic states over time (x-axis).

[0038] FIG. 12 illustrates that the network generated from MIC scores can be used to select target microorganisms for use as a supplement to prevent and treat colic.

[0039] FIG. 13 represents the taxonomies of colic-associated microbes (MIC) and healthy colic-associated microbes (+MIC) identified through platform analysis.

[0040] FIG. 14 illustrates the fecal microbiome of horses with major colonic volvulus and healthy horses.

[0041] FIG. 15 shows the abundance of microorganisms in the fecal microbiome of Patient #1 before (left), after administration of native microorganisms for 2 weeks (center), and 1 month after administration was discontinued (right).

[0042] FIG. 16 shows the alpha diversity of the fecal microbiome of Patient #1 before (left) and after administration of native microorganisms for 2 weeks. Petition 870260102095, dated 02 / 10 / 2026, page 29 / 641 21 / 159 (center) and 1 month after the administration was interrupted (right).

[0043] FIG. 17 shows the abundance of microorganisms in the fecal microbiome of Patient #2 before and after administration of native microorganisms for 2 weeks. The microbiome goes from a healthy state (left) to an even healthier one (right).

[0044] FIG. 18 shows the alpha diversity of the fecal microbiome of Patient #2 before (left) and after administration (right) of native microorganisms for 2 weeks.

[0045] FIG. 19 shows the abundance of microorganisms in the fecal microbiome of Patient #3 before and after administration of native microorganisms for 2 weeks. The microbiome goes from a healthy state (left) to an even healthier one (right).

[0046] FIG. 20 shows the alpha diversity of the fecal microbiome of Patient #3 before (left) and after administration (right) of native microorganisms for 2 weeks.

[0047] FIG. 21 shows the abundance of microorganisms in the fecal microbiome of Patient #4 before and after administration of native microorganisms for 2 weeks. The microbiome undergoes a change from a colic state (left) to a healthy state (right).

[0048] FIG. 22 shows the alpha diversity of the fecal microbiome of Patient #4 before (left) and after administration (right) of native microorganisms for 2 weeks.

[0049] FIG. 23 shows the abundance of microorganisms in the fecal microbiome of Patient #5 before and after administration of native microorganisms for 2 weeks. The microbiome undergoes a change from a colic state (left) to a healthier state (right).

[0050] FIG. 24 shows the alpha diversity of Patient #5's fecal microbiome before (left), during (center), and after administration (right) of native microorganisms for 2 weeks.

[0051] FIG. 25 shows the abundance of microorganisms in the fecal microbiome of Patient #6 before and after the administration of native microorganisms for 2 Petition 870260102095, dated 02 / 10 / 2026, page 30 / 641 22 / 159 weeks (center) and 1 month after administration (right). The microbiome undergoes a change from a colic state (left) to a healthy state (right).

[0052] FIG. 26 shows the alpha diversity of the fecal microbiome of Patient #6 before (left) after administration of native microorganisms for 2 weeks (center) and 1 month after administration (right).

[0053] FIG. 27 shows the abundance of microorganisms in the fecal microbiome of Patient #7 before and after administration of native microorganisms for 2 weeks. The microbiome undergoes a change from a colic state (left) to a healthy state (right).

[0054] FIG. 28 shows the alpha diversity of the fecal microbiome of Patient #7 before (left) and after administration (right) of native microorganisms for 2 weeks.

[0055] FIG. 29 shows the relative abundance of healthy microorganisms associated with alpha diversity in various horses.

[0056] FIG. 30 illustrates the co-grouping of the microbiome of healthy, transient and colic-affected states.

[0057] FIG. 31 shows a general workflow of a method for determining the absolute abundance of one or more strains of active microorganisms.

[0058] FIG. 32 shows a general workflow of a method for determining the co-occurrence of one or more or two or more strains of active microorganisms in a sample with one or more metadata (environmental) parameters, followed by cluster analysis and community detection methods in the determined relationship network. Detailed Description

[0059] The ability to return to a healthy state after disturbance is partly regulated by the microbial populations and biochemical functions of the gut. A supplemented group of microbes isolated from the horse or other equine gut can regulate the community to a healthy state. The ability to adequately regulate the intestinal microbial community to a healthy state can prevent early-stage colic from negative internal or external pressures, as well as prevent the downward spiral of early-stage colic into other forms. Petition 870260102095, dated 02 / 10 / 2026, page 31 / 641 23 / 159 of severe colic. A supplemented group of microbes can be administered daily through animal feed, supplement, or water to prevent the onset and progression of the disease. This supplement can also be administered via fecal transplant and / or directly to target organs during pre / post / during surgery to treat a horse or other equine in a pre-existing chronic state.

[0060] The disclosure is generally designed for methods of administering one or more microbes of the present disclosure to equines. In some respects, the disclosure is generally designed for methods of treating or preventing colic in equines, the method comprising: administering to an equine an effective amount of a microbial composition comprising: (i) any one or more of the bacteria set forth in Table 2; and (ii) a carrier suitable for equine administration.

[0061] In some respects, the disclosure is generally designed for a microbial composition capable of treating or preventing colic in a horse, comprising: (i) a purified population of bacteria comprising one or more bacteria selected from Table 2; and (ii) a carrier suitable for equine administration, wherein the purified population of bacteria is present in the composition in an amount effective to reduce colic symptoms and / or change the gut microbiome, compared to a horse that has not received the composition. In some embodiments, the bacteria are encapsulated. In some embodiments, the microbial composition is stable in storage.

[0062] In some aspects, the microbial composition is administered via a fecal transplant from a healthy equine. In some aspects, the microbial composition is administered in addition to a fecal transplant from a healthy equine. In some aspects, the microbial composition is administered orally. In other aspects, oral administration includes administering the microbial composition powdered or mixed with food / feed. In some aspects, the microbial composition is administered rectally. In other aspects, rectal administration includes administering the microbial composition as a suppository. In some aspects, the microbial composition is administered during equine surgery. In some aspects, the microbial composition is administered after equine surgery. In some aspects, the microbial composition is administered before equine surgery. Petition 870260102095, dated 02 / 10 / 2026, page 32 / 641 24 / 159 Horses and colic

[0063] In some embodiments, this disclosure provides suitable microbial compositions for administration to an equine. In some embodiments, this disclosure provides methods for the prevention and / or treatment of colic in an equine. In this document, the term equine animal may be used interchangeably with the term equine and encompasses any member of the genus Equus. It includes, for example, any horse or pony, the taxonomic designations Equus ferus and / or Equus caballus and / or the subspecies Equus ferus caballus. The equine animal may, for example, be a domestic or wild horse, zebra, mule, or donkey.

[0064] The term colic generally refers to abdominal pain. Over the years, it has become a broad term for a variety of conditions that cause a horse to exhibit clinical signs of abdominal pain. Consequently, it is used to refer to conditions of widely varying etiologies and severities. Several clinical signs are associated with colic. The most common include one or more repeated kicking of the front foot, looking back at the flank region, curling the upper lip and arching the neck, repeatedly lifting a hind leg or kicking the abdomen, lying down, rolling from side to side, sweating, stretching as if to urinate, straining to defecate, abdominal distension, loss of appetite, depression, and / or decreased bowel movements.

[0065] Colic can be diagnosed and appropriate treatment initiated after examining the horse, considering the history of any previous problems or treatments, determining which part of the intestinal tract is involved, and identifying the cause of the particular colic episode. The physical examination should include assessment of the cardiopulmonary and gastrointestinal systems. Oral mucous membranes should be assessed for color, moisture, and capillary refill time. Mucous membranes may become cyanotic or pale in horses with acute cardiovascular compromise and eventually hyperemic or cloudy as peripheral vasodilation develops later in shock. Capillary refill time (normal ~ 1.5 sec.) may be reduced early on but usually becomes prolonged as vascular stasis (venous pooling) develops. The membranes become dry as the horse becomes dehydrated.Heart rate increases due to pain, hemoconcentration, and hypotension; therefore, higher heart rates have been associated with... Petition 870260102095, dated 02 / 10 / 2026, p. 33 / 641 25 / 159 more serious bowel problems (strangulating obstruction). However, it is important to note that not all conditions requiring surgery are accompanied by a high heart rate.

[0066] An important aspect of the physical examination is the response to the passage of a nasogastric tube. Since horses cannot regurgitate or vomit, adynamic ileus, obstructions involving the small intestine, or distension of the stomach with gas or fluid can result in gastric rupture. Passing a stomach tube can therefore save the horse's life and aid in the diagnosis of these conditions. If fluid reflux occurs, the volume and color of the fluid should be noted. In healthy horses, it is common to recover <1 L of stomach fluid.

[0067] The most definitive part of the examination is the rectal examination. The veterinarian must develop a consistent method of palpation for the following: aorta, cranial mesenteric artery, cecal base and ventral cecal band, bladder, peritoneal surface, inguinal rings in stallions and geldings or ovaries and uterus in mares, pelvic flexure, spleen, and left kidney. The intestine should be palpated for size, consistency of contents (gas, liquid, or retained intake), distension, edematous walls, and pain on palpation. In healthy horses, the small intestine cannot be palpated; with small bowel obstruction, strangulating obstruction, or entente, the distended duodenum can be palpated dorsal to the base of the cecum on the right side of the abdomen, and distended loops of the jejunum can be identified in the middle of the abdomen.

[0068] A sample of peritoneal fluid (obtained by aseptically performed midline paracentesis) generally reflects the degree of intestinal damage. Color, cell count and differential, and total protein concentration should be evaluated. Normal peritoneal fluid is clear to yellow, contains <5,000 leukocytes / pL (most of which are mononuclear cells) and <2.5 g of protein / dL.

[0069] The horse's age is important because a number of age-related conditions cause colic. The most common include the following: in foals - colitis, meconium retention, uroperitoneum, and gastroduodenal ulcers; in yearlings - roundworm impaction; in young horses - small bowel intussusception, non-strangulating infarction, and foreign body obstruction; in middle-aged horses - cecal impaction, enteroliths, and large colon volvulus; and in older horses - lipoma Petition 870260102095, dated 02 / 10 / 2026, page 34 / 641 26 / 159 pedunculated and mesocolic rupture.

[0070] In most cases, colic develops for one of four reasons: 1) The intestinal wall is excessively stretched by gas, fluid, or ingestion. This stimulates stretch-sensitive nerve endings located within the intestinal wall, and pain impulses are transmitted to the brain. 2) Pain develops due to excessive tension in the mesentery, as can occur with intestinal displacement. 3) Ischemia develops, most often as a result of incarceration or severe torsion of the intestine. 4) Inflammation develops and may involve the entire intestinal wall (entente) or the lining of the intestine (peritonitis). Under such circumstances, pro-inflammatory mediators in the intestinal wall lower the threshold for painful stimuli.

[0071] The list of possible conditions that cause colic is long, and it is reasonable to first determine the most likely type of disease and initiate appropriate treatments, and then make a more specific diagnosis if possible. General types of disease that cause colic include excessive gas in the intestinal lumen (flatulent colic), simple obstruction of the intestinal lumen, obstruction of both the intestinal lumen and the blood supply to the intestine (strangulating obstruction), interruption of the blood supply to the intestine alone (non-strangulating infarction), inflammation of the intestine (entente), inflammation of the lining of the abdominal cavity (peritonitis), erosion of the intestinal lining (ulceration), and unexplained colic.

[0072] Horses with colic may require medical or surgical treatment. Almost all require some type of medical treatment, but only those with certain mechanical bowel obstructions need surgery. The type of medical treatment is determined by the cause of the colic and the severity of the disease. In some cases, the horse may be treated clinically first and the response evaluated; this is particularly appropriate if the horse is mildly sore and the cardiovascular system is functioning normally. Ultrasound can be used to assess the effectiveness of non-surgical treatment. If necessary, surgery can be used for both diagnosis and treatment.

[0073] If there is evidence of intestinal obstruction with dry bowel movements on rectal examination, the primary goal of treatment is to rehydrate and evacuate the intestinal contents. If the horse is in severe pain and has clinical signs indicating fluid loss from the Petition 870260102095, dated 02 / 10 / 2026, page 35 / 641 27 / 159 bloodstream (high heart rate, prolonged capillary refill time, and discoloration of mucous membranes), the initial treatment goals are to relieve pain, restore tissue perfusion, and correct any abnormalities in blood and body fluid composition. If intestinal wall damage is suspected (as a result of severe inflammation or displacement or strangulating obstruction), measures should be taken to prevent or neutralize the harmful effects of bacterial endotoxins that cross the damaged intestinal wall and enter the bloodstream. Finally, if there is evidence that the colic episode is caused by parasites, one of the treatment goals is to eliminate the parasites.

[0074] The microbiomes of healthy and colicky horses differ significantly. FIG. 1 shows the significant differences in beta diversity (left) and alpha diversity (right) between colicky and healthy states in horses. In the left panel, each point represents a microbiome sample from a horse with colic diagnosed by a veterinarian (light gray) or a healthy horse (black). The clear separation of the samples (p-value = 0.001) suggests clear microbiome differences between healthy and colicky states. The right panel represents the differences in alpha diversity between colicky (left) and healthy (right) animals with violin plots. As shown, colicky animals tend to have greater alpha diversity / more species diversity than healthy animals. FIG. 29 shows the relative abundance of healthy microorganisms associated with alpha diversity in various horses. The differences in microbiomes are further illustrated in FIG.Figure 2 shows the differences in microbial load and microbial populations (total cells / ml), as well as taxonomic differences at the phylum level in the fecal microbiome of horses with colic vs. without colic. Additional data demonstrating the differences in the fecal microbiome of horses with colic and healthy horses are provided in FIG. 14. Principal coordinate analysis of horses with colic with large colon volvulus and healthy horses shows distinct separation between animals with colic and healthy animals (p-value = 0.001). Additional data demonstrating the differences in the fecal microbiome of horses with colic and healthy horses are provided in FIG. 30, whose microbiome co-groups healthy, transient, and colic states.

[0075] Machine learning algorithms can be used to Petition 870260102095, dated 02 / 10 / 2026, page 36 / 641 28 / 159 determine whether a patient is in a colic state or not. FIG. 3 shows the receiver operator characteristic (ROC) curve for the performance of the binary classifier. Machine learning between colic and healthy states has an accuracy of 99.99% using a 5-fold 80:20 train:test split. Furthermore, multi-class classification algorithms can utilize the microbial composition of fecal samples to determine whether the source patient is in a symptomatic colic state, asymptomatic colic, or not. FIG. 4 shows the receiver operator characteristic (ROC) curve for the performance of the multi-class classifier. Machine learning across all states has a macro-average accuracy of 96%. Cross-validation scores of machine learning models in FIG. 8 show that fecal microbiome data can be used to accurately diagnose microorganism-mediated colic.

[0076] The differences in the microbiome of healthy horses compared to horses in various colic states are further illustrated in FIG. 5. Main coordinate analysis of samples classified as colic-free / healthy; colic; temporary / transient colic (colic / symptomatic); or temporary / transient colic (colic-free / asymptomatic) suggests a clear distinction between the β diversity of patients in each state (p-value = 0.001). Similar data are provided in FIG. 6 for α diversity. Some overlap is observed between transient colic and other states, but this is expected as it represents an active and temporary change to a true colic state or healthy state.

[0077] Further differences in microbiomes of healthy and colic-affected horses are illustrated by MIC scores. As shown in FIG. 7, the MIC score network and colic-based classification are anticorrelated. Microorganisms with positive MIC scores (healthy state) are more abundant in healthy and transient / non-colic states. Microorganisms with negative MIC scores (colic state) are more abundant in colic and transient / colic states. The network generated from MIC scores was used to select target microorganisms for use as a supplement to prevent and treat colic, illustrated in FIG. 12. FIG. 13 shows the taxonomies of colic-associated microbes (-MIC) and healthy microbes (+MIC) identified through platform analysis.

[0078] The microbial status of horses over time during periods Petition 870260102095, dated 02 / 10 / 2026, page 37 / 641 29 / 159 of colic and non-colic further emphasizes the differences between the microbiomes of healthy and colic-affected horses. As shown in FIG. 9, heat maps of fecal microbial abundances (y-axis) reveal clear differences between healthy and colic states over time (x-axis). Patient 1 was diagnosed with colic (far left) and underwent antibiotic treatment. The patient appeared to recover and entered a healthy state for a few months. However, patient 1 experienced a second colic episode (far right), where microbes related to the original colic resurfaced and caused colic symptoms in the patient. Patient 2 was diagnosed with colic (far left). Treatment began to push the patient's fecal microbiome toward a healthier state; however, the patient relapsed and was ultimately euthanized. Similar results are shown in FIG. 11.

[0079] Principal coordinate analysis can also be used to determine the effectiveness of fecal transplantation, as shown in FIG. 10.0. Donor horse fecal material was used as a fecal transplant for Patients 1 and 2. To predict the effectiveness of the procedure, the fecal microbiome compositions of Patients 1 and 2 before transplantation (S1) were averaged with the microbiome composition of the donor horse. The predicted microbiomes are shown as a white circle (Patient 1) and a white triangle (Patient 2). The direction / location of the predicted microbes is similar to the actual post-fecal transplant samples (S2). Patient 1 had a successful transplant. Patient 2 relapsed and was eventually euthanized (post-mortem sample). Microbial compositions

[0080] In some embodiments, this disclosure provides microbial compositions comprising one or more target microbes. The target microbe may be any microorganism suitable for use in accordance with this disclosure. As used in this document, the term microorganism should be understood in a broad sense. It includes, but is not limited to, the two prokaryotic domains, bacteria and Archaea, as well as eukaryotic fungi, protists, and viruses. As an example, microorganisms may include species of the genera: Arcanobacterium, Acidaminococcus, Phascolarctobacterium, Bacteroides, Sutterella, Sutterella, Duodenibacillus, Catabacter, Christensenella, Clostridium, Clostridium sensu stricto, Anaerococcus, Finegoldia, Parvimonas, Helcococcus, Anaerovorax, Ihubacter, Petition 870260102095, dated 02 / 10 / 2026, p. 38 / 641 30 / 159 Mogibacterium, Corynebacterium, Algoriphagus, Cecembia, Flavobacterium, Atlantibacterium, Escherichia, Shigella, Erysipelothrix, Spiroplasma, Eubacterium, Flavobacterium, Devosia, Maritalea, Anaerocolumna, Anaerostipes, Butyrivibrio, Coprococcus, Cellulosilyticum, Clostridium XlVa, Frisingicoccus, Howardella, Oribacterium, Pediococcus, Peptococcus, Peptoniphilus, Terrisporobacter Peptostreptococcus, Barnesiella, Butyricimonas, Parabacteroides, Porphyromonas, Prevotella, Odoribacter, Alloprevotella, Bacteroides, Prevotella, Anaerocella Alistipe, Oscillibacter, Clostridium III, Intestinimonas, Ruminiclostridium, Monoglobus, Pedobacter, Streptococcus, Schwartzia, Selenomonas, Phascolarctobacterium, and Negativicoccus.

[0081] In one embodiment, microbes are obtained from animals (e.g., mammals, reptiles, birds, and the like), soil (e.g., rhizosphere), air, water (e.g., marine, freshwater, wastewater sludge), sediments, oils, plants (e.g., roots, leaves, stems), agricultural products, and extreme environments (e.g., acid mine drainage or hydrothermal systems). In some embodiments, microbes are obtained from marine or freshwater environments, such as an ocean, river, or lake. In some embodiments, microbes may be from the surface of the water body or from any depth of the water body (e.g., a sample from the seabed).

[0082] Microorganisms for dissemination can be isolated in substantially pure or mixed cultures. They can be concentrated, diluted, or supplied at the concentrations found in the natural source material. For example, microorganisms from saline sediments can be isolated for use in this dissemination by suspending the sediment in fresh water and allowing the sediment to settle to the bottom. The water containing most of the microorganisms can be removed by decantation after an appropriate sedimentation period and administered to the gastrointestinal tract of an ungulate, or concentrated by filtration or centrifugation, diluted to an appropriate concentration, and administered to the gastrointestinal tract of an ungulate with most of the salt removed. As a further example, microorganisms from mineralized or toxic sources can be treated similarly to recover the microbes for application to the ungulate to minimize the potential for harm to the animal.

[0083] In some embodiments, microorganisms are used in a form Petition 870260102095, dated 02 / 10 / 2026, page 39 / 641 31 / 159 crude, in which they are not isolated from the source material in which they naturally reside. For example, microorganisms are supplied in combination with the source material in which they reside; for example, fecal matter, rumination, or other composition found in the gastrointestinal tract. In such embodiments, the source material may include one or more species of microorganisms.

[0084] In some embodiments, a mixed population of microorganisms is used in the disclosure methods. In disclosure embodiments where microorganisms are isolated from a source material (e.g., the material where they naturally reside), any one or a combination of a number of standard techniques will be readily known to those skilled in the art to use. However, by way of example, they generally employ processes by which a liquid or solid culture of a single microorganism can be obtained in a substantially pure form, usually by physical separation on the surface of a solid microbial growth medium or by volumetric dilutive isolation in a liquid microbial growth medium.These processes may include the isolation of dry material, liquid suspension, suspensions or homogenates in which the material is spread in a thin layer on a suitable solid gel growth medium, or serial dilutions of the material in a sterile medium and inoculated into liquid or solid culture media.

[0085] In some embodiments, the material containing the microorganisms may be pre-treated before the isolation process in order to multiply all microorganisms in the material. The microorganisms may then be isolated from the enriched materials.

[0086] The target microbes can be derived from any type of sample that includes a microbial community. For example, samples for use with this disclosure include, without limitation, an animal sample (e.g., mammal, reptile, bird), soil, air, water (e.g., marine, freshwater, wastewater sludge), sediment, oil, plant, agricultural product, plant, soil (e.g., rhizosphere), and an extreme environmental sample (e.g., acid mine drainage, hydrothermal systems). In the case of marine or freshwater samples, the sample can be from the surface of the water body or from any depth of the water body, for example, a sample from the seabed. The water sample, in one embodiment, is a sample from an ocean, river, or lake. Petition 870260102095, dated 02 / 10 / 2026, page 40 / 641 32 / 159

[0087] In some embodiments, the animal sample is a bodily fluid. In some embodiments, the animal sample is a tissue sample. Non-limiting animal samples include tooth, sweat, nail, skin, hair, feces, urine, semen, mucus, saliva, and the gastrointestinal tract. The animal sample may be, for example, a human, primate, bovine, porcine, canine, feline, rodent (e.g., mouse or rat), equine, or avian sample. In some embodiments, the avian sample comprises a sample from one or more chickens. In some embodiments, the sample is a human sample. The human microbiome comprises collecting microorganisms found on the surface and in the deep layers of the skin, in the mammary glands, saliva, oral mucosa, conjunctiva, and gastrointestinal tract. Microorganisms found in the microbiome include bacteria, fungi, protozoa, viruses, and archaea. Different parts of the body exhibit varying diversity of microorganisms.The quantity and type of microorganisms can indicate a state of health or disease for an individual. The number of bacterial taxa is in the thousands, and viruses can be abundant. The bacterial composition of a given site on the body varies from person to person, not only in type but also in abundance or quantity.

[0088] In another embodiment, the sample is a soil sample (e.g., bulk soil or rhizosphere sample). It is estimated that 1 gram of soil contains tens of thousands of bacterial taxa and up to 1 billion bacterial cells, as well as about 200 million fungal hyphae (Wagg et al. (2010). Proc Natl. Acad. Sci. USA 111, pp. 5266-5270, incorporated by reference in its entirety for all purposes). Bacteria, actinomycetes, fungi, algae, protozoa, and viruses are found in soil. The diversity of the soil microorganism community has been implicated in the structure and fertility of the soil microenvironment, in plant nutrient acquisition, in plant diversity and growth, as well as in the resource cycle between above- and below-soil communities.Therefore, evaluating the microbial content of a soil sample over time and the co-occurrence of active microorganisms (as well as the number of active microorganisms) provides insight into the microorganisms associated with an environmental metadata parameter, such as nutrient acquisition and / or plant diversity.

[0089] The soil sample in one embodiment is a rhizosphere sample, that is, the narrow region of soil that is directly influenced by root secretions. Petition 870260102095, dated 02 / 10 / 2026, page 41 / 641 33 / 159 and associated soil microorganisms. The rhizosphere is a densely populated area where high microbial activity has been observed, and plant roots interact with soil microorganisms through the exchange of nutrients and growth factors (San Miguel et al. (2014). Appl. Microbiol. Biotechnol. DOI 10.1007 / s00253-014-5545-6, incorporated by reference in its entirety for all purposes). Because plants secrete many compounds into the rhizosphere, analysis of the types of organisms in the rhizosphere can be useful in determining the characteristics of the plants that grow there.

[0090] In another modality, the sample is a marine or freshwater sample. Ocean water contains up to one million microorganisms per milliliter and several thousand microbial types. These numbers can be an order of magnitude higher in coastal waters with their greater productivity and higher load of organic matter and nutrients. Marine microorganisms are crucial for the functioning of marine ecosystems; maintaining the balance between carbon dioxide produced and fixed; producing more than 50% of Earth's oxygen through marine phototrophic microorganisms such as cyanobacteria, diatoms, and pico- and nanophytoplankton; providing new bioactive compounds and metabolic pathways; ensuring a sustainable supply of seafood, occupying the critical lower trophic level in marine food webs. Organisms found in the marine environment include viruses, bacteria, archaea, and some eukaryotes.Marine viruses can play a significant role in controlling marine bacterial populations through viral lysis. Marine bacteria are important as a food source for other small microorganisms, as well as being producers of organic matter. Archaea found throughout the ocean water column are pelagic Archaea, and their abundance rivals that of marine bacteria.

[0091] In another embodiment, the sample comprises a sample from an extreme environment, that is, an environment that harbors conditions that are detrimental to most life on Earth. Organisms that thrive in extreme environments are called extremophiles. Although the Archaea domain contains well-known examples of extremophiles, bacteria in the domain may also have representatives of these microorganisms. Extremophiles include: acidophiles that grow at pH levels of 3 or below; alkaliphiles that grow at pH levels of Petition 870260102095, dated 02 / 10 / 2026, p. 42 / 641 34 / 159 or above; anaerobes such as Spinoloricus Cinzia that do not require oxygen for growth; cryptoendoliths that live in microscopic spaces within rocks, fissures, aquifers, and faults filled with groundwater in the deep subsurface; halophiles that grow in a salt concentration of at least 0.2 M; hyperthermophiles that thrive in high temperatures (around 80-122 °C), such as those found in hydrothermal systems; hypoliths that live under rocks in cold deserts; lithoautotrophs such as Nitrosomonas europaea that derive energy from reduced mineral compounds such as pyrites and are active in geochemical cycles; metallotolerant organisms that tolerate high levels of dissolved heavy metals such as copper, cadmium, arsenic, and zinc; oligotrophs that grow in nutritionally limited environments; osmophiles that grow in environments with high sugar concentrations;Piezophiles (or barophiles) that thrive in high pressures, such as those found in the ocean depths or underground; psychrophiles / cryophiles that survive, grow, and / or reproduce at temperatures of about -15°C or less; radioresistant organisms that are resistant to high levels of ionizing radiation; thermophiles that thrive at temperatures between 45-122°C; xerophiles that can grow in extremely dry conditions. Polyextremophiles are organisms that qualify as extremophiles in more than one category and include thermoacidophiles (preferring temperatures of 70-80°C and pH between 2 and 3). The Crenarchaeota group of Archaea includes thermoacidophiles.

[0092] The sample may include microorganisms from one or more domains. For example, in some embodiments, the sample comprises a heterogeneous population of bacteria and / or fungi (also referred to herein as bacterial or fungal strains). For example, one or more microorganisms may be from the domain Bacteria, Archaea, Eukarya, or a combination thereof. Bacteria and Archaea are prokaryotic, possessing a very simple cellular structure without internal organelles. Bacteria can be classified as Gram-positive / without an outer membrane, Gram-negative / outer membrane present, and ungrouped phyla. Archaea constitute a domain or kingdom of unicellular microorganisms. Although visually similar to bacteria, archaea possess genes and several metabolic pathways that are more closely related to those of eukaryotes, particularly the enzymes involved in transcription and translation. Other aspects of archaeal biochemistry are unique, such as the presence of lipid ether in their Petition 870260102095, dated 02 / 10 / 2026, page 43 / 641 35 / 159 cell membranes. Archaea are divided into four recognized phyla: Thaumarchaeota, Aigarchaeota, Crenarchaeota, and Korarchaeota.

[0093] The domain Eukarya comprises eukaryotic organisms, which are defined by membrane-bound organelles, such as the nucleus. Protozoa are unicellular eukaryotic organisms. All multicellular organisms are eukaryotes, including animals, plants, and fungi. Eukaryotes have been classified into four kingdoms: Protista, Plantae, Fungi, and Animalia. However, several alternative classifications exist. Another classification divides Eukarya into six kingdoms: Excavata (various flagellated protozoa); Amoebozoa (amoeboid lobose and filamentous slime fungi); Opisthokonta (animals, fungi, choanoflagellates); Rhizaria (Foraminifera, Radiolaria, and various other amoeboid protozoa); Chromalveolata (Stramenopiles (brown algae, diatoms), Haptophyta, Cryptophyta (or cryptomonads), and Alveolata); Archaeplastida / Primoplantae (land plants, green algae, red algae and glaucophytes).

[0094] Within the domain of Eukarya, fungi are the predominant microorganisms in microbial communities. Fungi include microorganisms such as yeasts and filamentous fungi, as well as the familiar mushrooms. Fungal cells have cell walls that contain glucans and chitin, a unique characteristic of these organisms. Fungi form a single group of related organisms, called Eumycota, that share a common ancestor. The kingdom Fungi has been estimated at 1.5 million to 5 million species, with about 5% of them formally classified. The cells of most fungi grow as elongated, filamentous, tubular structures called hyphae, which may contain multiple nuclei. Some species grow as single-celled yeasts that reproduce by budding or binary fission. The major phyla (sometimes called divisions) of fungi have been classified primarily based on the characteristics of their sexual reproductive structures.Currently, seven phyla are proposed: Microsporidia, Chytridiomycota, Blastocladiomycota, ... Neocallimastigomycota, Glomeromycota, Ascomycota and Basidiomycota.

[0095] The microorganisms for detection and quantification by the methods described in this document may also be viruses. A virus is a small infectious agent that replicates only within the living cells of other organisms. Viruses can infect all types of life forms in the Eukaryotes, Petition 870260102095, dated 02 / 10 / 2026, page 44 / 641 36 / 159 Bacteria and Archaea. Virus particles (known as virions) consist of two or three parts: (i) genetic material, which can be DNA or RNA; (ii) a protein coat that protects these genes; and in some cases (iii) a lipid envelope that surrounds the protein coat when they are outside a cell. Seven orders have been established for viruses: Caudovirales, Herpesvirales, Ligamenvirales, Mononegavirales, Nidovirales, Picornavirales, and Tymovirales. Viral genomes can be single-stranded (ss) or double-stranded (ds), RNA or DNA, and may or may not use reverse transcriptase (RT). Furthermore, ssRNA viruses can be sense (+) or antisense (-).This classification categorizes viruses into seven groups: I: dsDNA viruses (such as Adenovirus, Herpesvirus, Poxvirus); II: (+) ssDNA viruses (such as Parvovirus); III: dsRNA viruses (such as Reovirus); IV: (+) ssRNA viruses (such as Picornavirus, Togavirus); V: (-) ssRNA viruses (such as Orthomyxoviruses, Rhabdoviruses); VI: (+) ssRNA-RT viruses with DNA intermediates in the life cycle (such as Retroviruses); VII: dsDNA-RT viruses (such as Hepadnaviruses).

[0096] The microorganisms for detection and quantification by the methods described in this document may also be viroids. Viroids are the smallest known infectious pathogens, consisting solely of short strands of single-stranded circular RNA without protein coats. They are primarily phytopathogens, some of which are of economic importance. Viroid genomes are extremely small in size, ranging from about 246 to about 467 nucleobases. Isolated microbes

[0097] As used in this document, isolate, isolated, isolated microbe, and similar terms mean that one or more microorganisms have been separated from at least one of the materials to which it is associated in a specific environment (e.g., soil, water, animal tissue). Thus, an isolated microbe does not exist in its natural environment; rather, it is through the various techniques described in this document that the microbe has been removed from its natural environment and placed in a state of existence that does not occur naturally. Thus, the isolated strain may exist as, for example, a biologically pure culture, or as spores (or other forms of the strain) in association with an acceptable carrier.

[0098] In certain forms of dissemination, isolated microbes exist Petition 870260102095, dated 02 / 10 / 2026, p. 45 / 641 37 / 159 as isolated and biologically pure cultures. It will be appreciated by one skilled in the art that an isolated and biologically pure culture of a particular microbe denotes that said culture is substantially free (within scientific reason) of other living organisms and contains only the individual microbe in question. The culture may contain varying concentrations of said microbe. The present disclosure notes that isolated and biologically pure microbes generally differ necessarily from less pure or impure materials. See, for example, In re Bergstrom, 427 F.2d 1394, (CCPA 1970) (discussing purified prostaglandins), see also In re Bergy, 596 F.2d 952 (CCPA 1979) (discussing purified microbes), see also, Parke-Davis & Co. v. HK Mulford & Co., 189 F. 95 (SDNY 1911) (Learned Hand discussing purified adrenaline), published in part, revised in part, 196 F. 496 (2nd Cir. 1912), each of which is incorporated herein by reference.Furthermore, in some respects, the disclosure provides certain quantitative measures of concentration, or purity limitations, that must be found within an isolated and biologically pure microbial culture. The presence of these purity values, in certain embodiments, is another attribute that distinguishes presently disclosed microbes from microbes existing in a natural state. See, for example, Merck & Co. v. Olin Mathieson Chemical Corp., 253 F.2d 156 (4th Cir. 1958) (discussing purity limitations for vitamin B12 produced by microbes), incorporated herein by reference.

[0099] In some embodiments, this disclosure provides microbial compositions comprising isolated microbial species belonging to the taxonomic families Actinomycetaceae, Acidaminococcaceae, Bacteroidaceae, Burkholderiaceae, Catabacteriaceae, Christensenellaceae, Clostridiaceae, Clostridiales Incertae Sedis XI, Clostridiales Incertae Sedis XIII, Corynebacteriaceae, Cyclobacteriaceae, Enterobacteriaceae, Erysipelotrichaceae, Eubacteriaceae, Flavobacteriaceae, Lactobacillaceae, Lachnospiraceae, Hyphomicrobiaceae, Peptoniphilaceae, Peptococcaceae, Peptostreptococcaceae, Porphyromonadaceae, Prevotellaceae, Rikenellaceae, Ruminococcaceae, Sphingobacteriaceae, Spiroplasmataceae, Streptococcaceae, Sutterellaceae, and Veillonellaceae.

[00100] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Arcanobacterium of the family Actinomycetaceae. Petition 870260102095, dated 02 / 10 / 2026, p. 46 / 641 38 / 159

[00101] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Acidaminococcaceae, including Acidaminococcus and Phascolarctobacterium.

[00102] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Bacteroides of the family Bacteroidaceae.

[00103] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Sutterella of the family Burkholderiaceae.

[00104] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Sutterellaceae, including Sutterella and Duodenibacillus.

[00105] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Catabacter of the family Catabacteriaceae.

[00106] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Christensenella of the family Christensenellaceae.

[00107] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the Clostridiaceae family, including Clostridium and Clostridium sensu stricto.

[00108] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Clostridiales Incertae Sedis XI, including Anaerococcus, Finegoldia, Parvimonas and Helcococcus.

[00109] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Clostridiales Incertae Sedis XIII, including Anaerovorax, Ihubacter, and Mogibacterium.

[00110] In some forms, this disclosure provides compositions Petition 870260102095, dated 02 / 10 / 2026, p. 47 / 641 39 / 159 microbial species comprising microbial species isolated from the genus Corynebacterium of the family Corynebacteriaceae.

[00111] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the Cyclobacteriaceae family, including Algoriphagus, Cecembia and Flavobacterium.

[00112] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the Enterobacteriaceae family, including Atlantibacter, Escherichia and Shigella.

[00113] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Erysipelothrix of the family Erysipelothrichaceae.

[00114] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Spiroplasma of the family Spiroplasmataceae.

[00115] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Eubacterium of the family Eubacteriaceae.

[00116] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Flavobacterium of the family Flavobacteriaceae.

[00117] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Hyphomicrobiaceae, including Devosia and Maritalea.

[00118] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Lachnospiraceae, including Anaerocolumna, Anaerostipes, Butyrivibrio, Coprococcus, Cellulosilyticum, Clostridium XlVa, Frisingicoccus, Howardella and Oribacterium.

[00119] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Petition 870260102095, dated 02 / 10 / 2026, p. 48 / 641 40 / 159 Pediococcus from the Lactobacillaceae family.

[00120] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Peptococcus of the family Peptococcaceae.

[00121] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Peptoniphilus of the family Peptoniphilaceae.

[00122] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Peptostreptococcaceae, including Terrisporobacter and Peptostreptococcus.

[00123] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Porphyromonadaceae, including Barnesiella, Butyricimonas, Parabacteroides, Porphyromonas, Prevotella and Odoribacter.

[00124] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Prevotellaceae, including Alloprevotella, Bacteroides and Prevotella.

[00125] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Rikenellaceae, including Anaerocella and Alistipes.

[00126] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Ruminococcaceae, including Oscillibacter, Clostridium III, Intestinimonas, Ruminiclostridium and Monoglobus.

[00127] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Pedobacter of the family Sphingobacteriaceae.

[00128] In some embodiments, this disclosure provides microbial compositions comprising microbial species isolated from the genus Streptococcus of the family Streptococcaceae. Petition 870260102095, dated 02 / 10 / 2026, p. 49 / 641 41 / 159

[00129] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from genera of the family Veillonellaceae, including Schwartzia, Selenomonas, Phascolarctobacterium and Negativicoccus.

[00130] In some embodiments, this disclosure provides microbial compositions comprising selected isolated microbial species from the genera of: Clostridium, Sarcina, Streptococcus, Escherichia, Atlantibacter and Shigella.

[00131] In some embodiments, the microbial strains isolated in the compositions described in this document have been genetically modified. In some embodiments, the genetically modified or recombinant microbes comprise polynucleotide sequences that do not occur naturally in said microbes. In some embodiments, the microbes may comprise heterologous polynucleotides. In other embodiments, the heterologous polynucleotides may be operationally linked to one or more polynucleotides native to the microbes.

[00132] In some embodiments, heterologous polynucleotides can be reporter genes or selectable markers. In some embodiments, reporter genes can be selected from any family of fluorescent proteins (e.g., GFP, RFP, YFP, and the like), β-galactosidase, or luciferase. In some embodiments, selectable markers can be selected from: neomycin phosphotransferase, hygromycin phosphotransferase, aminoglycoside adenyltransferase, dihydrofolate reductase, acetolactase synthase, bromoxynil nitrilase, β-glucuronidase, dihydrogolate reductase, and chloramphenicol acetyltransferase. In some embodiments, the heterologous polynucleotide can be operationally linked to one or more promoters.

[00133] In some modalities, isolated microbes are identified by ribosomal nucleic acid sequences. Ribosomal RNA (rDNA) genes, especially small subunit ribosomal RNA genes, i.e., 18S rRNA (18S rDNA) genes in the case of eukaryotes and 16S rRNA (16S rDNA) genes in the case of prokaryotes, have been the predominant target for assessing organism types and lineages in a microbial community. However, large subunit ribosomal RNA genes, 28S rDNAs, have also been targeted. The rDNAs Petition 870260102095, dated 02 / 10 / 2026, p. 50 / 641 42 / 159 are suitable for taxonomic identification because: (i) they are ubiquitous in all known organisms; (ii) they possess both conserved and variable regions; (iii) there is an exponentially expanding database of their sequences available for comparison. In community sample analysis, conserved regions serve as annealing sites for corresponding universal PCR and / or sequencing primers, while variable regions can be used for phylogenetic differentiation. Furthermore, the high copy number of rDNA in cells facilitates the detection of environmental samples.

[00134] The internal transcribed spacer (ITS), located between 18S rDNA and 28S rDNA, was also targeted. The ITS is transcribed but spliced ​​before ribosome assembly. The ITS region is composed of two highly variable spacers, ITS1 and ITS2, and the 5.8S intercalary gene. This rDNA operon occurs in multiple copies across genomes. Since the ITS region does not encode ribosomal components, it is highly variable. In some embodiments, the unique RNA marker may be an mRNA marker, an siRNA marker, or a ribosomal RNA marker.

[00135] The primary structure of the main 16S rRNA subunit comprises a particular combination of conserved, variable, and hypervariable regions that evolve at different rates and allow the resolution of very ancient lineages, such as domains, and more modern lineages, such as genera. The secondary structure of the 16S subunit includes approximately 50 helices that result in base pairing of about 67% of the residues. These highly conserved secondary structural features are of great functional importance and can be used to ensure positional homology in various sequence alignments and phylogenetic analyses. In previous decades, the 16S rRNA gene has become the most sequenced taxonomic marker and is the basis of the current systematic classification of bacteria and archaea (Yarza et al. 2014. Nature Rev. Micro. 12:635-45).

[00136] In some embodiments, sequence identity of 94.5% or less for two 16S rRNA genes is strong evidence for distinct genera, 86.5% or less is strong evidence for distinct families, 82% or less is strong evidence for distinct orders, 78.5% is strong evidence for distinct classes, and 75% or less is strong evidence for distinct phyla. Comparative analysis of 16S gene sequences Petition 870260102095, dated 02 / 10 / 2026, page 51 / 641 43 / 159 rRNA allows the establishment of useful taxonomic thresholds not only for the classification of cultured microorganisms, but also for the classification of various environmental sequences. (Yarza et al. 2014. Nature Rev. Micro. 12:635-45).

[00137] Exemplary isolated microbes for use in accordance with this disclosure are provided below in Table 2. The designation of a strain with the identifier Ascus followed by a letter (e.g., AscusEQ_4A, AscusEQ_4B, AscusEQ_4C, etc.) indicates that these strains are variants of the parental strain with the corresponding Ascus identifier. For example, AscusEQ_4A, AscusEQ_4B, AscusEQ_4C, etc. are all variants of the parental strain AscusEQ_4. Each variant strain shares at least 97% sequence identity with the parental strain. Petition 870260102095, dated 02 / 10 / 2026, page 52 / 641 44 / 159 Table 2: Example Isolated Microbes Strain designation MIC Predicted taxonomy (Utax) Predicted taxonomy (BLAST) % Identity for BLAST taxonomic hit % Identity to parent strain SEQ ID: AscusEQ_0 0.99885 Arcanobacterium hippocoleae Arcanobacterium hippocolea 95 1 AscusEQ_1 0.99885 Anaerovorax odorimutans Ihubacter massiliensis 90.73 2 AscusEQ_2 0.99885 Peptoniphilus indolicus Peptoniphilus asaccharolyticus 91.95 3 AscusEQ_3 0.99885 Anaerococcus octavius ​​Anaerococcus vaginalis 89.37 4 AscusEQ_4 0.99885 Clostridium butyricum Clostridium butyricum 99.67 5 AscusEQ_4A Clostridium butyricum Clostridium butyricum 97.3 6 AscusEQ_4B Clostridium butyricum Clostridium butyricum 98.7 7 AscusEQ_4C Clostridium butyricum Clostridium butyricum 99,1 8 AscusEQ_4D Clostridium butyricum Clostridium butyricum 99,6 9 AscusEQ_4E Clostridium butyricum Clostridium butyricum 98,2 10 Ascus EQ_4F Clostridium butyricum Clostridium butyricum 100 11 AscusEQ_4G Clostridium butyricum Clostridium butyricum 97,8 12 AscusEQ_4H Clostridium butyricum Clostridium butyricum 97.4 13, Petition 870260102095, dated 02 / 10 / 2026, page 53 / 641 45 / 159 AscusEQ_5 0.99885 Terrisporobacter mayombei Terrisporobacter mayombei 97.66 14 AscusEQ_5A Terrisporobacter mayombei Terrisporobacter mayombei 98.2 15 AscusEQ_5B Terrisporobacter mayombei Terrisporobacter mayombei 98.7 16 AscusEQ_5C Terrisporobacter mayombei Terrisporobacter mayombei 99.6 17 AscusEQ_5D Terrisporobacter mayombei Terrisporobacter mayombei 97.3 18 AscusEQ_7 0.91885 Mogibacterium neglectum Mogibacterium pumilum 91.06 19 AscusEQ_7A Mogibacterium neglectum Mogibacterium pumilum 99.1 20 AscusEQ_7B Mogibacterium neglectum Mogibacterium pumilum 97.3 21 AscusEQ_7C Mogibacterium neglectum Mogibacterium pumilum 98.2 22 AscusEQ_7D Mogibacterium neglectum Mogibacterium pumilum 97.8 23 AscusEQ_8 0.84284 Arcanobacterium phocae Arcanobacterium phocae 97.37 24 AscusEQ_9 0.83885 Christensenella minuta Catabacter hongkongensis 85.81 25 AscusEQ_9A Christensenella minuta Catabacter hongkongensis 99.1 26 AscusEQ_10 0.83885 Parabacteroides merdae Parabacteroides distasonis 97 27 AscusEQ_11 0.83318 Finegoldia magna Finegoldia magna 99.33 28 AscusEQ_12 0.82490 Clostridium baratii Clostridium nitritogenes 98.67 29, Petition 870260102095, dated 02 / 10 / 2026, p. 54 / 641 46 / 159 AscusEQ_12A Clostridium baratii Clostridium nitritogenes 100 30 AscusEQ_12B Clostridium baratii Clostridium nitritogenes 99.6 31 AscusEQ_12C Clostridium baratii Clostridium nitritogenes 99.1 32 AscusEQ_12D Clostridium baratii Clostridium nitritogenes 97.8 33 AscusEQ_12E Clostridium baratii Clostridium nitritogenes 98.7 34 AscusEQ_12F Clostridium baratii Clostridium nitritogenes 97.3 35 AscusEQ_12G Clostridium baratii Clostridium nitritogenes 98.2 36 AscusEQ_13 0.81767 Corynebacterium pyruviciproducens Corynebacterium glaucum 94.3 37 AscusEQ_14 0.80865 Clostridium xylanovorans Oribacterium sp. 87.21 38 AscusEQ_14A Clostridium xylanovorans Oribacterium sp. 99.1 39 AscusEQ_14B Clostridium xylanovorans Oribacterium sp.99,6 40 AscusEQ_15 0,80865 Clostridium symbiosum Lachnospiraceae bacterium 96,32 41 AscusEQ_15A Clostridium symbiosum Lachnospiraceae bacterium 99,6 42 AscusEQ_15B Clostridium symbiosum Lachnospiraceae bacterium 98,2 43 AscusEQ_15C Clostridium symbiosum Lachnospiraceae bacterium 98,7 44 AscusEQ_15D Clostridium symbiosum Lachnospiraceae bacterium 97,3 45 AscusEQ_15E Clostridium symbiosum Lachnospiraceae bacterium 100 46. Petição 870260102095, de 02 / 10 / 2026, pág. 55 / 641 47 / 159 AscusEQ_16 0.80865 Eubacterium hadrum Lachnospiraceae bacterium 92.69 47 AscusEQ_16A Eubacterium hadrum Lachnospiraceae bacterium 98.7 48 AscusEQ_16B Eubacterium hadrum Lachnospiraceae bacterium 99.6 49 AscusEQ_16C Eubacterium hadrum Lachnospiraceae bacterium 100 50 AscusEQ_16D Eubacterium hadrum Lachnospiraceae bacterium 99.1 51 AscusEQ_17 0.75885 Parabacteroides chinchillae Odoribacter splanchnicus 80.58 52 AscusEQ_17A Parabacteroides chinchillae Odoribacter splanchnicus 97.3 53 AscusEQ_17B Parabacteroides chinchillae Odoribacter splanchnicus 98.2 54 AscusEQ_17C Parabacteroides chinchillae Odoribacter splanchnicus 99.1 55 AscusEQ_17D Parabacteroides chinchillae Odoribacter splanchnicus 99.6 56 AscusEQ_17E Parabacteroides chinchillae Odoribacter splanchnicus 98.7 57 AscusEQ_17F Parabacteroides chinchillae Odoribacter splanchnicus 100 58 AscusEQ_18 0.75717 Bacteroides thetaiotaomicron Bacteroides thetaiotaomicron 99.67 59 AscusEQ_19 0.73924 Peptoniphilus coxii Peptoniphilus sp.86.29 60 AscusEQ_20 0.72865 Intestinimonas butyriciproducens Intestinimonas butyriciproducens 99.67 61 AscusEQ_21 0.72547 Terrisporobacter glycolicus Terrisporobacter glycolicus 98.33 62. Petition 870260102095, dated 02 / 10 / 2026, p. 56 / 641 48 / 159 Ascus EQ_2 ΊΑ Terrisporobacter glycolicus Terrisporobacter glycolicus 97.3 63 Ascus EQ_21 B Terrisporobacter glycolicus Terrisporobacter glycolicus 99.1 64 Ascus EQ_21C Terrisporobacter glycolicus Terrisporobacter glycolicus 100 65 Ascus EQ_21 D Terrisporobacter glycolicus Terrisporobacter glycolicus 97.8 66 Ascus EQ_21 E Terrisporobacter glycolicus Terrisporobacter glycolicus 98.2 67 Ascus EQ_21 F Terrisporobacter glycolicus Terrisporobacter glycolicus 98.7 68 Ascus EQ_21G Terrisporobacter glycolicus Terrisporobacter glycolicus 99.6 69 AscusEQ_22 0.72373 Porphyromonas somerae Porphyromonas canoris 87 70 AscusEQ_23 0.72373 Peptococcus niger Peptococcus sp.86,6 71 AscusEQ_24 0,70904 Eubacterium barkeri Eubacterium barkeri 92,08 72 Ascus EQ24A Eubacterium barkeri Eubacterium barkeri 97,8 73 Ascus EQ_24B Eubacterium barkeri Eubacterium barkeri 99,6 74 AscusEQ_24C Eubacterium barkeri Eubacterium barkeri 99,1 75 Ascus EQ_24D Eubacterium barkeri Eubacterium barkeri 100 76 AscusEQ_32 0,69845 Coprococcus eutactus Lachnospiraceae bacterium 95 77 Ascus EQ_32A Coprococcus eutactus Lachnospiraceae bacterium 100 78. Petição 870260102095, de 02 / 10 / 2026, pág. 57 / 641 49 / 159 AscusEQ_26 0.68284 Clostridium alkalicellulosi Monoglobus pectinolyticus 84.11 79 AscusEQ_31 0.64865 Cellulosilyticum ruminicola Cellulosilyticum ruminicola 99.33 80 AscusEQ_31A Cellulosilyticum ruminicola Cellulosilyticum ruminicola 99.1 81 Ascus EQ_31 B Cellulosilyticum ruminicola Cellulosilyticum ruminicola 98.7 82 Ascus EQ_31C Cellulosilyticum ruminicola Cellulosilyticum ruminicola 97.8 83 Ascus EQ_31 D Cellulosilyticum ruminicola Cellulosilyticum ruminicola 98.2 84 AscusEQ_28 0.64865 Schwartzia succinivorans Erysipelotrichacea e bacterium 82.12 85 Ascus EQ_28A Schwartzia succinivorans Erysipelotrichacea e bacterium 97,3 86 Ascus EQ_28B Schwartzia succinivorans Erysipelotrichacea e bacterium 98,7 87 AscusEQ_28C Schwartzia succinivorans Erysipelotrichacea e bacterium 100 88 AscusEQ_28D Schwartzia succinivorans Erysipelotrichacea e bacterium 99,1 89 Ascus EQ_28E Schwartzia succinivorans Erysipelotrichacea e bacterium 982 90 Ascus EQ_28F Schwartzia succinivorans Erysipelotrichacea and bacterium 99.6 91 AscusEQ_28G Schwartzia succinivorans Erysipelotrichacea and bacterium 97.8 92 AscusEQ_29 0.64865 Howardella ureilytica Howardella ureilytica 86.84 93 Ascus EQ_29A Howardella ureilytica Howardella ureilytica 99.6 94, Petition 870260102095, dated 02 / 10 / 2026, p. 58 / 641 50 / 159 Ascus EQ_29B Howardella ureilytica Howardella ureilytica 100 95 AscusEQ_30 0.64633 Negativicoccus succinicivorans Negativicoccus massiliensis 88 96 AscusEQ_33 0.64298 Clostridium lava lense Butyrivibrio fibrisolvens 86.56 97 AscusEQ_33A Clostridium lava lense Butyrivibrio fibrisolvens 100 98 AscusEQ_33B Clostridium lava lense Butyrivibrio fibrisolvens 98.2 99 AscusEQ_33C Clostridium lava lense Butyrivibrio fibrisolvens 98.7 100 AscusEQ_33D Clostridium lava lense Butyrivibrio fibrisolvens 99.1 101 AscusEQ_33E Clostridium lava lense Butyrivibrio fibrisolvens 99.6 102 AscusEQ_34 0.64206 Peptostreptococcus anaerobius Peptostreptococcus anaerobius 95,39 103 AscusEQ_35 0,62904 Clostridium fimetarium Lachnospiraceae bacterium 92,72 104 Ascus EQ_35A Clostridium fimetarium Lachnospiraceae bacterium 99,1 105 Ascus EQ_35B Clostridium fimetarium Lachnospiraceae bacterium 99,6 106 AscusEQ_35C Clostridium fimetarium Lachnospiraceae bacterium 100 107 AscusEQ_35D Clostridium fimetarium Lachnospiraceae bacterium 98.7 108 Ascus EQ_35E Clostridium fimetarium Lachnospiraceae bacterium 98.2 109 AscusEQ_36 0.61446 Oral lacnoanaerobaculum Anaerocolumna sp. 87,54 110 Petition 870260102095, dated 02 / 10 / 2026, p. 59 / 641 51 / 159 AscusEQ_37 0.61343 Ruminococcus gnavus Frisingicoccus caecimuris 93.02 111 AscusEQ_37A Ruminococcus gnavus Frisingicoccus caecimuris 98.2 112 AscusEQ_37B Ruminococcus gnavus Frisingicoccus caecimuris 97.4 113 AscusEQ_37C Ruminococcus gnavus Frisingicoccus caecimuris 99.6 114 AscusEQ_37D Ruminococcus gnavus Frisingicoccus caecimuris 99.1 115 AscusEQ_37E Ruminococcus gnavus Frisingicoccus caecimuris 98.7 116 AscusEQ_37F Ruminococcus gnavus Frisingicoccus caecimuris 100 117 AscusEQ_37G Ruminococcus gnavus Frisingicoccus caecimuris 97.3 118 AscusEQ_37H Ruminococcus gnavus Frisingicoccus caecimuris 97.8 119 AscusEQ_38 0.61279 Catabacter hongkongensis Ruminiclostridium thermocellum 84.19 120 Ascus EQ_38A Catabacter hongkongensis Ruminiclostridium thermocellum 97.3 121 AscusEQ_39 0.57924 Erysipelothrix tonsillarum Spiroplasma sp. 81.46 122 Ascus EQ_39A Erysipelothrix tonsillarum Spiroplasma sp.98.2 123 AscusEQ_62 0.35661 Finegoldia magna Finegoldia magna 99.67 124 AscusEQ_130 0.31894 Parabacteroides merdae Algoriphagus ratkowskyi 83.17 125 AscusEQ_1 Parabacteroides merdae Algoriphagus ratkowskyi 97.3 126 AscusEQ_130B Parabacteroides merdae Algoriphagus ratkowskyi 100 127. Petition 870260102095, of 02 / 10 / 2026, p. 60 / 641 52 / 159 AscusEQ_130C Parabacteroides merdae Algoriphagus ratkowskyi 99.6 128 AscusEQ_130D Parabacteroides merdae Algoriphagus ratkowskyi 98.7 129 AscusEQ_130E Parabacteroides merdae Algoriphagus ratkowskyi 97.8 130 AscusEQ_130F Parabacteroides merdae Algoriphagus ratkowskyi 99,1 131 AscusEQ_130G Parabacteroides merdae Algoriphagus ratkowskyi 98,2 132 AscusEQ_344 0,31222 Parabacteroides merdae Prevote lia copri 82,7 133 Ascus EQ 344A Parabacteroides merdae Prevote lia copri 100 134 Ascus EQ_344B Parabacteroides merdae Prevotella copri 97.8 135 AscusEQ_344C Parabacteroides merdae Prevotella copri 98.2 136 AscusEQ_344D Parabacteroides merdae Prevotella copri 99.1 137 Ascus EQ 344E Parabacteroides merdae Prevotella copri 97.3 138 Ascus EQ_344F Parabacteroides merdae Prevotella copri 99.6 139 AscusEQ_344G Parabacteroides merdae Prevotella copri 98.7 140 AscusEQ_140 0.30829 Streptococcus infantarius subsp. coli Streptococcus equinus 99.67 141 AscusEQ_140A Streptococcus infantarius subsp.coli Streptococcus equinus 100 142 AscusEQ_140B Streptococcus infantarius subsp. coli Streptococcus equinus 97.8 143 AscusEQ_140C Streptococcus infantarius subsp. coli Streptococcus equinus 98.2 144 AscusEQ_140D Streptococcus infantarius subsp. coli Streptococcus equinus 99.1 145 AscusEQ_140E Streptococcus infantarius subsp. coli Streptococcus equinus 97.3 146. Petition 870260102095, dated 02 / 10 / 2026, p. 61 / 641 53 / 159 AscusEQ_140F Streptococcus infantarius subsp. coli Streptococcus equinus 99.6 147 AscusEQ_140G Streptococcus infantarius subsp. coli Streptococcus equinus 98.7 148 AscusEQ_484 0.30764 Parabacteroides merdae Prevotella copri 82.39 149 Ascus EQ 484A Parabacteroides merdae Prevotella copri 97.3 150 Ascus EQ_484B Parabacteroides merdae Prevotella copri 99.1 151 AscusEQ_484C Parabacteroides merdae Prevotella copri 98.7 152 AscusEQ_484D Parabacteroides merdae Prevotella copri 99.6 153 Ascus EQ 484E Parabacteroides merdae Prevotella copri 97.8 154 Ascus EQ_484F Parabacteroides merdae Prevotella copri 100 155 AscusEQ_484G Parabacteroides merdae Prevotella copri 98.2 156 AscusEQ_1187 0.29874 Sutterella stercoricanis Duodenibacillus massiliensis 93.36 157 AscusEQ_1187 A Sutterella stercoricanis Duodenibacillus massiliensis 99.1 158 AscusEQ_1187 B Sutterella stercoricanis Duodenibacillus massiliensis 100 159 AscusEQ_1187 C Sutterella stercoricanis Duodenibacillus massiliensis 98.2 160 AscusEQ_1187 D Sutterella stercoricanis Duodenibacillus massiliensis 99.6 161 AscusEQ_200 0.29193 Pedobacter bauzanensis Bacteroidales bacterium 88.08 162 Ascus EQ_200A Pedobacter bauzanensis Bacteroidales bacterium 98.7 163 Ascus EQ_200B Pedobacter bauzanensis Bacteroidales bacterium 100 164 AscusEQ_200C Pedobacter bauzanensis Bacteroidales bacterium 99.6 165, Petition 870260102095, dated 02 / 10 / 2026, p. 62 / 641 54 / 159 AscusEQ_200D Pedobacter bauzanensis Bacteroidales bacterium 99,1 166 Ascus EQ_200E Pedobacter bauzanensis Bacteroidales bacterium 97,3 167 Ascus EQ_200F Pedobacter bauzanensis Bacteroidales bacterium 97,8 168 AscusEQ_200G Pedobacter bauzanensis Bacteroidales bacterium 98,2 169 AscusEQ_183 0,27773 Pedobacter bauzanensis Bacteroidia bacterium 85,62 170 AscusEQ_183A Pedobacter bauzanensis Bacteroidia bacterium 100 171 AscusEQ_183B Pedobacter bauzanensis Bacteroidia bacterium 99,1 172 AscusEQ_183C Pedobacter bauzanensis Bacteroidia bacterium 98,2 173 AscusEQ_183D Pedobacter bauzanensis Bacteroidia bacterium 97,3 174 AscusEQ_183E Pedobacter bauzanensis Bacteroidia bacterium 97,8 175 AscusEQ_183F Pedobacter bauzanensis Bacteroidia bacterium 98,7 176 AscusEQ_183G Pedobacter bauzanensis Bacteroidia bacterium 99,6 177 AscusEQ_226 0,27722 Prevotella bryantii Cecembia lonarensis 83,71 178 Ascus EQ 226A Prevotella bryantii Cecembia lonarensis 97,3 179 Ascus EQ_226B Prevotella bryantii Cecembia lonarensis 99.6 180 AscusEQ_226C Prevotella bryantii Cecembia lonarensis 98.2 181, Petition 870260102095, dated 02 / 10 / 2026, pp. 63 / 641 55 / 159 AscusEQ_226D Prevotella briantii Cecembia lonarensis 97.8 182 Ascus EQ_226E Prevotella briantii Cecembia lonarensis 98.7 183 Ascus EQ_226F Prevotella briantii Cecembia lonarensis 100 184 AscusEQ_226G Prevotella bryantii Cecembia lonarensis 99.1 185 AscusEQ_369 0.27637 Tea alistipes Bacteroidea bacterium 85.33 186 Ascus EQ_369A Tea alistipes Bacteroidea bacterium 99.1 187 Ascus EQ_369B Tea alistipes Bacteroidea bacterium bacterium 97.3 188 AscusEQ_369C Alistipes shahii Bacteroidia bacterium 100 189 AscusEQ_369D Alistipes shahii Bacteroidia bacterium 98.2 190 Ascus EQ_369E Alistipes shahii Bacteroidea bacterium 99.6 191 Ascus EQ_369F Alistipes shahii Bacteroidia bacterium 97.8 192 AscusEQ_369G Alistipes shahii Bacteroidia bacterium 98.7 193 AscusEQ_820 0.2734 Pedobacter bauzanensis Bacteroidales bacterium 88.93 194 Ascus EQ_820A Pedobacter bauzanensis Bacteroides bacterium 97.8 195 Ascus EQ_820B Pedobacter bauzanensis Bacteroides bacterium 99.8 .1 196 AscusEQ_820C Pedobacter bauzanensis Bacteroidales bacterium 100 197, Petition 870260102095, dated 02 / 10 / 2026, pp. 64 / 641 56 / 159 AscusEQ_820D Pedobacter bauzanensis Bacteroidales bacterium 98.7 198 Ascus EQ_820E Pedobacter bauzanensis Bacteroidales bacterium 99.6 199 AscusEQ_253 0.25933 Sarcina maxima Clostridium maximum 99.64 200 AscusEQ_253A Sarcina maxima Clostridium maximum 97.3 201 AscusEQ_253B Sarcina maxima Clostridium maximum 98.2 202 AscusEQ_253C Sarcina maxima Clostridium maximum 97.8 203 AscusEQ_253D Sarcina maxima Clostridium maximum 99.6 204 AscusEQ_253E Sarcina maxima Clostridium maximum 98.7 205 AscusEQ_253F Sarcina maxima Clostridium maximum 100 206 AscusEQ_253G Sarcina maxima Clostridium maximum 99.1 207 AscusEQ_111 0.25846 Finegoldia magna Finegoldia magna 99.33 208 AscusEQ_126 0.25749 Pedobacter bauzanensis Bacteroidales bacterium 86.09 209 AscusEQ_126A Pedobacter bauzanensis Bacteroidales bacterium 99.6 210 AscusEQ_126B Pedobacter bauzanensis Bacteroidales bacterium 98,7 211 AscusEQ_126C Pedobacter bauzanensis Bacteroidales bacterium 97,8 212 AscusEQ_126D Pedobacter bauzanensis Bacteroidales bacterium 97.3 213, Petition 870260102095, dated 02 / 10 / 2026, pp. 65 / 641 57 / 159 AscusEQ_126E Pedobacter bauzanensis Bacteroidales bacterium 99,1 214 AscusEQ_126F Pedobacter bauzanensis Bacteroidales bacterium 98,2 215 AscusEQ_126G Pedobacter bauzanensis Bacteroidales bacterium 100 216 AscusEQ_1029 0,25642 Butyricimonas paravirosa Bacteroidales bacterium 88,22 217 AscusEQ_1029 A Butyricimonas paravirosa Bacteroidales bacterium 99,1 218 AscusEQ_1029 B Butyricimonas paravirosa Bacteroidales bacterium 100 219 AscusEQ 1029 C Butyricimonas paravirosa Bacteroidales bacterium 99,6 220 AscusEQ_980 0,25083 Pedobacter bauzanensis Bacteroidales bacterium 85,76 222 Ascus EQ_980A Pedobacter bauzanensis Bacteroidales bacterium 99,1 223 Ascus EQ_980B Pedobacter bauzanensis Bacteroidales bacterium 98,2 224 AscusEQ_980C Pedobacter bauzanensis Bacteroidales bacterium 97,3 225 AscusEQ_980D Pedobacter bauzanensis Bacteroidales bacterium 99,6 226 Ascus EQ_980E Pedobacter bauzanensis Bacteroidales bacterium 97,8 227 Ascus EQ_980F Pedobacter bauzanensis Bacteroidales bacterium 98,7 228 AscusEQ_1166 0.24945 Pedobacter bauzanensis Bacteroidia bacterium 88.7 229 AscusEQ_1166 A Pedobacter bauzanensis Bacteroidia bacterium 97.3 230, Petition 870260102095, dated 02 / 10 / 2026, p. 66 / 641 58 / 159 AscusEQ_1166 B Pedobacter bauzanensis Bacteroidia bacterium 100 231 AscusEQ_1166 C Pedobacter bauzanensis Bacteroidia bacterium 98,2 232 AscusEQ_1166 D Pedobacter bauzanensis Bacteroidia bacterium 97,8 233 AscusEQ_1166 E Pedobacter bauzanensis Bacteroidia bacterium 99,6 234 AscusEQ_1166 F Pedobacter bauzanensis Bacteroidia bacterium 98,7 235 AscusEQ_1166 G Pedobacter bauzanensis Bacteroidia bacterium 99,1 236 AscusEQ_105 0,24427 Selenomonas sputigena Acidaminococcus sp. 88,89 237 AscusEQ_105A Selenomonas sputigena Acidaminococcus sp. 97,3 238 AscusEQ_105B Selenomonas sputigena Acidaminococcus sp. 100 239 AscusEQ_105C Selenomonas sputigena Acidaminococcus sp. 98,7 240 AscusEQ_105D Selenomonas sputigena Acidaminococcus sp. 99,1 241 AscusEQ_105E Selenomonas sputigena Acidaminococcus sp. 99,6 242 AscusEQ_105F Selenomonas sputigena Acidaminococcus sp. 97,8 243 AscusEQ_105G Selenomonas sputigena Acidaminococcus sp.98.2 244 AscusEQ_145 0.24394 Butyricimonas paravirosa Bacteroidales bacterium 88.63 245 AscusEQ_145A Butyricimonas paravirosa Bacteroidales bacterium 99.1 246. Petition 870260102095, dated 02 / 10 / 2026, p. 67 / 641 59 / 159 AscusEQ_145B Butyricimonas paravirosa Bacteroidales bacterium 100 247 AscusEQ_145C Butyricimonas paravirosa Bacteroidales bacterium 99.6 248 AscusEQ_128 0.24327 Streptococcus orisasini Streptococcus orisasini 94.37 249 AscusEQ_669 0.23805 Prevotella brevis Bacteroides graminisolvens 83.33 250 Ascus EQ_669A Prevotella brevis Bacteroides graminisolvens 100 251 Ascus EQ_669B Prevotella brevis Bacteroides graminisolvens 97.3 252 AscusEQ_669C Prevotella brevis Bacteroides graminisolvens 98.7 253 AscusEQ_669D Prevotella brevis Bacteroides graminisolvens 98.2 254 Ascus EQ_669E Prevotella brevis Bacteroides graminisolvens 99.6 255 Ascus EQ_669F Prevotella brevis Bacteroides graminisolvens 97.8 256 AscusEQ_669G Prevotella brevis Bacteroides graminisolvens 99.1 257 AscusEQ_703 0.23805 Pedobacter bauzanensis Bacteroides bacterium 89,26 258 AscusEQ_703A Pedobacter bauzanensis Bacteroidales bacterium 99,1 259 AscusEQ_703B Pedobacter bauzanensis Bacteroidales bacterium 99,6 260 AscusEQ_703C Pedobacter bauzanensis Bacteroidales bacterium 98.2 261 AscusEQ_703D Pedobacter bauzanensis Bacteroidales bacterium 100 262, Petition 870260102095, dated 02 / 10 / 2026, pp. 68 / 641 60 / 159 AscusEQ_436 0.23361 Bacteroides plebeius Parabacteroides distasonis 83.71 263 AscusEQ_436A Bacteroides plebeius Parabacteroides distasonis 97.8 264 AscusEQ_436B Bacteroides plebeius Parabacteroides distasonis 98.7 265 AscusEQ_436C Bacteroides plebeius Parabacteroides distasonis 98.2 266 AscusEQ_436D Bacteroides plebeius Parabacteroides distasonis 99.6 267 AscusEQ_436E Bacteroides plebeius Parabacteroides distasonis 100 268 AscusEQ_436F Bacteroides plebeius Parabacteroides distasonis 99.1 269 AscusEQ_436G Bacteroides plebeius Parabacteroides distasonis 97.3 270 AscusEQ_680 . AscusEQ_680D Alloprevotella rava Bacteroides coprophilus 99,1 275 Ascus EQ_680E Alloprevotella rava Bacteroides coprophilus 99,6 276 Ascus EQ_680F Alloprevotella rava Bacteroides coprophilus 97.3 277 AscusEQ_533 0.233 Phascolarctobacterium succinatutens Acidaminococcus fermentans 88.31 278, Petition 870260102095, 02 / 10 / 2026, pág. 69 / 641 61 / 159 AscusEQ_762 0.23246 Prevotella stercorea Bacteroidales bacterium 89.8 279 Ascus EQ_762A Prevotella stercorea Bacteroidales bacterium 99.6 280 Ascus EQ_762B Prevotella stercorea Bacteroidales bacterium 98.2 281 AscusEQ_762C Prevotella stercorea Bacteroidales bacterium 100 282 AscusEQ_762D Prevotella stercorea Bacteroidales bacterium 98.7 283 Ascus EQ_762E Prevotella stercorea Bacteroidales bacterium 99.1 284 Ascus EQ_762F Prevotella stercorea Bacteroidales bacterium 97.3 285 AscusEQ_762G Prevotella stercorea Bacteroidales bacterium 97.8 286 AscusEQ_67 0.23225 Streptococcus saliviloxodontae Streptococcus sp. 99.66 287 AscusEQ_773 0.23225 Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 91,72 288 AscusEQ_773A Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 100 289 AscusEQ_773B Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 97.8 290 AscusEQ_773C Phascolarctobacterium succinatutens Phascolarctobacter ium sp.99.6 291 AscusEQ_773D Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 99.1 292 AscusEQ_773E Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 97.3 293 AscusEQ_773F Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 98.2 294. Petition 870260102095, dated 02 / 10 / 2026, page 70 / 641 62 / 159 AscusEQ_773G Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 98.7 295 AscusEQ_100 0.23179 Bacteroides Bacteroides vulgatus 100 296 AscusEQ_625 0.23167 Phascolarctobacterium succinatutens Phascolarctobacterium sp 93.07 297 Ascus EQ_625A Phascolarctobacterium succinatutens Phascolarctobacterium sp 98.7 298 Ascus EQ_625B Phascolarctobacterium succinatutens Phascolarctobacterium sp 98.2 299 AscusEQ_625C Phascolarctobacterium succinatutens Phascolarctobacterium sp 97.8 300 AscusEQ_625D Phascolarctobacterium succinatutens Phascolarctobacterium sp 99.6 301 Ascus EQ_625E Phascolarctobacterium succinatutens Phascolarctobacterium sp 99.1 302 Ascus EQ_625F Phascolarctobacterium succinatutens Phascolarctobacterium sp 100 303 AscusEQ_121 0.23115 Streptococcus orisasini Streptococcus orisasini 94.04 304 AscusEQ_783 0.2294 Prevotella brevis Bacteroides graminisolvens 83.99 305 AscusEQ_783A Prevotella brevis Bacteroides graminisolvens 99.1 306 AscusEQ_783B Prevotella brevis Bacteroides graminisolvens 97.8 307 AscusEQ_783C Prevotella brevis Bacteroides graminisolvens 97.3 308 AscusEQ_783D Prevotella brevis Bacteroides graminisolvens 39.78 AscusEQ_783E Prevotella brevis Bacteroides graminisolvens 98.2 310, Petition 870260102095, of 02 / 10 / 2026, p. 71 / 641 63 / 159 AscusEQ_1316 0,22636 Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 93,02 311 AscusEQ_1316 A Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 98,2 312 AscusEQ_1316 B Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 100 313 AscusEQ_1316 C Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 97,3 314 AscusEQ_1316 D Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 98,7 315 AscusEQ_1316 E Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 99,1 316 AscusEQ_1316 F Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 97,8 317 Ascus EQ 1316 G Phascolarctobacterium succinatutens Phascolarctobacter ium sp.99.6 318 AscusEQ_61 0.22822 Escherichia coli Escherichia coli 99.56 319 AscusEQ_61A Escherichia coli Escherichia coli 100 320 Ascus EQ_61 B Escherichia coli Escherichia coli 99.6 321 Ascus EQ_61C Escherichia coli Escherichia coli 97.3 322 Ascus EQ_61 D Escherichia coli Escherichia coli 98.2 323 Ascus EQ_61 E Escherichia coli Escherichia coli 97.8 324 Ascus EQ_61 F Escherichia coli Escherichia coli 99.1 325 Ascus EQ_61G Escherichia coli Escherichia coli 98.7 326 AscusEQ_1022 0.22542 Butyricimonas paravirosa Bacteroidetes bacterium 85.62 327 AscusEQ_1022 A Butyricimonas paravirosa Bacteroidetes bacterium 100 328 AscusEQ_1022 B Butyricimonas paravirosa Bacteroidetes bacterium 99.6 329. Petition 870260102095, dated 02 / 10 / 2026, p. 72 / 641 64 / 159 AscusEQ 1022 C Butyricimonas paravirosa Bacteroidetes bacterium 98.7 330 AscusEQ_1022 D Butyricimonas paravirosa Bacteroidetes bacterium 99.1 331 AscusEQ_607 0.22533 Phascolarctobacterium succinatutens Phascolarctobacterium sp. 92.08 332 AscusEQ_607A Phascolarctobacterium succinatutens Phascolarctobacterium sp. 98.2 333 AscusEQ_607B Phascolarctobacterium succinatutens Phascolarctobacterium sp. 98.7 334 AscusEQ_607C Phascolarctobacterium succinatutens Phascolarctobacterium sp. 99.1 335 AscusEQ_607D Phascolarctobacterium succinatutens Phascolarctobacterium sp. 100 336 AscusEQ_607E Phascolarctobacterium succinatutens Phascolarctobacterium sp. 99.6 337 AscusEQ_412 0.22322 Bacteroides plebeius Alloprevotella sp. 87.83 338 AscusEQ 412A Bacteroides plebeius Alloprevotella sp. 98.7 339 AscusEQ 412B Bacteroides plebeius Alloprevotella sp. 97.8 340 AscusEQ 412C Bacteroides plebeius Alloprevotella sp. 98.2 341 AscusEQ 412D Bacteroides plebeius Alloprevotella sp.97.3 342 AscusEQ 412E Bacteroides plebeius Alloprevotella sp. 100 343 AscusEQ 412F Bacteroides plebeius Alloprevotella sp. 99.1 344 AscusEQ 412G Bacteroides plebeius Alloprevotella sp. 99.6 345 AscusEQ_1362 0.22297 Barnesiella viscericola Muribaculaceae bacterium 89.7 346 AscusEQ_1362 A Barnesiella viscericola Muribaculaceae bacterium 98.2 347 AscusEQ_696 0.22246 Cyclobacterium lianum Bacteroidia bacterium 85.34 348. Petition 870260102095, dated 02 / 10 / 2026, p. 73 / 641 65 / 159 Ascus EQ_696A Cyclobacterium lianum Bacteroidia bacterium 97.3 349 Ascus EQ_696B Cyclobacterium lianum Bacteroidia bacterium 98.2 350 AscusEQ_696C Cyclobacterium lianum Bacteroidia bacterium 99.1 351 AscusEQ_696D Cyclobacterium lianum Bacteroidia bacterium 99.6 352 Ascus EQ_696E Cyclobacterium lianum Bacteroidia bacterium 100 353 Ascus EQ_696F Cyclobacterium lianum Bacteroidia bacterium 98.7 354 AscusEQ_53 0.22093 Finegoldia magna Bacteroides massiliensis 99.33 355 AscusEQ_835 0.22041 Bacteroides massiliensis Bacteroides massiliensis 82.52 356 AscusEQ_835A Bacteroides massiliensis Bacteroides massiliensis 97.8 357 AscusEQ_835B Bacteroides massiliensis Bacteroides massiliensis 99.1 358 AscusEQ_835C Bacteroides massiliensis Bacteroides massiliensis 99.6 359 AscusEQ_835D Bacteroides massiliensis Bacteroides massiliensis 100 360 AscusEQ_595 0.22036 Oscillibacter valericigenes Oscillibacter valericigenes 90.13 361 Ascus EQ_595A Oscillibacter valericigenes Oscillibacter valericigenes 98.7362 Petition 870260102095, dated 02 / 10 / 2026, page 74 / 641 66 / 159 AscusEQ_595D Oscillibacter valericigenes Oscillibacter valericigenes 99,6 365 Ascus EQ_595E Oscillibacter valericigenes Oscillibacter valericigenes 97,3 366 Ascus EQ_595F Oscillibacter valericigenes Oscillibacter valericigenes 99,1 367 AscusEQ_595G Oscillibacter valericigenes Oscillibacter valericigenes 98,2 368 AscusEQ_1850 0,21965 Pediococcus ethanolidurans TM7 bacterium 81,79 369 AscusEQ_1850 A Pediococcus ethanolidurans TM7 bacterium 97,3 370 AscusEQ_1850 B Pediococcus ethanolidurans TM7 bacterium 99,6 371 AscusEQ 1850 C Pediococcus ethanolidurans TM7 bacterium 100 372 AscusEQ_298 0,21933 Phascolarctobacterium succinatutens Phascolarctobacter ium succinatutens 80,48 373 Ascus EQ_298A Phascolarctobacterium succinatutens Phascolarctobacter ium succinatutens 99,6 374 Ascus EQ_298B Phascolarctobacterium succinatutens Phascolarctobacter ium succinatutens 99,1 375 AscusEQ_298C Phascolarctobacterium succinatutens Phascolarctobacterium succinatutens 100 376 AscusEQ_298D Phascolarctobacterium succinatutens Phascolarctobacterium succinatutens 98.7 377 Ascus EQ_298E Phascolarctobacterium succinatutens Phascolarctobacterium succinatutens 98.2 378 AscusEQ_743 0.2193 Prevotella brevis Bacteroides graminisolvens 83.66 379 AscusEQ_743A Prevotella brevis Bacteroides graminisolvens 97.3 380. Petition 870260102095, dated 02 / 10 / 2026, p. 75 / 641 67 / 159 AscusEQ_743B Prevotella brevis Graminisolvent bacteroides 97.8 381 AscusEQ_743C Prevotella brevis Graminisolvent bacteroides 99.1 382 AscusEQ_743D Prevotella brevis Graminisolvent bacteroides 98.2 383 AscusEQ_743E Prevotella brevis Graminisolvent bacteria 98.7 384 AscusEQ_722 0.219 Maritalea mobilis Alphaproteobacteria 91.72 385 Ascus EQ 722A Maritalea mobilis Alphaproteobacteria 98.7 386 Ascus EQ_722B Maritalea mobilis Alphaproteobacteria a bacterium 98.2 387 AscusEQ_722C Maritalea mobilis Alphaproteobacteria 97.3 388 AscusEQ_722D Maritalea mobilis Alphaproteobacteria 97.8 389 Ascus EQ 722E Maritalea mobilis Alphaproteobacteria Ascus EQ722F Maritalea mobilis Alphaproteobacteria 99.6 391 AscusEQ_722G Maritalea mobilis Alphaproteobacteria 99.1 392 AscusEQ_50 0.21805 Parvimonas micra Parvimonas sp.92.64 393 AscusEQ_603 0.21616 Prevotella copri Cecembia lonarensis 84.36 394 AscusEQ_603A Prevotella copri Cecembia lonarensis 97.8 395 AscusEQ_603B Prevotella copri Cecembia lonarensis 100 396. Petition 870260102095, dated 02 / 10 / 2026, page 76 / 641 68 / 159 AscusEQ_603C Prevotella copri Cecembia lonarensis 97.3 397 AscusEQ_603D Prevotella copri Cecembia lonarensis 98.7 398 AscusEQ_603E Prevotella copri Cecembia lonarensis 99.6 399 AscusEQ_603F Prevotella copri Cecembia lonarensis 99.1 400 AscusEQ_603G Prevotella copri Cecembia lonarensis 98.2 401 AscusEQ_91 0.21505 Streptococcus minor Streptococcus pluranimalium 98.66 402 AscusEQ_1567 0.21432 Phascolarctobacterium succinatutens Phascolarctobacterium sp. 93.02 403 AscusEQ_1567 A Phascolarctobacterium succinatutens Phascolarctobacterium sp. 98.7 404 AscusEQ_1567 B Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 97.3 405 AscusEQ 1567 C Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 98.2 406 AscusEQ_1567 D Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 99.1 407 AscusEQ_1567 E Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 100 408 AscusEQ_1567 F Phascolarctobacterium succinatutens Phascolarctobacter ium sp.97.8 409 AscusEQ_1567 G Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 99.6 410 AscusEQ_1921 0.21344 Alistipes shahii Bacteroidia bacterium 86 411 AscusEQ_1921 A Alistipes shahii Bacteroidia bacterium 98.7 412. Petition 870260102095, dated 02 / 10 / 2026, p. 77 / 641 69 / 159 AscusEQ_1921 B Alistipes shahii Bacteroidia bacterium 99,1 413 AscusEQ_1921 C Alistipes shahii Bacteroidia bacterium 98,2 414 AscusEQ_1921 D Alistipes shahii Bacteroidia bacterium 100 415 AscusEQ_1921 E Alistipes shahii Bacteroidia bacterium 97,8 416 AscusEQ_1921 F Alistipes shahii Bacteroidia bacterium 99.6 417 AscusEQ_1921 G Alistipes shahii Bacteroidia bacterium 97.3 418 AscusEQ_476 0.21308 Prevotella brevis Bacteroides graminisolvens 83.01 419 AscusEQ_476A Prevotella brevis Bacteroides graminisolvens 97.8 420 AscusEQ_476B Prevotella brevis Bacteroides graminisolvens 98.2 421 AscusEQ_476C Prevotella brevis Bacteroides graminisolvens 98.7 422 AscusEQ_476D Prevotella brevis Bacteroides graminisolvens 100 423 AscusEQ_476E Prevotella brevis Bacteroides graminisolvens 97.3 424 AscusEQ_476F Prevotella brevis Bacteroides graminisolvens 99.6 425 AscusEQ_414 0.21285 Sarcina maxima Clostridium maximum 99.64 426 Ascus EQ_414A Sarcina maxima Clostridium maximum 98.2 427 AscusEQ_414B Sarcina maxima Clostridium maximum 98.7 428, Petition 870260102095, dated 02 / 10 / 2026, page 78 / 641 70 / 159 AscusEQ_414C Sarcina maxima Clostridium maximum 97,8 429 AscusEQ_414D Sarcina maxima Clostridium maximum 99,6 430 AscusEQ_414E Sarcina maxima Clostridium maximum 97,3 431 AscusEQ_414F Sarcina maxima Clostridium maximum 99,1 432 AscusEQ_414G Sarcina maxima Clostridium maximum 100 433 AscusEQ_1253 0,21205 Pedobacter bauzanensis Bacteroidia bacterium 88,96 434 AscusEQ_1253 A Pedobacter bauzanensis Bacteroidia bacterium 100 435 AscusEQ_1253 B Pedobacter bauzanensis Bacteroidia bacterium 99,6 436 AscusEQ_1253 C Pedobacter bauzanensis Bacteroidia bacterium 99,1 437 AscusEQ_324 0,21122 Bacteroides coprocola Bacteroides mediterraneensis 81,93 438 Ascus EQ 324A Bacteroides coprocola Bacteroides mediterraneensis 98,2 439 Ascus EQ_324B Bacteroides coprocola Bacteroides mediterraneensis 98,7 440 AscusEQ_324C Bacteroides coprocola Bacteroides mediterraneensis 100 441 AscusEQ_324D Bacteroides coprocola Bacteroides mediterraneensis 99,6 442 Ascus EQ_324E Bacteroides coprocola Bacteroides mediterraneensis 99.1 443 AscusEQ_1536 0.21109 Phascolarctobacterium succinatutens Phascolarctobacter lum sp. 93.05 444, Petition 870260102095, dated 02 / 10 / 2026, p. 79 / 641 71 / 159 AscusEQ_1536 A Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 98,7 445 AscusEQ_1536 B Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 98,2 446 AscusEQ_1536 C Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 100 447 AscusEQ_1536 D Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 99,6 448 AscusEQ_1536 E Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 97,8 449 AscusEQ_1536 F Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 97,3 450 AscusEQ 1536 G Phascolarctobacterium succinatutens Phascolarctobacter ium sp.99.1 451 AscusEQ_971 0.21101 Bacteroides massiliensis Bacteroides massiliensis 82.79 452 AscusEQ_971A Bacteroides massiliensis Bacteroides massiliensis 98.2 453 AscusEQ_971 B Bacteroides massiliensis Bacteroides massiliensis 98.7 454 AscusEQ_971C Bacteroides massiliensis Bacteroides massiliensis 100 455 AscusEQ_971 D Bacteroides massiliensis Bacteroides massiliensis 99.1 456 AscusEQ_971 E Bacteroides massiliensis Bacteroides massiliensis 99.6 457 AscusEQ_257 0.21002 Anaerophaga thermohalophila Algoriphagus taiwanensis 82.85 458 AscusEQ_257A Anaerophaga thermohalophila Algoriphagus taiwanensis 98.2 459 AscusEQ_257B Anaerophaga thermohalophila Algoriphagus taiwanensis 99.6 460. Petition 870260102095, dated 02 / 10 / 2026, p. 80 / 641 72 / 159 AscusEQ_257C Anaerophaga thermohalophila Algoriphagus taiwanensis 98.7 461 AscusEQ_257D Anaerophaga thermohalophila Algoriphagus taiwanensis 97.3 462 AscusEQ_257E Anaerophaga thermohalophila Algoriphagus taiwanensis 99.1 463 AscusEQ_257F Anaerophaga thermohalophila Algoriphagus taiwanensis 97,8 464 AscusEQ_452 0,2092 Prevotella stercorea Bacteroidales bacterium 90,13 465 Ascus EQ_452A Prevotella stercorea Bacteroidales bacterium 97,8 466 Ascus EQ_452B Prevotella stercorea Bacteroidales bacterium 97,3 467 AscusEQ_452C Prevotella stercorea Bacteroides bacteria 100 468 AscusEQ_452D Prevotella stercorea Bacteroidales bacterium 99.6 469 Ascus EQ_452E Prevotella stercorea Bacteroidales bacterium 99.1 470 Ascus EQ_452F Prevotella stercorea Bacteroidales bacterium 98.7 471 AscusEQ_452G Prevotella stercorea Bacteroidales bacterium 98.2 472 AscusEQ_167 0.20793 Butyricimonas paravirosa Bacteroidales bacterium 88.29 473 AscusEQ_167A Shigella sonnei Atlantibacter hermannii 99,1 482 AscusEQ_167B Shigella sonnei Atlantibacter hermannii 99.6 483 AscusEQ_167C Shigella sonnei Atlantibacter hermannii 100 484, Petition 870260102095, of 02 / 10 / 2026, p. 81 / 641 73 / 159 AscusEQ_197 0,20789 Parabacteroides merdae Parabacteroides distasonis 96,67 474 AscusEQ_109 0,20839 Shigella sonnei Atlantibacter hermannii 100 475 AscusEQ_109A Shigella sonnei Atlantibacter hermannii 100 476 AscusEQ_109B Shigella sonnei Atlantibacter hermannii 99,1 477 AscusEQ_109C Shigella sonnei Atlantibacter hermannii 99,6 478 AscusEQ_109D Shigella sonnei Atlantibacter hermannii 98,2 479 AscusEQ_109E Shigella sonnei Atlantibacter hermannii 97,8 480 AscusEQ_109F Shigella sonnei Atlantibacter hermannii 97,3 481 AscusEQ_363 0,20779 Anaerophaga thermohalophila Prevotella copri 82,08 485 AscusEQ_363A Anaerophaga thermohalophila Prevotella copri 100 486 AscusEQ_363B Anaerophaga thermohalophila Prevotella copri 98,7 487 AscusEQ_363C Anaerophaga thermohalophila Prevotella copri 97,8 488 AscusEQ_363D Anaerophaga thermohalophila Prevotella copri 99,1 489 AscusEQ_363E Anaerophaga thermohalophila Prevotella copri 98,2 490 AscusEQ_363F Anaerophaga thermohalophila Prevotella copri 97,3 491 AscusEQ_363G Anaerophaga thermohalophila Prevotella copri 99.6 492, Petition 870260102095, dated 02 / 10 / 2026, p. 82 / 641 74 / 159 AscusEQ_299 0.20694 Prevotella stercorea Bacteroidales bacterium 89.8 493 Ascus EQ_299A Prevotella stercorea Bacteroidales bacterium 97.3 494 Ascus EQ_299B Prevotella stercorea Bacteroidales bacterium 99.1 495 AscusEQ_299C Prevotella stercorea Bacteroidales bacterium 100 496 AscusEQ_299D Prevotella stercorea Bacteroidales bacterium 97.8 497 Ascus EQ_299E Prevotella stercorea Bacteroidales bacterium 99.6 498 Ascus EQ_299F Prevotella stercorea Bacteroidales bacterium 98.2 499 AscusEQ_299G Prevotella stercorea Bacteroidales bacterium 98.7 500 AscusEQ_456 0.20595 Prevotella oulorum Prevotella oris 84.21 501 Ascus EQ 456A Prevotella oulorum Prevotella oris 97.3 502 AscusEQ 456B Prevotella oulorum Prevotella oris 99.1 503 AscusEQ 456C Prevotella oulorum Prevotella oris 100 504 AscusEQ 456D Prevotella oulorum Prevotella oris 99.6 505 AscusEQ 456E Prevotella oulorum Prevotella oris 98.2 506 AscusEQ 456F Prevotella oulorum Prevotella oris 98.7 507 AscusEQ_232 0.20589 Bacteroides coprocola Bacteroides caecicola 81,82 508 AscusEQ_232A Bacteroides coprocola Bacteroides caecicola 98,2 509 AscusEQ_232B Bacteroides coprocola Bacteroides caecicola 100 510 AscusEQ_232C Bacteroides coprocola Bacteroides caecicola 99,6 511, Petição 870260102095, de 02 / 10 / 2026, pág. 83 / 641 75 / 159 AscusEQ_235 0,20536 Parabacteroides merdae Algoriphagus ratkowskyi 83,17 512 AscusEQ_235A Parabacteroides merdae Algoriphagus ratkowskyi 98,7 513 AscusEQ_235B Parabacteroides merdae Algoriphagus ratkowskyi 100 514 AscusEQ_235C Parabacteroides merdae Algoriphagus ratkowskyi 97.8 515. Parabacteroides merdae Algoriphagus ratkowskyi 99.6 519 AscusEQ_490 0.20524 Bacteroides plebeius Parabacteroides distasonis 83.39 520 Ascus EQ_490A Bacteroides plebeius Parabacteroides distasonis 98.2 521 Ascus EQ_490B Bacteroides plebeius Parabacteroides distasonis 97.8 522 AscusEQ_490C Bacteroides plebeius Parabacteroides distasonis 98.7 523 AscusEQ_490D Bacteroides plebeius Parabacteroides distasonis 100 524 Ascus EQ_490E Bacteroides plebeius Parabacteroides distasonis 99.1 525 Ascus EQ_490F Bacteroides plebeius Parabacteroides distasonis 97.3 526 AscusEQ_490G Bacteroides plebeius Parabacteroides distasonis 99.6 527, Petition 870260102095, dated 02 / 10 / 2026, p. 84 / 641 76 / 159 AscusEQ_106 0,20492 Helcococcus ovis Helcococcus ovis 92,38 528 AscusEQ_588 0,2049 Pedobacter bauzanensis Bacteroidales bacterium 88,22 529 Ascus EQ_588A Pedobacter bauzanensis Bacteroidales bacterium 98,2 530 Ascus EQ_588B Pedobacter bauzanensis Bacteroidales bacterium 99,1 531 AscusEQ_588C Pedobacter bauzanensis Bacteroidales bacterium 100 532 AscusEQ_588D Pedobacter bauzanensis Bacteroidales bacterium 99,6 533 Ascus EQ_588E Pedobacter bauzanensis Bacteroidales bacterium 98,7 534 AscusEQ_1234 0,20382 Devosia pacifica Alphaproteobacteri a bacterium 93,26 535 AscusEQ_1234 A Devosia pacifica Alphaproteobacteri a bacterium 99,1 536 AscusEQ_1234 B Devosia pacifica Alphaproteobacteri a bacterium 100 537 AscusEQ_1234 C Devosia pacifica Alphaproteobacteri a bacterium 97,8 538 AscusEQ_1234 D Devosia pacifica Alphaproteobacteri a bacterium 99,6 539 AscusEQ_1234 E Devosia pacifica Alphaproteobacteri a bacterium 97,3 540 AscusEQ_962 0,20356 Anaerocella delicata Anaerocella delicata 85,86 541 Ascus EQ_962A Delicate anaerocell Delicate anaerocell 99.1 542 Ascus EQ_962B Delicate anaerocell Delicate anaerocell 99.6 543, Petition 870260102095, 02 / 10 / 2026, pág. 85 / 641 77 / 159 AscusEQ_962C Anaerocella delicata Anaerocella delicata 100 544 AscusEQ_916 0,20303 Sphingomicrobium astaxanthinifaciens Alphaproteobacteri a bacterium 93,26 545 Ascus EQ_916A Sphingomicrobium astaxanthinifaciens Alphaproteobacteri a bacterium 99,1 546 AscusEQ_916B Sphingomicrobium astaxanthinifaciens Alphaproteobacteri a bacterium 99,6 547 AscusEQ_916C Sphingomicrobium astaxanthinifaciens Alphaproteobacteri a bacterium 97,3 548 AscusEQ_916D Sphingomicrobium astaxanthinifaciens Alphaproteobacteri a bacterium 100 549 AscusEQ_916E Sphingomicrobium astaxanthinifaciens Alphaproteobacteri a bacterium 97,8 550 AscusEQ_1095 0,20119 Prevotella stercorea Prevotella sp. 89,87 551 AscusEQ_1095 A Prevotella stercorea Prevotella sp. 97,3 552 AscusEQ_1095 B Prevotella stercorea Prevotella sp. 98,7 553 AscusEQ_1095 C Prevotella stercorea Prevotella sp. 99,1 554 AscusEQ_1095 D Prevotella stercorea Prevotella sp. 99,6 555 AscusEQ_1095 E Prevotella stercorea Prevotella sp.97.8 556 AscusEQ_1095 F Prevotella stercorea Prevotella sp. 100 557 AscusEQ 1095 G Prevotella stercorea Prevotella sp. 98.2 558 AscusEQ_614 0.20074 Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 92.05 559. Petition 870260102095, dated 02 / 10 / 2026, p. 86 / 641 78 / 159 Ascus EQ_614A Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 99,1 560 AscusEQ_614B Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 98,7 561 AscusEQ_614C Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 100 562 AscusEQ_614D Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 99,6 563 AscusEQ_614E Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 97,8 564 AscusEQ_614F Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 98,2 565 AscusEQ_614G Phascolarctobacterium succinatutens Phascolarctobacter ium sp. 97,3 566 AscusEQ_698 0,20029 Phascolarctobacterium succinatutens Phascolarctobacter ium sp.91.36 567 AscusEQ_678 0.2002 Pedobacter bauzanensis Bacteroidales bacterium 88.33 568 Ascus EQ_698A Pedobacter bauzanensis Bacteroidales bacterium 100 569 Ascus EQ_698B Pedobacter bauzanensis Bacteroidales bacterium 98.7 570 AscusEQ_698C Pedobacter bauzanensis Bacteroidales bacterium 98.2 571 AscusEQ_698D Pedobacter bauzanensis Bacteroidales bacterium 97.3 572 Ascus EQ_698E Pedobacter bauzanensis Bacteroidales bacterium 99.1 573 Ascus EQ_698F Pedobacter bauzanensis Bacteroidales bacterium 99.6 574 AscusEQ_698G Pedobacter bauzanensis Bacteroidales bacterium 97.8 575. Petition 870260102095, dated 02 / 10 / 2026, p. 87 / 641 79 / 159

[00138] In some embodiments, the present disclosure provides microbial compositions comprising selected isolated microbial species from a Clostridium spp. bacterium, a Sarcina spp. bacterium, a Streptococcus spp. bacterium, an Escherichia spp. bacterium, an Atlantibacter spp. bacterium, and a Shigella spp. bacterium.

[00139] In some embodiments, the present disclosure provides microbial compositions comprising selected isolated microbial species from a bacterium Clostridium butyricum, a bacterium Streptococcus infantarius subsp. coli, a bacterium Streptococcus equinius, a bacterium Escherichia coli, a bacterium Sacina maxima, a bacterium Clostridium maximum, a bacterium Shigella sonnei, and a bacterium Atlantibacter hermannii.

[00140] In some embodiments, the present disclosure provides microbial compositions comprising a Clostridium butyricum bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99,4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical to a nucleic acid if sequence selected from SEQ ID Nos: 5-13.

[00141] In some embodiments, the present disclosure provides microbial compositions comprising a bacterium Streptococcus infantarius subsp. coli comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, by Petition 870260102095, dated 02 / 10 / 2026, page 88 / 641 80 / 159 less 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical to a nucleic acid sequence selected from SEQ ID Nos: 143-150.

[00142] In some embodiments, the present disclosure provides microbial compositions comprising a Streptococcus equinis bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99,4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical to a nucleic acid if sequence selected from SEQ ID Nos: 143-150.

[00143] In some embodiments, the present disclosure provides microbial compositions comprising an Escherichia coli bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2% Petition 870260102095, dated 02 / 10 / 2026, page 89 / 641 81 / 159 at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to a nucleic acid sequence selected from SEQ ID Nos: 321-328.

[00144] In some embodiments, the present disclosure provides microbial compositions comprising a Sarcina maxima bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%,at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical to a nucleic acid sequence selected from SEQ ID Nos: 430-437.

[00145] In some embodiments, the present disclosure provides microbial compositions comprising a Clostridium maximum bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, by Petition 870260102095, dated 02 / 10 / 2026, page 90 / 641 82 / 159 less than 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to a nucleic acid sequence once selected from SEQ ID Nos: 430-437.

[00146] In some embodiments, the present disclosure provides microbial compositions comprising a Shigella sonnei bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%,at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical to a nucleic acid sequence selected from SEQ ID Nos: 480-486.

[00147] In some embodiments, the present disclosure provides microbial compositions comprising an Atlantibacter hermannii bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least Petition 870260102095, dated 02 / 10 / 2026, page 91 / 641 83 / 159 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to a nucleic acid sequence selected from SEQ ID Nos: 480-486.

[00148] In some embodiments, the present disclosure provides microbial compositions comprising one or more isolated bacteria comprising a 16S nucleic acid sequence selected from SEQ ID NOs: 1-574. In some embodiments, the microbial composition comprises one or more isolated bacteria comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%,at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to a nucleic acid sequence selected from SEQ ID NOs: 1-574. In some embodiments, the microbial composition comprises one or more isolated bacteria comprising a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from SEQ ID NOs: 1-574.

[00149] In some embodiments, this disclosure provides a microbial composition comprising one or more of the following: (a) AscusEQ_4 (SEQ ID NO: 5) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, by Petition 870260102095, dated 02 / 10 / 2026, page 92 / 641 84 / 159 less than 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 5; (b) AscusEQ_140 (SEQ ID NO: 141) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, by at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99,8% or at least 99.9% identical to SEQ ID NO: 141;, (c) AscusEQ_61 (SEQ ID NO: 319) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least Petition 870260102095, dated 02 / 10 / 2026, page 93 / 641 85 / 159 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 319; (d) AscusEQ_414 (SEQ ID NO: 426) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, by at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99,8% or at least 99.9% identical to SEQ ID NO: 426;, (e) AscusEQ_109 (SEQ ID NO: 475) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, by at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99,8% or at least 99.9% identical to SEQ ID NO: 475;, Petition 870260102095, dated 02 / 10 / 2026, p. 94 / 641 86 / 159

[00150] In some embodiments, this disclosure provides a microbial composition comprising one or more of the following: (f) AscusEQ_4F (SEQ ID NO: 11) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99,8% or at least 99.9% identical to SEQ ID NO: 11;, (g) AscusEQ_140A (SEQ ID NO: 142) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99,8% or at least 99.9% identical to SEQ ID NO: 142;, (h) AscusEQ_61A (SEQ ID NO: 320) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least Petition 870260102095, dated 02 / 10 / 2026, p. 95 / 641 87 / 159 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 320; (i) AscusEQ_414G (SEQ ID NO: 433) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, at least 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99,8% or at least 99.9% identical to SEQ ID NO: 433;, (j) AscusEQ_109A (SEQ ID NO: 476) or an isolated bacterium comprising a 16S nucleic acid sequence that is at least 95.0%, at least 95.1%, at least 95.2%, at least 95.3%, at least 95.4%, at least 95.5%, at least 95.6%, at least 95.7%, at least at least 95.8%, at least 95.9%, at least 96%, at least 96.1%, at least 96.2%, at least 96.3%, at least 96.4%, at least 96.5%, at least 96.6%, at least 96.7%, at least 96.8%, at least 96.9%, at least 97%, at least 97.1%, at least 97.2%, at least 97.3%, at least 97.4%, at least 97.5%, by Petition 870260102095, dated 02 / 10 / 2026, page 96 / 641 88 / 159 less than 97.6%, at least 97.7%, at least 97.8%, at least 97.9%, at least 98%, at least 98.1%, at least 98.2%, at least 98.3%, at least 98.4%, at least 98.5%, at least 98.6%, at least 98.7%, at least 98.8%, at least 98.9%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8% or at least 99.9% identical to SEQ ID NO: 476.

[00151] Tables 3-6 provide the various combinations of (a)-(e) above that are contemplated under this disclosure. Table 3: Compositions comprising 5 isolated bacteria (a)(b)(c)(d)(e) Table 4: Compositions comprising 4 isolated bacteria (a)(b)(c)(d) (a)(b)(c)(e) (a)(b)(d)(e) (a)(c)(d)(e) (b)(c)(d)(e) Table 5: Compositions comprising 3 isolated bacteria Table 6: Compositions comprising 2 isolated bacteria Petition 870260102095, dated 02 / 10 / 2026, p. 97 / 641 89 / 159

[00152] In some embodiments, the microbial compositions include foodstuffs such as cereals (barley, corn, oats and the like); starches (tapioca and the like); oilseed cakes; and plant residues. In some embodiments, the microbial compositions include vitamins, minerals, trace elements, emulsifiers, flavoring products, binders, colorants, odorants, thickening agents and the like. In some embodiments, the microbial compositions include one or more ionophores; vaccines; antibiotics; anthelmintics; virucides; nematicides; amino acids such as methionine, glycine and arginine; fish oil; oregano; and biologically active molecules such as enzymes.

[00153] In some embodiments, the microbial compositions of this disclosure are solid. Where solid compositions are used, it may be desirable to include one or more carrier materials, including, but not limited to: earthy minerals such as silicas, talc, kaolin, limestone, chalk, clay, dolomite, diatomaceous earth; calcium sulfate; magnesium sulfate; magnesium oxide; zeolites; calcium carbonate; magnesium carbonate; trehalose; chitosan; shellac; albumins; starch; skimmed milk powder; sweet whey powder; maltodextrin; lactose; inulin; dextrose; products of vegetable origin such as cereal flours, tree bark bran, wood bran and walnut shell bran.

[00154] In some embodiments, the microbial compositions of the present disclosure are liquid. In other embodiments, the liquid comprises a solvent. Petition 870260102095, dated 02 / 10 / 2026, p. 98 / 641 90 / 159 which may include water or an alcohol or a saline solution or carbohydrate and other solvents safe for animals. In some embodiments, the microbial compositions of this disclosure include binders such as animal-safe polymers, carboxymethylcellulose, starch, polyvinyl alcohol and the like.

[00155] In some embodiments, the microbial compositions of this disclosure comprise thickening agents such as silica, clay, natural extracts of seeds or algae, synthetic cellulose derivatives, guar gum, locust bean gum, agar, gelatin, xanthan gum, alginates and methylcellulose. In some embodiments, the microbial compositions comprise anti-settling agents such as modified starches, polyvinyl alcohol, xanthan gum and the like.

[00156] In some embodiments, the microbial compositions of this disclosure comprise dyes, including organic chromophores classified as nitroso; nitro; azo, including monoazo, bisazo and polyazo; acridine, anthraquinone, azine, diphenylmethane, indamine, indophenol, methine, oxazine, phthalocyanine, thiazine, thiazole, triarylmethane, xanthene. In some embodiments, the microbial compositions of this disclosure comprise trace nutrients, such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc. In some embodiments, the microbial compositions comprise dyes, both natural and artificial. In some embodiments, the dye is green.

[00157] In some embodiments, the microbial compositions of the present disclosure comprise a virucide, bactericide or nematicide that is safe for animals.

[00158] In some embodiments, the microbial compositions of the present disclosure comprise saccharides (for example, monosaccharides, disaccharides, trisaccharides, polysaccharides, oligosaccharides and the like), polymeric saccharides, lipids, polymeric lipids, lipopolysaccharides, proteins, polymeric proteins, lipoproteins, nucleic acids, nucleic acid polymers, silica, inorganic salts and combinations thereof. In another embodiment, the microbial compositions comprise polymers of agar, agarose, gelrite and gellan gum, and the like. In some embodiments, the microbial compositions comprise plastic capsules, emulsions (for example, water and oil), Petition 870260102095, dated 02 / 10 / 2026, page 99 / 641 91 / 159 membranes and artificial membranes. In some embodiments, the bonded polymer emulsions or solutions may comprise the microbial compositions of the present disclosure. See Harel and Bennett (US Patent 8,460,726B2). In one embodiment, the microbial composition comprises glucose. In one embodiment, the formulations of the microbial composition comprise glucose.

[00159] In some embodiments, the microbial compositions of this disclosure comprise one or more oxygen scavengers, denitrifiers, nitrifiers, heavy metal chelators and / or dechlorinators; and combinations thereof. In one embodiment, the one or more oxygen scavengers, denitrifiers, nitrifiers, heavy metal chelators and / or dechlorinators are not chemically active when the microbial compositions are mixed with feed and / or water to be administered to horses. In one embodiment, the one or more oxygen scavengers, denitrifiers, nitrifiers, heavy metal chelators and / or dechlorinators are not chemically active when administered to horses.

[00160] In some embodiments, the microbial compositions of the present disclosure comprise a solidifying agent and a sweetening agent. In some embodiments, the sweetening agent is selected from corn syrup, molasses, cane molasses, brewer's yeast, and honey. In some embodiments, the sweetening agent is molasses. In some embodiments, the solidifying agent is selected from gelatin, xanthan gum, agar, a starch, alginin, guar gum, collagen, pectin, and carboxymethylcellulose. In some embodiments, the solidifying agent is gelatin. In some embodiments, the microbial composition comprises between about 0.1% and about 1.5% gelatin. In some embodiments, the solidifying agent is xanthan gum. In some embodiments, the microbial composition comprises between about 0.2% and about 2.0% xanthan gum. In some embodiments, the microbial composition comprises more than 1.4% xanthan gum. In some embodiments, the solidifying agent is agar.In some embodiments, the microbial composition comprises between about 0.25% and about 2.5% of agar. In some embodiments, the microbial composition comprises more than about 1.0% of agar.

[00161] In some embodiments, the microbial compositions of the present disclosure occur in a solid form (e.g., lyophilized spores). Petition 870260102095, dated 02 / 10 / 2026, page 100 / 641 92 / 159 dispersed) or in a liquid or gel form (microbes intercalated in a storage medium). In some embodiments, the microbial compositions of this disclosure are added in dry form to a liquid or gel to form a suspension before administration.

[00162] In some embodiments, the microbial compositions of the present disclosure are formulated as a gel, a liquid, a powder, a tablet, a capsule, a pill, a feed additive, a feed ingredient, a feed supplement, a water additive, a heat-stabilized additive, a moisture-stabilized additive, a pelleted feed additive, a pre-pelleted applied feed additive, a post-pelleted applied feed additive, or a spray additive.

[00163] In some embodiments, the microbial compositions of this disclosure comprise one or more preservatives. The preservatives may be in liquid or gaseous formulations. Preservatives may be selected from one or more of the following: monosaccharide, disaccharide, trisaccharide, polysaccharide, acetic acid, ascorbic acid, calcium ascorbate, erythorbic acid, isoascorbic acid, erythrobolic acid, potassium nitrate, sodium ascorbate, sodium erythorbate, sodium isoascorbate, sodium nitrate, sodium nitrite, nitrogen, benzoic acid, calcium sorbate, lauroyl ethyl arginate, hydroxyl methyl p-benzoate, methylparaben, potassium acetate, potassium benzoate, potassium bisulfite, potassium diacetate, potassium lactate, potassium metabisulfite, potassium sorbate, propyl p-hydroxybenzoate, propylparaben, sodium acetate, sodium benzoate, sodium bisulfite, sodium nitrite, sodium diacetate, sodium lactate, sodium metabisulfite.Methyl p-hydroxybenzoic acid sodium salt, propyl p-hydroxybenzoic acid sodium salt, sodium sulfate, sodium sulfite, sodium dithionite, sulfurous acid, calcium propionate, dimethyl dicarbonate, natamycin, potassium sorbate, potassium bisulfite, potassium metabisulfite, propionic acid, sodium diacetate, sodium propionate, sodium sorbate, sorbic acid, ascorbic acid, ascorbyl palmitate, ascorbyl stearate, butylated hydroxyanisole, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), citric acid, citric acid esters of mono- and / or diglycerides, L-cysteine, L-cysteine ​​hydrochloride, guaiacum gum, guayaco gum, lecithin, lecithin citrate, monoglyceride citrate, citrate of monoisopropyl propyl gallate, sodium metabisulfite, tartaric acid, tertiary butylhydroquinone, stannous chloride, thiodipropionic acid, dilauryl thiodipropionate, distearyl Petition 870260102095, dated 02 / 10 / 2026, page 101 / 641 93 / 159 distipropionate, ethoxyquin, sulfur dioxide, formic acid or tocopherol(s).

[00164] In some embodiments, the microbial compositions of the present disclosure include bacterial and / or fungal cells in the form of spores, vegetative cell form, dormant cell form and / or lysed form. In one embodiment, the lysed cell forms acts as a mycotoxin binder, for example, mycotoxins that bind to dead cells.

[00165] In some embodiments, the microbial compositions are shelf-stable in a refrigerator (35-40 °F) for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial compositions are shelf-stable in a refrigerator (35-40 °F) for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 weeks.

[00166] In some embodiments, the microbial compositions are shelf-stable at room temperature (68-72°F) or between 50-77°F for a period of at least 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial compositions are shelf-stable at room temperature (68-72°F) or between 50-77°F for a period of at least 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54, 55, 56, 57, 58, 59, or 60 weeks.

[00167] In some embodiments, the microbial compositions are shelf-stable at -23-35°F for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial compositions are shelf-stable at -23-35°F for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, Petition 870260102095, dated 02 / 10 / 2026, p. 102 / 641 94 / 159 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 weeks.

[00168] In some embodiments, the microbial compositions are shelf-stable at 77-100°F for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial compositions are shelf-stable at 77-100°F for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 55, 56, 57, 58, 59, or 60 weeks.

[00169] In some embodiments, the microbial compositions are shelf-stable at 101-213°F for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial compositions are shelf-stable at 101-213°F for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 weeks.

[00170] In some embodiments, the microbial compositions of the present disclosure are shelf-stable at refrigeration temperatures (35-40°F), at room temperature (68-72°F), between 50-77°F, between -23-35°F, between 70-100°F or between 101-213°F for a period of about 1 to 100, about 1 to 95, about 1 to 90, about 1 to 85, about 1 to 80, about 1 to 75, about 1 to 70, about 1 to 65, about 1 to 60, about 1 to 55, about 1 to 50, about 1 to 45, about 1 to 40, about 1 to 35, about 1 to 30, about 1 to 25, about 1 to 20, about 1 to 15, about 1 to 10, about 1 to 5, about 5 to 100, about 5 to 95, about 5 to 90, about 5 to 85, about 5 to 80, about 5 to 75, about 5 to 70, about 5 to 65, about 5 to 60, about 5 to 55, about 5 to 50, about 5 to 45, about 5 to 40, about 5 to 35, about 5 to 30, about 5 to 25, about 5 to 20, about 5 to 15, about 5 to 10, about 10 to 100, about 10 to 95, about 10 to 90, about 10 to 85, about 10 to 80, about 10 to 75, about 10 to 70, about 10 to 65, about Petition 870260102095, dated 02 / 10 / 2026, page 103 / 641 95 / 159 from 10 to 60, close to 10 to 55, close to 10 to 50, close to 10 to 45, close to 10 to 40, close to 10 to 35, close to 10 to 30, close to 10 to 25, close to 10 to 20, close to 10 to 15, close to 15 to 100, close to 15 to 95, close to 15 to 90, close to 15 to 85, close to 15 to 80, close to 15 to 75, close to 15 to 70, close to 15 to 65, close to 15 to 60, close to 15 to 55, close to 15 to 50, close to 15 to 45, close to 15 to 40, close to 15 to 35, approximately 15 to 30, approximately 15 to 25, approximately 15 to 20, approximately 20 to 100, approximately 20 to 95, approximately 20 to 90, approximately 20 to 85, approximately 20 to 80, approximately 20 to 75, approximately 20 to 70, approximately 20 to 65, approximately 20 to 60, approximately 20 to 55, approximately 20 to 50, approximately 20 to 45, approximately 20 to 40, approximately 20 to 35, approximately 20 to 30, approximately 20 to 25, approximately 25 to 100, approximately 25 to 95, approximately 25 to 90, approximately 25 to 85, approximately 25 to 80 approximately 25 to 75, approximately 25 to 70, approximately 25 to 65, approximately 25 to 60, approximately 25 to 55, approximately 25 to 50, approximately 25 to 45,approximately 25 to 40, approximately 25 to 35, approximately 25 to 30, approximately 30 to 100, approximately 30 to 95, approximately 30 to 90, approximately 30 to 85, approximately 30 to 80, approximately 30 to 75, approximately 30 to 70, approximately 30 to 65, approximately 30 to 60, approximately 30 to 55, approximately 30 to 50, approximately 30 to 45, approximately 30 to 40, approximately 30 to 35, approximately 35 to 100, approximately 35 to 95, approximately 35 to 90, approximately 35 to 85, approximately 35 to 80, approximately 35 to 75, approximately 35 to 70, approximately 35 to 65, approximately 35 to 60, approximately 35 to 55, approximately 35 to 50, approximately 35 to 45, approximately 35 to 40, approximately 40 to 100, approximately 40 to 95, approximately 40 to 90, approximately 40 to 85, approximately 40 to 80, approximately 40 to 75, approximately 40 to 70, approximately 40 to 65, approximately 40 to 60, approximately 40 to 55, approximately 40 to 50, approximately 40 to 45, approximately 45 to 100, approximately 45 to 95, approximately 45 to 90, approximately 45 to 85, approximately 45 to 80, approximately 45 to 75, approximately 45 to 70, approximately 45 to 65, approximately 45 to 60, approximately 45 to 55, approximately 45 to 50, approximately 50 to 100, approximately 50 to 95,approximately 50 to 90, approximately 50 to 85, approximately 50 to 80, approximately 50 to 75, approximately 50 to 70, approximately 50 to 65, approximately 50 to 60, approximately 50 to 55, approximately 55 to 100, approximately 55 to 95, approximately 55 to 90, approximately 55 to 85, approximately 55 to 80, approximately 55 to 75, approximately 55 to 70, approximately 55 to 65, approximately 55 to 60, approximately 60 to 100, approximately 60 to 95, approximately 60 to 90, approximately 60 to 85, approximately 60 to 80, approximately 60 to 75, approximately 60 to 70, approximately 60 to 65, approximately 65 to 100, approximately 65 to 95, approximately 65 to 90, approximately 65 to 85, approximately 65 to 80, approximately 65 to 75, approximately 65 to 70, approximately 70 to 100, approximately 70 to 95, approximately 70 to 90, approximately 70 to 85, approximately 70 to 80, approximately 70 to 75, approximately 75 to 100, approximately 75 to 95, approximately 75 to 90, approximately 75 to 85, approximately 75 to 80, approximately 80 to 100, approximately 80 to 95, approximately 80 to 90, approximately 80 to 85, approximately 85 to 100, approximately 85 to 95, Petition 870260102095, dated 02 / 10 / 2026, page. 104 / 641 96 / 159 about 85 to 90, about 90 to 100, about 90 to 95 or 95 to 100 weeks

[00171] In some embodiments, the microbial compositions of the present disclosure are shelf-stable at refrigeration temperatures (35-40°F), at room temperature (68-72°F), between 50-77°F, between -23-35°F, between 70-100°F or between 101-213°F for a period of 1 to 100, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1 to 70, 1 to 65, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 5 to 100, 5 to 95, 5 to 90, 5 to 85, 5 to 80, 5 to 75, 5 to 70, 5 to 65, 5 to 60, 5 to 55, 5 to 50, 5 to 45, 5 to 40, 5 to 35, 5 to 30, 5 to 25, 5 to 20, 5 to 15, 5 to 10, 10 to 100, 10 to 95, 10 to 90, 10 to 85, 10 to 80, 10 to 75, 10 to 70, 10 to 65, 10 to 60, 10 to 55, 10 to 50, 10 to 45, 10 to 40, 10 to 35, 10 to 30, 10 to 25, 10 to 20, 10 to 15, 15 to 100, 15 to 95, 15 to 90, 15 to 85, 15 to 80, 15 to 75, 15 to 70, 15 to 65, 15 to 60, 15 to 55, 15 to 50, 15 to 45, 15 a 40, 15 a 35, 15 a 30, 15 a 25, 15 a 20, 20 a 100, 20 a 95, 20 a 90, 20 a 85, a 80, 20 a 75, 20 a 70, 20 a 65, 20 a 60, 20 a 55, 20 a 50, 20 a 45, 20 a 40, 20 a 35, 20 a 30, 20 a 25, 25 a 100, 25 a 95, 25 a 90, 25 a 85, 25 a 80, 25 a 75, 25 a 70, a 65, 25 a 60, 25 a 55, 25 a 50, 25 a 45, 25 a 40, 25 a 35, 25 a 30, 30 a 100, 30 a 95, 30 a 90, 30 a 85, 30 a 80, 30 a 75, 30 a 70, 30 a 65, 30 a 60, 30 a 55, 30 a 50, 30 a 45, 30 a 40, 30 a 35, 35 a 100, 35 a 95, 35 a 90, 35 a 85, 35 a 80, 35 a 75, 35 a 70, 35 a 65, 35 a 60, 35 a 55, 35 a 50, 35 a 45, 35 a 40, 40 a 100, 40 a 95, 40 a 90, 40 a 85, 40 a 80, 40 a 75, 40 a 70, 40 a 65, 40 a 60, 40 a 55, 40 a 50, 40 a 45, 45 a 100, 45 a 95, 45 a 90, 45 a 85, 45 a 80, 45 a 75, 45 a 70, 45 a 65, 45 a 60, 45 a 55, 45 a 50, 50 a 100, 50 a 95, 50 a 90, 50 a 85, 50 a 80, 50 a 75, 50 a 70, 50 a 65, 50 a 60, 50 a 55, 55 a 100, 55 a 95, 55 a 90, 55 a 85, 55 a 80, 55 a 75, 55 a 70, 55 a 65, 55 a 60, 60 a 100, 60 a 95, 60 a 90, 60 a 85, 60 a 80, 60 a 75, 60 a 70, 60 a 65, 65 a 100, 65 a 95, 65 a 90, 65 a 85, 65 a 80, 65 a 75, 65 a 70, 70 a 100, 70 a 95, 70 a 90, 70 a 85, 70 a 80, 70 a 75, 75 a 100, 75 a 95, 75 a 90,75 to 85, 75 to 80, 80 to 100, 80 to 95, 80 to 90, 80 to 85, 85 to 100, 85 to 95, 85 to 90, 90 to 100, 90 to 95 or 95 to 100 weeks.

[00172] In some embodiments, the microbial compositions of the present disclosure are shelf-stable at refrigeration temperatures (35-40°F), at room temperature (68-72°F), between 50-77°F, between -23-35°F, between 70-100°F, or between 101 and 213°F for a period of about 1 to 36, about 1 to 34, about 1 to 32, about 1 to 30, about 1 to 28, about 1 to 26, about 1 to 24, about 1 to 22, about 1 to 20, about 1 to 18, about 1 to 16, about 1 to 14, about 1 to Petition 870260102095, dated 02 / 10 / 2026, p. 105 / 641 97 / 159 12, about 1 to 10, about 1 to 8, about 1 to 6, about 1 to 4, about 1 to 2, about 4 to 36, about 4 to 34, about 4 to 32, about 4 to 30, about 4 to 28, about 4 to 26, about 4 to 24, about 4 to 22, about 4 to 20, about 4 to 18, about 4 to 16, about 4 to 14, about 4 to 12, about 4 to 10, about 4 to 8, about 4 to 6, about 6 to 36, about 6 to 34, about 6 to 32, about 6 to 30, about 6 to 28, about 6 to 26, about 6 to 24, about 6 to 22, about 6 to 20, about 6 to 18, about 6 to 16, about 6 to 14, about 6 to 12, about 6 to 10, about 6 to 8, about 8 to 36, about 8 to 34, about 8 to 32, about 8 to 30, about 8 to 28, about 8 to 26, about 8 to 24, about 8 to 22, about 8 to 20, about 8 to 18, about 8 to 16, about 8 to 14, about 8 to 12, about 8 to 10, about 10 to 36, about 10 to 34, about 10 to 32, about 10 to 30, about 10 at 28, about 10 to 26, about 10 to 24, about 10 to 22,approximately 10 to 20, approximately 10 to 18, approximately 10 to 16, approximately 10 to 14, approximately 10 to 12, approximately 12 to 36, approximately 12 to 34, approximately 12 to 32, approximately 12 to 30, approximately 12 to 28, approximately 12 to 26, approximately 12 to 24, approximately 12 to 22, approximately 12 to 20, approximately 12 to 18, approximately 12 to 16, approximately 12 to 14, approximately 14 to 36, approximately 14 to 34, approximately 14 to 32, approximately 14 to 30, approximately 14 to 28, approximately 14 to 26, approximately 14 to 24, approximately 14 to 22, about 14 to 20, about 14 to 18, about 14 to 16, about 16 to 36, about 16 to 34, about 16 to 32, about 16 to 30, about 16 to 28, about 16 to 26, about 16 to 24, about 16 to 22, about 16 to 20, about 16 to 18, about 18 to 36, about 18 to 34, about 18 to 32, about 18 to 30, about 18 to 28, about 18 to 26, about 18 to 24, about 18 to 22, about 18 to 20, about 20 to 36, about 20 to 34, about 20 to 32, approximately 20 to 30, approximately 20 to 28, approximately 20 to 26, approximately 20 to 24, approximately 20 to 22,about 22 to 36, about 22 to 34, about 22 to 32, about 22 to 30, about 22 to 28, about 22 to 26, about 22 to 24, about 24 to 36, about 24 to 34, about 24 to 32, about 24 to 30, about 24 to 28, about 24 to 26, about 26 to 36, about 26 to 34, about 26 to 32, about 26 to 30, about 26 to 28, about 28 to 36, about 28 to 34, about 28 to 32, about 28 to 30, about 30 to 36, about 30 to 34, about From 30 to 32, about 32 to 36, about 32 to 34 or from about 34 to 36 months.

[00173] In some embodiments, the microbial compositions of the present disclosure are shelf-stable at any of the disclosed temperatures and / or temperature ranges and extend for a period of time at a humidity Petition 870260102095, dated 02 / 10 / 2026, p. 106 / 641 98 / 159 relative to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97 or 98%.

[00174] Moisture content is a measure of the total amount of water in a composition, usually expressed as a percentage of the total weight. Moisture content is a useful measure for determining the dry weight of a composition and can be used to confirm whether the dehydration / drying process of a composition is complete. Moisture content is calculated by dividing the (wet weight of the composition minus the weight after dehydration / drying) by the wet weight of the composition and multiplying by 100.

[00175] Moisture content defines the amount of water in a composition, but water activity explains how the water in the composition will react with microorganisms. The higher the water activity, the faster microorganisms are able to grow. Water activity is calculated by finding the ratio of the vapor pressure in a composition to the vapor pressure of pure water. More specifically, water activity is the partial vapor pressure of water in a composition divided by the partial vapor pressure of standard state pure water. Pure distilled water has a water activity of 1. Determining the water activity of a composition is not the amount of water in a composition, but rather the amount of excess water that is available for microorganisms to use. Microorganisms have a minimum and ideal water activity for growth.

[00176] In some embodiments, the microbial compositions of this disclosure are dehydrated. A microbial composition is dehydrated if the moisture content of the composition is between 0% and 20%.

[00177] In some embodiments, the microbial compositions of the present disclosure have a moisture content of about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, Petition 870260102095, dated 02 / 10 / 2026, p. 107 / 641 99 / 159 about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, ou about 100%.

[00178] In some embodiments, the microbial compositions of the present disclosure have a moisture content of less than 0.5%, less than 0.6%, less than 0.7%, less than 0.8%, less than 0.9%, less than 1%, less than 2%, less than 3%, less than 4%, less than 5%, less than 6%, less than 7%, less than 8%, less than 9%, less than 10%, less than 11%, less than 12%, less than 13%, less than 14%, less than 15%, less than 16%, less than 17%, less than 18%, less than 19%, less than 20%, less than 21%, less than 22%, less than 23%, less than 24%, less than 25%, less than 26%, less than 27%, less than 28%, less than 29%, less than 30%, less than 31%, less than 32%, less than 33%, less than 34%, less than 35%, less than 36%, less than 37%, less than 38%, less than 39%, less than 40%, less than 41%, less than 42%, less than 43%, less than 44%, less than 45%, less than 46%, less than 47%, less than 48%, less than 49%, less than 50%, less than 51%, less than 52%, less than 53%, less than 54%, less than 55%,less than 56%, less than 57%, less than 58%, less than 59%, less than 60%, less than 61%, less than 62%, less than 63%, less than 64%, less than 65%, less than 66%, less than 67%, less than 68%, less than 69%, less than 70%, less than 71%, less than 72%, less than 73%, less than 74%, less than 75%, less than 76%, less than 77%, less than 78%, less than 79%, less than 80%, less than 81%, less than 82%, less than 83%, less than 84%, less than 85%, less than 86%, less than 87%, less than 88%, less than 89%, less than 90%, less than 91%, less than 92%, less than 93%, Petition 870260102095, dated 02 / 10 / 2026, page 108 / 641 100 / 159 less than 94%, less than 95%, less than 96%, less than 97%, less than 98%, less than 99%, or less than 100%.

[00179] In some embodiments, the microbial compositions of the present disclosure have a moisture content of less than about 0.5%, less than about 0.6%, less than about 0.7%, less than about 0.8%, less than about 0.9%, less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 11%, less than about 12%, less than about 13%, less than about 14%, less than about 15%, less than about 16%, less than about 17%, less than about 18%, less than about 19%, less than about 20%, less than about 21%, less than about 22%, less than about 23%, less than about 24%, less than about 25%, less than about 26%, less than about 27%, less than about 28%, less than about 29%, less than about 30%, less than about 31%, less than about 32%,less than approximately 33%, less than approximately 34%, less than approximately 35%, less than approximately 36%, less than approximately 37%, less than approximately 38%, less than approximately 39%, less than approximately 40%, less than approximately 41%, less than approximately 42%, less than approximately 43%, less than approximately 44%, less than approximately 45%, less than approximately 46%, less than approximately 47%, less than approximately 48%, less than approximately 49%, less than approximately 50%, less than approximately 51%, less than approximately 52%, less than approximately 53%, less than approximately 54%, less than approximately 55%, less than approximately 56%, less than approximately 57%, less than approximately 58%, less than approximately 59%, less than approximately of 60%, less than approximately 61%, less than approximately 62%, less than approximately 63%, less than approximately 64%, less than approximately 65%, less than approximately 66%, less than approximately 67%, less than approximately 68%, less than approximately 69%, less than approximately 70%, less than approximately 71%, less than approximately 72%, less than approximately 73%,less than about 74%, less than about 75%, less than about 76%, less than about 77%, less than about 78%, less than about 79%, less than about 80%, less than about 81%, less than about 82%, less than about 83%, less than about 84%, less than about 85%, less than about 86%, less than about 87%, less than about 88%, less than about 89%, less than about 90%, Petition 870260102095, dated 02 / 10 / 2026, page 109 / 641 101 / 159 less than approximately 91%, less than approximately 92%, less than approximately 93%, less than approximately 94%, less than approximately 95%, less than approximately 96%, less than approximately 97%, less than approximately 98%, less than approximately 99%, or less than approximately 100%.

[00180] In some embodiments, the microbial compositions of the present disclosure have a moisture content of 1% to 100%, 1% to 95%, 1% to 90%, 1% to 85%, 1% to 80%, 1% to 75%, 1% to 70%, 1% to 65%, 1% to 60%, 1% to 55%, 1% to 50%, 1% to 45%, 1% to 40%, 1% to 35%, 1% to 30%, 1% to 25%, 1% to 20%, 1% to 15%, 1% to 10%, 1% to 5%, 5% to 100%, 5% to 95%, 5% to 90%, 5% to 85%, 5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to 50%, 5% to 45%, 5% to 40%, 5% to 35%, 5% to 30%, 5% to 25%, 5% to 20%, 5% to 15%, 5% to 10%, 10% to 100%, 10% to 95%, 10% to 90%, 10% to 85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to 55%, 10% to 50%, 10% to 45%, 10% to 40%, 10% to 35%, 10% to 30%, 10% to 25%, 10% to 20%, 10% to 15%, 15% to 100%, 15% to 95%, 15% to 90%, 15% to 85%, 15% to 80%, 15% to 75%, 15% to 70%, 15% to 65%, 15% to 60%, 15% to 55%, 15% to 50%, 15% to 45%, 15% to 40%, 15% to 35%, 15% to 30%, 15% to 25%, 15% to 20%, 20% to 100%, 20% to 95%, 20% to 90%, 20% to 85%, 20% to 80%, 20% to 75%, 20% to 70%, 20% to 65%, 20% to 60%, 20% to 55%,20% a 50%, 20% a 45%, 20% a 40%, 20% a 35%, 20% a 30%, 20% a 25%, 25% a 100%, 25% a 95%, 25% a 90%, 25% a 85%, 25% a 80%, 25% a 75%, 25% a 70%, 25% a 65%, 25% a 60%, 25% a 55%, 25% a 50%, 25% a 45%, 25% a 40%, 25% a 35%, 25% a 30%, 30% a 100%, 30% a 95%, 30% a 90%, 30% a 85%, 30% a 80%, 30% a 75%, 30% a 70%, 30% a 65%, 30% a 60%, 30% a 55%, 30% a 50%, 30% a 45%, 30% a 40%, 30% a 35%, 35% a 100%, 35% a 95%, 35% a 90%, 35% a 85%, 35% a 80%, 35% a 75%, 35% a 70%, 35% a 65%, 35% a 60%, 35% a 55%, 35% a 50%, 35% a 45%, 35% a 40%, 40% a 100%, 40% a 95%, 40% a 90%, 40% a 85%, 40% a 80%, 40% a 75%, 40% a 70%, 40% a 65%, 40% a 60%, 40% a 55%, 40% a 50%, 40% a 45%, 45% a 100%, 45% a 95%, 45% a 90%, 45% a 85%, 45% a 80%, 45% a 75%, 45% a 70%, 45% a 65%, 45% a 60%, 45% a 55%, 45% a 50%, 50% a 100%, 50% a 95%, 50% a 90%, 50% a 85%, 50% a 80%, 50% a 75%, 50% a 70%, 50% a 65%, 50% a 60%, 50% a 55%, 55% a 100%, 55% a 95%, 55% a 90%, 55% a 85%, 55% a 80%, 55% a 75%, 55% a 70%, 55% a 65%, 55% a 60%,60% to 100%, 60% to 95%, 60% to 90%, 60% to 85%, 60% to 80%, 60% to 75%, 60% to 70%, 60% to 65%, 65% to 100%, 65% to, Petition 870260102095, dated 02 / 10 / 2026, page 110 / 641 102 / 159 95%, 65% to 90%, 65% to 85%, 65% to 80%, 65% to 75%, 65% to 70%, 70% to 100%, 70% to 95%, 70% to 90%, 70% to 85%, 70% to 80%, 70% to 75%, 75% to 100%, 75% to 95%, 75% to 90%, 75% to 85%, 75% to 80%, 80% to 100%, 80% to 95%, 80% to 90%, 80% to 85%, 85% to 100%, 85% to 95%, 85% to 90%, 90% a 100%, 90% to 95%, or 95% to 100%. Encapsulated Microbes

[00181] In some embodiments, the microbes and microbial compositions of the dissemination are encapsulated in an encapsulation composition. An encapsulation composition protects the microbes from external aggressors before entering the equine gastrointestinal tract. In some embodiments, external stressors include thermal, dehydrating, and physical stressors associated with granulation and extrusion. In some embodiments, external stressors include chemicals present in the compositions for which the encapsulating compositions create an environment that may be beneficial to the microbes, such as minimizing oxidative stress from an aerobic environment in anaerobic microbes, preserving the viability of microbes in which vegetative cells or spores form during the granulation / extrusion process, etc. See Kalsta et al. (US 5,104,662A), Ford (US 5,733,568A) and Mosbach and Nilsson (US 4,647.536A) for microbial encapsulation compositions and methods of microbial encapsulation.

[00182] In one embodiment, the compositions of the present disclosure exhibit thermal tolerance, which is used interchangeably with heat tolerance and heat resistance. In one embodiment, the heat-tolerant compositions of the present disclosure are tolerant to the high temperatures associated with feed manufacturing, feed mixing and compositions of the present disclosure, storage in high-heat environments, etc. In one embodiment, the heat-tolerant compositions of the present disclosure are resistant to heat death and denaturation of cell wall components and the intracellular environment. In one embodiment, the compositions of the present disclosure are tolerant or resistant to dehydration / water loss.

[00183] In one embodiment, the encapsulation is a reservoir-type encapsulation. In one embodiment, the encapsulation is a type of encapsulation. Petition 870260102095, dated 02 / 10 / 2026, p. 111 / 641 103 / 159 matrix. In one embodiment, the package is a coated matrix-type package. Burgain et al. (2011. J. Food Eng. 104:467-483) disclose numerous embodiments and encapsulation techniques, all incorporated by reference.

[00184] In some embodiments, the compositions of this disclosure are encapsulated in one or more of the following items: gellan gum, xanthan gum, K-carrageenan, cellulose acetate phthalate, chitosan, starch, milk fat, whey protein, calcium alginate, raftilose, raftilin, pectin, saccharide, glucose, maltodextrin, gum arabic, guar gum, seed flour, alginate, dextrins, dextrans, celluloase, gelatin, gelatin, gelatin, albumin, casein, gluten, gum arabic, tragacanth, wax, paraffin, stearic acid, mono- and diglycerides. In some embodiments, the compositions of this disclosure are encapsulated by one or more of a polymer, carbohydrate, sugar, plastic, glass, polysaccharide, lipid, wax, oil, fatty acid, or glyceride. In one embodiment, the microbial composition is encapsulated by a glucose-containing composition.In one embodiment, the microbial composition formulations comprise a glucose encapsulator. In another embodiment, the microbial composition formulations comprise a glucose-encapsulated composition.

[00185] In some embodiments, the encapsulation of the compositions of the present disclosure is carried out by extrusion, emulsification, coating, agglomeration, freeze-drying, vacuum drying or spray drying.

[00186] In one embodiment, the encapsulation composition comprises microcapsules with a multiplicity of liquid cores encapsulated in a solid coating material. For disclosure purposes, a multiplicity of cores is defined as two or more.

[00187] A first category of useful fuse protection materials is that of normally solid fats, including fats that already have adequate hardness and animal or vegetable fats and oils that are hydrogenated until their melting points are sufficiently high to meet the objectives of this disclosure. Depending on the desired process and storage temperatures and the specific material selected, a particular fat may be a normally solid or normally liquid material. The terms Petition 870260102095, dated 02 / 10 / 2026, page 112 / 641 104 / 159 Normally solid and normally liquid, as used in this document, refer to the state of a material at the desired temperatures for storing the resulting microcapsules. Since hydrogenated fats and oils do not, strictly speaking, have melting points, the term melting point is used to describe the minimum temperature at which the fusible material becomes sufficiently softened or liquid to be emulsified and spray-cooled, roughly corresponding to the maximum temperature at which the coating material has sufficient integrity to prevent the release of choline cores. Melting point is defined here similarly for other materials that do not have a sharp melting point.

[00188] Specific examples of fats and oils useful in this document (some of which require hardening) are: animal oils and fats, such as beef tallow, mutton tallow, lamb tallow, lard or pork fat, fish oil and sperm oil; vegetable oils, such as canola oil, cottonseed oil, peanut oil, corn oil, olive oil, soybean oil, sunflower oil, coconut oil, palm oil, linseed oil, tung oil and castor oil; monoglycerides and diglycerides of fatty acids; free fatty acids, such as stearic acid, palmitic acid and oleic acid; and mixtures thereof. The above list of oils and fats is not intended to be exhaustive, but merely exemplary.

[00189] Specific examples of fatty acids include linoleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, docosatetraenoic acid, vaccenic acid, nervosa, hydromel acid, erucic acid, gondoic acid, elaidic acid, oleic acid, palloleic acid, stearidonic acid, eicosapentaenoic acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecyclic acid, myristic acid, pentadecyclic acid, palmitic acid, margaric acid, stearic acid, nonadecyclic acid, arachidic acid, heneicosilic acid, behenic acid, tricosylic acid, lignoceric acid, pentacosylic acid, cerotic acid, heptacosylic acid, montanic acid, acid nonacosyl acid, melissic acid, henatriacontanoic acid, laceroic acid, psilic acid, gedic acid, ceroplastic acid, hexatriacontanoic acid, heptatriacontanoic acid, and octatriacontanoic acid.

[00190] Another category of fusible materials useful as encapsulation coating materials is waxes. Representative waxes contemplated Petition 870260102095, dated 02 / 10 / 2026, p. 113 / 641 105 / 159 for use in this invention are as follows: animal waxes, such as beeswax, lanolin, bark wax and Chinese insect wax; vegetable waxes, such as carnauba, candelilla, bush wax and sugarcane wax; mineral waxes, such as paraffin, microcrystalline petroleum, ozokerite, ceresin and montane; synthetic waxes, such as low molecular weight polyolefin (e.g., CARBOWAX) and polyol ether esters (e.g., sorbitol); Fischer-Tropsch process synthetic waxes; and mixtures thereof. Water-soluble waxes, such as CARBOWAX and sorbitol, are not contemplated herein if the core is aqueous.

[00191] In other fusible compounds, natural fusible resins such as rosin, balsam, shellac and mixtures thereof are also useful.

[00192] Various adjunct materials are contemplated for incorporation into fusible materials, according to the present disclosure. For example, antioxidants, light stabilizers, colorants and lakes, flavors, essential oils, anti-caking agents, fillers, pH stabilizers, sugars (monosaccharides, disaccharides, trisaccharides and polysaccharides) and the like may be incorporated into the fusible material in amounts that do not diminish its usefulness for the present disclosure.

[00193] The core material contemplated herein constitutes about 0.1% to about 50%, about 1% to about 35%, or about 5% to about 30% by weight of the microcapsules. In some embodiments, the core material contemplated herein constitutes no more than about 30% by weight of the microcapsules. In some embodiments, the core material contemplated herein constitutes about 5% by weight of the microcapsules. The core material is contemplated as liquid or solid at the contemplated storage temperatures of the microcapsules.

[00194] Cores may include other additives well known in the pharmaceutical art, including edible sugars such as sucrose, glucose, maltose, fructose, lactose, cellobiose, monosaccharides, disaccharides, trisaccharides, polysaccharides and mixtures thereof; artificial sweeteners such as aspartame, saccharin, cyclamate salts and mixtures thereof; edible acids such as acetic acid (vinegar), citric acid, ascorbic acid, tartaric acid and mixtures thereof; edible starches such as corn starch; hydrolyzed vegetable protein; water-soluble vitamins such as vitamin C; water-soluble drugs; materials Petition 870260102095, dated 02 / 10 / 2026, page 114 / 641 106 / 159 water-soluble nutritional ingredients, such as ferrous sulfate; flavorings; salts; monosodium glutamate; antimicrobial agents, such as ascorbic acid; antifungal agents, such as potassium sorbate, sorbic acid, sodium benzoate, and benzoic acid; food-grade pigments and colorants; and mixtures thereof. Other potentially useful supplementary core materials will become apparent to those skilled in the art.

[00195] Emulsifying agents can be used to aid in the formation of stable emulsions. Representative emulsifying agents include glyceryl monostearate, polysorbate esters, ethoxylated mono- and diglycerides, and mixtures thereof.

[00196] For ease of processing, and particularly to allow the successful formation of a reasonably stable emulsion, the viscosities of the core material and the protective material should be similar at the temperature at which the emulsion is formed. In particular, the ratio of the viscosity of the protective material to the viscosity of the core material, expressed in centipoise units or comparable, and both measured at the emulsion temperature, should be from about 22:1 to about 1:1, desirably from about 8:1 to about 1:1 and preferably from about 3:1 to about 1:1. A ratio of 1:1 would be ideal, but a viscosity ratio within the quoted ranges is useful.

[00197] Encapsulation compositions are not limited to microcapsule compositions as disclosed above. In some embodiments, the encapsulation compositions encapsulate the microbial compositions in an adhesive polymer that may be natural or synthetic without toxic effect. In some embodiments, the encapsulating composition may be a matrix selected from a sugar matrix, gelatin matrix, polymer matrix, silica matrix, starch matrix, foam matrix, glass / vitreous matrix, etc. See Pirzio et al. (US Patent 7,488,503).In some embodiments, the encapsulation composition may be selected from polyvinyl acetates; polyvinyl acetate copolymers; ethylene vinyl acetate (EVA) copolymers; polyvinyl alcohols; polyvinyl alcohol copolymers; celluloses, including ethylcelluloses, methylcelluloses, hydroxymethylcelluloses, hydroxypropylcelluloses and carboxymethylcellulose; polyvinylpyrrolidones; polysaccharides, including starch, modified starch, dextrins, maltodextrins, alginate and chitosans; monosaccharides; fats; fatty acids, including oils; proteins, including gelatin and zeins; gum arabic; shellac; vinylidene chloride and chloride copolymers. Petition 870260102095, dated 02 / 10 / 2026, page 115 / 641 107 / 159 vinylidene; calcium lignosulfonates; acrylic copolymers; polyvinyl acrylates; polyethylene oxide; acrylamide polymers and copolymers; polyhydroxyethyl acrylate, methylacrylamide monomers; and polychloroprene.

[00198] In some embodiments, the microbial composition or a subcomponent thereof is encapsulated in a solid glass matrix or in a flexible glass matrix (rubber matrix) comprising one or more polysaccharides, one or more saccharides and / or one or more sugar alcohols. In some embodiments, the matrix comprises a monosaccharide or a disaccharide. In some embodiments, the disaccharide may be selected from sucrose, maltose, lactose, lactulose, trehalose, cellobiose and chitobiose. In some embodiments, the polysaccharides, saccharides and / or sugar alcohols are added to the microbial composition or a subcomponent exogenously. In some embodiments, the matrix is ​​an amorphous matrix. In some embodiments, the microbial composition or a subcomponent thereof is vitrified. In some embodiments, the microbial composition or a subcomponent thereof is dehydrated. In some forms, the microbial composition or a subcomponent thereof is freeze-dried.In some embodiments, the microbial composition or a subcomponent thereof is spray-dried. In some embodiments, the microbial composition or a subcomponent thereof is spray-frozen. In some embodiments, the microbial composition is preserved / stabilized by vaporization preservation. l / erHarel and Kohavi-Beck (US Patent Application 8,097,245). 1 / erBronshtein (US Patent No. 9,469,835).

[00199] In some embodiments, the encapsulation compositions comprise at least one encapsulation layer. In some embodiments, the encapsulation compositions comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 encapsulation / encapsulating layers.

[00200] In some embodiments, the encapsulation compositions comprise at least two encapsulation layers. In some embodiments, each encapsulation layer imparts a different characteristic to the composition. In some embodiments, there are not two consecutive layers that Petition 870260102095, dated 02 / 10 / 2026, page 116 / 641 108 / 159 confer the same characteristic. In some embodiments, at least one layer of the at least two encapsulation layers confers thermostability, shelf stability, ultraviolet resistance, moisture resistance, desiccation resistance, hydrophobicity, hydrophilicity, lipophobicity, lipophilicity, pH stability, acid resistance and base resistance.

[00201] In some embodiments, the encapsulation compositions comprise two encapsulation layers; the first layer provides thermostability and / or shelf stability, and the second layer provides pH resistance.

[00202] In some embodiments, the encapsulation layers provide a timed release of the microbial composition held in the center of the encapsulation layers. In some embodiments, the greater the number of layers, the greater the amount of time provided before the microbial composition is exposed after administration.

[00203] In some embodiments, the encapsulation envelope of this disclosure may be up to 10 pm, 20 pm, 30 pm, 40 pm, 50 pm, 60 pm, 70 pm, 80 pm, 90 pm, 100 pm, 110 pm, 120 pm, 130 pm, 140 pm, 150 pm, 160 pm, 170 pm, 180 pm, 190 pm, 200 pm, 210 pm, 220 pm, 230 pm, 240 pm, 250 pm, 260 pm, 270 pm, 280pm, 290pm, 300pm, 310pm, 320pm, 330pm, 340pm, 350pm, 360pm, 370pm, 380pm, 390pm, 400pm, 410pm, 420pm, 430pm, 440pm, 450pm, 460pm, 470pm, 480pm, 490pm, 500pm, 510pm, 520pm, 530pm, 540pm, 550pm, 560pm, 570pm, 580pm, 590pm, 600pm, 610pm, 620pm, 630pm, 640pm, 650pm, 660 pm, 670 pm, 680 pm, 690 pm, 700 pm, 710 pm, 720 pm, 730 pm, 740 pm, 750 pm, 760 pm, 770 pm, 780 pm, 790 pm, 800 pm, 810 pm, 820 pm, 830 pm, 840 pm, 850 pm, 860 pm, 870 pm, 880 pm, 890 pm, 900 pm, 910 pm, 920 pm, 930 pm, 940 pm, 950 pm, 960 pm, 970 pm, 980 pm, 990 pm, 1000 pm, 1010 pm, 1020 pm, 1030 pm, 1040 pm, 1050 pm, 1060 pm, 1070 pm, 1080 pm, 1090 pm, 1100 pm, 1110 pm, 1120 pm, 1130 pm, 1140 pm, 1150 pm, 1160 pm, 1170 pm, 1180 pm, 1190 pm, 1200 pm, 1210 pm, 1220 pm, 1230 pm, 1240 pm, 1250 pm, 1260 pm, 1270 pm, 1280 pm, 1290 pm, 1300 pm, 1310 pm, 1320 pm, 1330 pm, 1340 pm, 1350 pm, 1360 pm, 1370 pm, 1380 pm, 1390 pm, 1400 pm, 1410 pm, 1420 pm, 1430 pm, 1440 pm, 1450 pm, 1460 pm, 1470 pm, 1480 pm, 1490 pm, 1500 pm, 1510 pm, 1520 pm, 1530 pm, 1540 pm, 1550pm, 1560pm, 1570 pm, 1580 pm, 1590 pm, 1600 pm, 1610 pm, 1620 pm, Petition 870260102095, dated 02 / 10 / 2026, page. 117 / 641 109 / 159 1630 pm, 1640 pm, 1650 pm, 1660 pm, 1670 pm, 1680 pm, 1690 pm, 1700 pm, 1710 pm, 1720 pm, 1730 pm, 1740 pm, 1750 pm, 1760 pm, 1770 pm, 1780 pm, 1790 pm, 1800 pm, 1810 pm, 1820 pm, 1830 pm, 1840 pm, 1850 pm, 1860 pm, 1870 pm, 1880 pm, 1890 pm, 1900 pm, 1910 pm, 1920 pm, 1930 pm, 1940 pm, 1950 pm, 1960 pm, 1970 pm, 1980 pm, 1990 pm, 2000 pm, 2010 pm, 2020 pm, 2030 pm, 2040 pm, 2050 pm, 2060 pm, 2070 pm, 2080 pm, 2090 pm, 2100 pm, 2110 pm, 2120 pm, 2130 pm, 2140 pm, 2150 pm, 2160 pm, 2170 pm, 2180 pm, 2190 pm, 2200 pm, 2210 pm, 2220 pm, 2230 pm, 2240 pm, 2250 pm, 2260 pm, 2270 pm, 2280 pm, 2290 pm, 2300 pm, 2310 pm, 2320 pm, 2330 pm, 2340 pm, 2350 pm, 2360 pm, 2370 pm, 2380 pm, 2390 pm, 2400 pm, 2410 pm, 2420 pm, 2430 pm, 2440 pm, 2450 pm, 2460 pm, 2470 pm, 2480 pm, 2490 pm, 2500 pm, 2510 pm, 2520 pm, 2530 pm, 2540 pm, 2550 pm, 2560 pm, 2570 pm, 2580 pm, 2590 pm, 2600 pm, 2610 pm, 2620 pm, 2630 pm, 2640 pm, 2650 pm, 2660 pm, 2670 pm, 2680 pm, 2690 pm, 2700 pm, 2710 pm, 2720 pm, 2730 pm,2740 pm, 2750 pm, 2760 pm, 2770 pm, 2780 pm, 2790 pm, 2800 pm, 2810 pm, 2820 pm, 2830 pm, 2840 pm, 2850 pm, 2860 pm, 2870 pm, 2880 pm, 2890 pm, 2900 pm, 2910 pm, 2920 pm, 2930 pm, 2940 pm, 2950 pm, 2960 pm, 2970 pm, 2980 pm, 2990 pm or 3000 pm thick. Animal Feed

[00204] In some embodiments, the microbial products of this disclosure are mixed with animal feed. In some embodiments, the animal feed may be present in various forms, such as pellets, capsules, granules, powder, liquid or semi-liquid.

[00205] In some embodiments, the products of this disclosure are mixed into the premix at the feed mill (e.g., Cargill or Western Mill), either alone as a standalone premix and / or alongside other feed additives such as MONENSIN, vitamins, etc. In another embodiment, the products of this disclosure are mixed into the feed at the feed mill. In another embodiment, the products of this disclosure are mixed into the feed itself.

[00206] In some embodiments, the ration may be supplemented with water, premix or premixes, forage, forage, beans (e.g., whole, cracked or ground), grains (e.g., whole, cracked or ground), bean or grain-based oils, grain-based flours or grains, grain-based pellets or silage. Petition 870260102095, dated 02 / 10 / 2026, page 118 / 641 110 / 159 or grains, grain or grain-based syrups, fatty acids, sugar alcohols (e.g., polyhydric alcohols), commercially available food formulas and mixtures thereof.

[00207] In some embodiments, the microbial compositions of the present disclosure are mixed into the premix or macerated alongside a water additive. In some embodiments, the water additive comprises citric acid monohydrate, trisodium citrate dehydrate, and inulin. In some embodiments, citric acid monohydrate constitutes approximately 0.05%, 0.075%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4.5%, 4.75% or 5.0% of the water additive. In some formulations, citrus monohydrate constitutes 0.4% of the water additive.In some embodiments, dehydrated trisodium citrate constitutes approximately 0.5%, 0.75%, 1.0%, 1.25%, 1.5%, 1.75%, 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4.5%, 4.75%, 5.0%, 5.25%, 5.5%, 5.75%, 6.0%, 6.25%, 6.5%, 6.75%, 7.0%, 7.25%, 7.5%, 7.75%, 8.0%, 8.25%, 8.5%, 8.75%, 9.0%, 9.25%, 9.5%, 9.75% or approximately 10% of the water additive. In some embodiments, dehydrated trisodium citrate constitutes approximately 4.25% of the water additive. In some embodiments, inulin constitutes approximately 5%, 10%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75% of the water additive. In some embodiments, inulin constitutes 28% of the water additive. In some embodiments, the water additive comprises 0.4% citric acid monohydrate, 4.25% trisodium citrate dehydrate, and 28% inulin.

[00208] In some embodiments, forage includes hay, fodder, and silage. In some embodiments, hay includes grass hay (e.g., Sudan grass, crabgrass, or similar), alfalfa hay, and clover hay. In some embodiments, fodder includes grass fodder, sorghum fodder, and alfalfa fodder. In some embodiments, silage includes corn, oats, wheat, alfalfa, clover, and similar.

[00209] In some applications, premixes or premixes may be used in the feed. Premixes may comprise micro-ingredients such as vitamins, minerals, amino acids; chemical preservatives; compositions Petition 870260102095, dated 02 / 10 / 2026, p. 119 / 641 111 / 159 pharmaceuticals, such as antibiotics and other medications; fermentation products and other ingredients. In some embodiments, the premixes are mixed into the feed.

[00210] In some embodiments, the feed may include feed concentrates such as soybean hulls, beet pulp, molasses, high-protein soybean meal, ground corn, hulled corn, wheat middlings, distillers grain, cottonseed hulls, rumen-derived protein, and grease. See Luhman (Publication LIS20150216817A1), Anderson et al. (US Patent 3,484,243), and Porter and Luhman (US Patent 9,179,694B2) for animal feed and animal feed supplements capable of being used in the present compositions and methods.

[00211] In some forms, the feed is given in the form of a component, which includes, in a mixed composition capable of meeting the basic needs of a diet, the feed itself, vitamins, minerals, amino acids and other necessary components. The compound feed may also include premixes.

[00212] In some embodiments, the microbial compositions of this disclosure may be mixed with animal feed, premixes and / or compound feed. Individual components of animal feed may be mixed with the microbial compositions before feeding the feed to ruminants. The microbial compositions of this disclosure may be applied in or on a premix or on a feed and / or in or on a compound feed. Methods for determining microbial abundance and co-occurrence of microorganisms with environmental parameters.

[00213] According to the methods provided in this document, a sample is processed to detect the presence of one or more types of microorganisms in the sample (Fig. 31, 1001; Fig. 32, 2001). The absolute number of one or more types of microorganisms in the sample is determined (Fig. 31, 1002; Fig. 32, 2002). The determination of the presence of one or more types of organisms and the absolute number of at least one type of organism can be conducted in parallel or in series. For example, in the case of a sample comprising a microbial community comprising bacteria (i.e., one type of microorganism) and fungi (i.e., a second type of microorganism), the user in one embodiment detects the Petition 870260102095, dated 02 / 10 / 2026, page 120 / 641 112 / 159 presence of one or both types of organisms in the sample (Fig. 31, 1001; Fig. 32, 2001). The user, in another mode, determines the absolute number of at least one type of organism in the sample - in this example, the number of bacteria, fungi or combinations thereof, in the sample (Fig. 31, 1002; Fig. 32, 2002).

[00214] In one embodiment, the sample, or a portion thereof, is subjected to flow cytometry (FC) analysis in order to detect the presence and / or number of one or more types of microorganisms (Fig. 31, 1001, 1002; Fig. 32, 2001, 2002). In one flow cytometer embodiment, individual microbial cells pass through an illumination zone at a speed of at least about 300 s⁻¹, or at least about 500 s⁻¹, or at least about 1000 s⁻¹. However, one skilled in the art will recognize that this speed may vary depending on the type of instrument used. Detectors that are electronically controlled measure the magnitude of a pulse representing the extent of scattered light. The magnitudes of these pulses are electronically classified into boxes or channels, allowing the display of histograms of the number of cells that have a certain quantitative property (e.g., cell staining property, diameter, cell membrane) in relation to the channel number.This analysis allows the determination of the number of cells in each box, which, in the modalities described in this document, is a box of a specific type of microorganism, for example: bacteria, fungi, nematodes, protozoa, archaea, algae, dinoflagellates, viruses, viroids, etc.

[00215] In one embodiment, the sample is stained with one or more dyes, where a fluorescent dye is specific to a particular type of microorganism, in order to enable detection by a flow cytometer or some other detection and quantification method that makes use of fluorescence, such as fluorescence microscopy. The method can provide quantification of the number of cells and / or cell volume of a particular type of organism in a sample. In another embodiment, as described in this document, flow cytometry is used to determine the presence and quantity of a first unique marker and / or second unique marker of organism type, such as enzyme expression, cell surface protein expression, etc.Three-variable histograms or contour plots of, for example, light scattering versus fluorescence of a cell membrane stain (versus fluorescence of a protein or DNA stain) can also be generated, and thus an impression can be obtained of the distribution. Petition 870260102095, dated 02 / 10 / 2026, page 121 / 641 113 / 159 of a variety of properties of interest among cells in the population as a whole. A number of displays of these multi-parameter flow cytometric data are in common use and are amenable to use with the methods described in this document.

[00216] In one embodiment of sample processing to detect the presence and number of one or more types of microorganism, a microscopy assay is used (Fig. 31, 1001, 1002). In one embodiment, the microscopy is optical microscopy, where visible light and a lens system are used to magnify images of small samples. Digital images can be captured by a CCD (double-charged device) camera. Other microscopic techniques include, without limitation, scanning electron microscopy and transmission electron microscopy. The types of microorganisms are visualized and quantified according to the aspects provided here.

[00217] In another method for detecting the presence and number of one or more types of microorganisms, the sample, or a portion thereof, is subjected to fluorescence microscopy. Different fluorescent dyes can be used to directly stain the cells in the samples and to quantify the total cell counts using an epifluorescence microscope, as well as flow cytometry, described above. Useful dyes for quantifying microorganisms include, but are not limited to, acridine orange (AO), 4,6-diamino-2-phenylindole (DAPI), and 5-cyano-2,3-ditolyl-tetrazolium chloride (CTC). Viable cells can be estimated by a viability staining method, such as the LIVE / DEAD® Bacterial Viability Kit (Bac-Light™), which contains two nucleic acid stains: the green-fluorescent SYTO 9™ dye penetrates all membranes, and the red-fluorescent propidium iodide (PI) dye penetrates cells with damaged membranes.Therefore, cells with compromised membranes will appear red, while cells with undamaged membranes will appear green. Fluorescence in situ hybridization (FISH) extends epifluorescence microscopy, allowing for the rapid detection and enumeration of specific organisms. FISH uses fluorescently labeled oligonucleotide probes (typically 15-25 base pairs) that bind specifically to the organism's DNA in the sample, allowing visualization of the cells using an epifluorescence or confocal laser scanning microscope (CLSM). Fluorescence in situ hybridization... Petition 870260102095, dated 02 / 10 / 2026, page 122 / 641 114 / 159 Catalyzed reporter deposition (CARD-FISH) improves the FISH method by using oligonucleotide probes labeled with horseradish peroxidase (HRP) to amplify the signal intensity obtained from the microorganisms to be studied. FISH can be combined with other techniques to characterize microorganism communities. One combined technique is high-affinity peptide nucleic acid (PNA)-FISH, where the probe has an enhanced ability to penetrate through the extracellular polymeric substance (EPS) matrix. Another example is LIVE / DEAD-FISH, which combines the cell viability kit with FISH and has been used to evaluate the efficiency of disinfection in drinking water distribution systems.

[00218] In another embodiment, the sample, or a portion thereof, is subjected to Raman microspectroscopy in order to determine the presence of one type of microorganism and the absolute number of at least one type of microorganism (Fig. 31, 1001-1002; Fig. 32, 2001-2002). Raman microspectroscopy is a non-destructive, label-free technology capable of detecting and measuring a single-cell Raman spectrum (SCRS). A typical SCRS provides an intrinsic biochemical fingerprint of a single cell. An SCRS contains rich information on the biomolecules within it, including nucleic acids, proteins, carbohydrates, and lipids, allowing for the characterization of different cell species, physiological alterations, and cellular phenotypes. Raman microscopy examines the scattering of laser light by the chemical bonds of different cellular biomarkers. An SCRS is a sum of the spectra of all biomolecules in a single cell, indicating the phenotypic profile of that cell.Cellular phenotypes, as a consequence of gene expression, generally reflect genotypes. Thus, under identical growth conditions, different types of microorganisms give distinct SCRS corresponding to differences in their genotypes and can be identified by their Raman spectra.

[00219] In yet another embodiment, a sample, or a portion thereof, is subjected to centrifugation to determine the presence of one type of microorganism and the absolute number of at least one type of microorganism (Fig. 31, 1001-1002; Fig. 32, 2001-2002). This process sediments a heterogeneous mixture using the centrifugal force created by a centrifuge. The denser components of the mixture migrate away from the axis of the centrifuge, while the less dense components of the mixture migrate towards the axis. Centrifugation can allow the fractionation of Petition 870260102095, dated 02 / 10 / 2026, page 123 / 641 115 / 159 samples in cytoplasmic, membrane, and extracellular portions. It can also be used to determine location information regarding biological molecules of interest. Furthermore, centrifugation can be used to fractionate the total DNA of the microbial community. Different prokaryotic groups differ in their guanine plus cytosine (G+C) DNA content, so density gradient centrifugation based on G+C content is a method to differentiate organism types and the number of cells associated with each type. The technique generates a fractionated profile of the entire community's DNA and indicates DNA abundance as a function of G+C content.All the DNA from the community is physically separated into highly purified fractions, each representing a different G+C content that can be analyzed by additional molecular techniques such as denaturing gradient gel electrophoresis (DGGE) / amplified ribosomal DNA restriction analysis (ARDRA) (see discussion in this document) to assess the total diversity of the microbial community and the presence / quantity of one or more types of microorganisms.

[00220] In another embodiment, the sample, or a portion thereof, is subjected to staining to determine the presence of a type of microorganism and the absolute number of at least one type of microorganism (Fig. 31, 1001-1002; Fig. 32, 2001-2002). Stains and dyes can be used to visualize biological tissues, cells, or organelles within cells. Staining can be used in conjunction with microscopy, flow cytometry, or gel electrophoresis to visualize or label cells or biological molecules that are unique to different types of microorganisms. In vivo staining is the process of dyeing living tissues, while in vitro staining involves dyeing cells or structures that have been removed from their biological context.Examples of specific staining techniques for use with the methods described herein include, without limitation: Gram staining to determine the Gram state of bacteria, endospore staining to identify the presence of endospores, Ziehl-Neelsen staining, hematoxylin and eosin staining to examine tissue sections, Papanicolaou staining to examine cell samples from various bodily secretions, periodic acid-Schiff staining of carbohydrates, Masson's trichome staining employing a three-color staining protocol to distinguish cells from surrounding connective tissue, Romanowsky stains (or common variants including Wright's heart staining, etc.). Petition 870260102095, dated 02 / 10 / 2026, page 124 / 641 116 / 159 Jenner, May-Grunwald staining, Leishman and Giemsa staining) for examining blood or bone marrow samples, silver staining to reveal proteins and DNA, Sudan staining for lipids, and Conklin staining to detect true endospores. Common biological dyes include acridine orange for cell cycle determination; Bismarck marrow for acidic mucins; carmine for glycogen; alum carmine for nuclei; Coomassie blue for proteins; cresyl violet for the acidic components of neuronal cytoplasm; crystal violet for cell walls; DAPI for nuclei; eosin for cytoplasmic material, cell membranes, some extracellular structures, and red blood cells; ethidium bromide for DNA; acid fuchsin for collagen, smooth muscle, or mitochondria; hematoxylin for nuclei; Hoechst stains for DNA; iodine for starch; Malachite green is used for bacteria in the Gimenez staining technique and for spores;Methyl green for chromatin; methylene blue for animal cells; neutral red for Nissl substance; Nile blue for nuclei; Nile red for lipohylic entities; osmium tetroxide for lipids; rhodamine is used in fluorescence microscopy; safranin for nuclei. Stains are also used in transmission electron microscopy to increase contrast and include phosphotungstic acid, osmium tetroxide, ruthenium tetroxide, ammonium molybdate, cadmium iodide, carbohydrazide, ferric chloride, hexamine, indium trichloride, lanthanum nitrate, lead acetate, lead citrate, lead(II) nitrate, periodic acid, phosphomolybdic acid, potassium ferricyanide, potassium ferrocyanide, ruthenium red, silver nitrate, silver proteinate, sodium chloroaurate, thallium nitrate, thiosemicarbazide, uranyl acetate, uranyl nitrate, and vanadium sulfate.

[00221] In another embodiment, the sample, or a portion thereof, is subjected to mass spectrometry (MS) to determine the presence of a microorganism type and the absolute number of at least one microorganism type (Fig. 31, 1001-1002; Fig. 32, 2001-2002). MS, as discussed below, can also be used to detect the presence and expression of one or more unique markers in a sample (Fig. 31, 1003-1004; Fig. 32, 2003-2004). MS is used, for example, to detect the presence and quantity of protein and / or peptide markers unique to microorganism types and, therefore, to provide an assessment of the respective microorganism type number in the sample. Quantification can be with stable isotopic labeling or without labeling. De novo sequencing Petition 870260102095, dated 02 / 10 / 2026, page 125 / 641 117 / 159 of peptides can also occur directly from MS / MS spectra or from sequence labeling (producing a short label that can be compared to a database). MS can also reveal post-translational modifications of proteins and identify metabolites. MS can be used in conjunction with chromatographic and other separation techniques (such as gas chromatography, liquid chromatography, capillary electrophoresis, ion mobility) to improve resolution and mass determination.

[00222] In another embodiment, the sample, or a portion thereof, is subjected to lipid analysis to determine the presence of one type of microorganism and the absolute number of at least one type of microorganism (Fig. 31, 1001-1002; Fig. 32, 2001-2002). Fatty acids are present in a relatively constant proportion of cell biomass, and there are signature fatty acids in microbial cells that can differentiate types of microorganisms within a community. In one embodiment, fatty acids are extracted by saponification, followed by derivatization to generate the respective fatty acid methyl esters (FAMEs), which are then analyzed by gas chromatography. The FAME profile in one embodiment is then compared to a reference FAME database to identify the fatty acids and their corresponding microbial signatures by multivariate statistical analyses.

[00223] In the aspects of the methods provided in this document, the number of the first unique markers in the sample, or part thereof (e.g., sample aliquot), is measured, as well as the abundance of each of the first unique markers (Fig. 31, 1003; Fig. 32, 2003). A unique marker is a marker of a strain of microorganism. It should be understood by one skilled in the art that, depending on the unique marker to be investigated and measured, it is not necessary to analyze the entire sample. For example, if the unique marker is unique to bacterial strains, then the fungal portion of the sample does not need to be analyzed. As described above, in some embodiments, the measurement of the absolute abundance of one or more types of organisms in a sample comprises separating the sample by organism type, for example, via flow cytometry.

[00224] Any marker that is unique to a strain of organism may be used in this document. For example, markers may include, but are not limited to, small subunit ribosomal RNA genes (16S / 18S rDNA), Petition 870260102095, dated 02 / 10 / 2026, p. 126 / 641 118 / 159 large subunit ribosomal RNA genes (23S / 25S / 28S rDNA), 5.8S intercalary gene, cytochrome c oxidase, beta-tubulin, elongation factor, RNA polymerase and internal transcribed spacer (ITS).

[00225] Ribosomal RNA (rDNA) genes, especially small subunit ribosomal RNA genes, i.e., 18S rRNA (18S rDNA) genes in eukaryotes and 16S rRNA (16S rDNA) genes in prokaryotes, have been the predominant target for assessing organism types and lineages in a microbial community. However, large subunit ribosomal RNA genes, 28S rDNAs, have also been targeted. rDNAs are suitable for taxonomic identification because: (i) they are ubiquitous in all known organisms; (ii) they possess both conserved and variable regions; (iii) there is an exponentially expanding database of their sequences available for comparison. In community sample analysis, conserved regions serve as annealing sites for corresponding universal PCR and / or sequencing primers, while variable regions can be used for phylogenetic differentiation.Furthermore, the high number of rDNA copies in cells facilitates the detection of environmental samples.

[00226] The internal transcribed spacer (ITS), located between 18S rDNA and 28S rDNA, was also targeted. The ITS is transcribed but processed before ribosome assembly. The ITS region is composed of two highly variable spacers, ITS1 and ITS2, and the 5.8S intercalary gene. This rDNA operon occurs in multiple copies across genomes. Since the ITS region does not encode ribosomal components, it is highly variable.

[00227] In one embodiment, the single RNA marker may be an mRNA marker, an siRNA marker, or a ribosomal RNA marker.

[00228] Functional protein-coding genes can also be used here as a single first marker. These markers include, without limitation: the recombinase A gene family (bacterial RecA, Archaea RadA and RadB, eukaryotic Rad51 and Rad57, and phage UvsX); the RNA polymerase β subunit gene (RpoB), responsible for transcription initiation and elongation; chaperonins. Candidate marker genes have also been identified for bacteria and archaea: ribosomal protein S2 (rpsB), ribosomal protein S10 Petition 870260102095, dated 02 / 10 / 2026, page 127 / 641 119 / 159 (rpsJ), ribosomal protein L1 (rplA), translation elongation factor EF-2, translation initiation factor IF-2, metalloendopeptidase, ribosomal protein L22, signal recognition particle protein ffh, ribosomal protein L4 / L1e (rplD), ribosomal protein L2 (rplB), ribosomal protein S9 (rpsl), ribosomal protein L3 (rplC), phenylalanine synthetase beta subunit, ribosomal protein L14b / L23e (rplN), ribosomal protein S5, ribosomal protein S19 (rpsS), ribosomal protein S7, ribosomal protein L16 / L10E (rplP), ribosomal protein S13 (rpsM), phenosalanyl tRNA synthetase α subunit, ribosomal protein L15, ribosomal protein L25 / L23, ribosomal protein L6 (rplF), ribosomal protein L11 (rplK), ribosomal protein L5 (rplE), ribosomal protein S12 / S23, ribosomal protein L29, ribosomal protein S3 (rpsC), ribosomal protein S11 (rpsK), ribosomal protein L10, ribosomal protein S8, tRNA ps eudouridine synthase B,ribosomal protein L18P / L5E, ribosomal protein S15P / S13e, porphobilinogen deaminase, ribosomal protein S17, ribosomal protein L13 (rpIM), phosphoribosylformylglycinamidine cycloligase (rpsE), ribonuclease H11, and ribosomal protein L24. Other candidate marker genes from bacteria include: transcription elongation proteins NusA (nusA), DNA-directed RNA polymerase beta subunit rpoB (rpoB), GTP-binding protein EngA, DNA-directed RNA polymerase beta subunit rpoC, primosome assembly protein priA, transcription repair coupling factor, CTP synthase (pyrG), preprotein translocase SecY subunit secY, GTP-binding protein Obg / CgtA, DNA polymerase I, ribosomal protein S6 30S rpsF, DNA-directed RNA polymerase alpha subunit poA, peptide chain release factor 1, ribosomal protein L9 rpll 50S, polyribonucleotide nucleotidyltransferase, elongation factor Ts (tsf),L17 rplQ 50S ribosomal protein, tRNA (guanine-N(1)-)-methyltransferase (rpIS), probable L25 rplY 50S ribosomal protein, RadA DNA repair protein, glucose-inhibited cleavage protein A, ribosome-binding factor A, MutL DNA mismatch repair protein, SsrA-binding protein smpB (smpB), N-acetylglucosaminyl transferase, S-adenosyl methyltransferase MraW, UDP-N-acetylmuramoilanine-D-glutamate ligase, L19 rpIS ribosomal protein, L20 rpIT ribosomal protein, Holliday junction DNA helicase ruvA, Holliday junction DNA helicase ruvB, seryl-tRNA synthetase serS, L21 ribosomal protein 50S rplll, ribosomal protein S18 rpsR 30S, repair protein, Petition 870260102095, dated 02 / 10 / 2026, page 128 / 641 120 / 159 MutS DNA mismatch, ribosomal protein S20 30S rpsT, DNA repair protein RecN, ribosome recycling factor frr, recombination protein RecR, protein of unknown function UPF0054, tRNA isopentenyltransferase miaA, GTP-binding protein YchF, chromosome replication initiator protein DnaA, dephospho-CoA kinase, 16S rRNA processing protein RimM, ATP-cone domain protein, 1-deoxy-D-xylulose 5-phosphate reductoisomerase, 2C-methyl-D-erythritol 2,4-cyclobisphosphate synthase, fatty acid / phospholipid synthesis protein PlsX, tRNA(lle)-lysidine synthetase, DNA primase dnaG (dnaG), Holliday junction resolvase ruvC, ribosomal protein S16 30S rpsP, recombinase A recA, riboflavin biosynthesis protein RibF, glycyl-tRNA synthetase beta subunit, trmll tRNA (5-methylaminomethyl-2-thiourylate)-methyltransferase, ribosomal protein L35 50S rpm I, uroporphyrogen decarboxylase hemE,Rod shape-determining protein, L27 50S rpmA ribosomal protein (rpmA), peptidyl-tRNA hydrolase, translation initiation factor IF-3 (infC), UDP-N-acetylmuramyl-tripeptide synthetase, L32 50S rpmF ribosomal protein, L7 / L12 50S rpIL ribosomal protein (rpIL), leucyl-tRNA synthetase leuS, NAD-dependent DNA ligase ligA, FtsA cell division protein, TypA GTP-binding protein, ATP-dependent Clp protease, CIpX ATP-binding subunit, RecF DNA repair and replication protein, and UDP-N-acetylenelpyruvylglucosamine reductase.

[00229] Phospholipid fatty acids (PLFAs) can also be used as unique first markers according to the methods described in this document. Since PLFAs are rapidly synthesized during microbial growth, they are not found in storage molecules and degrade rapidly during cell death, providing an accurate census of the current living community. All cells contain fatty acids (FAs) that can be extracted and esterified to form fatty acid methyl esters (FAMEs). When FAMEs are analyzed using gas chromatography-mass spectrometry, the resulting profile constitutes a fingerprint of the microorganisms in the sample. The chemical compositions of membranes of organisms in the Bacteria and Eukarya domains are composed of fatty acids linked to glycerol by an ester-type bond (phospholipid fatty acids (PLFAs)).In contrast, the membrane lipids of Archaea are composed of long, branched hydrocarbons. Petition 870260102095, dated 02 / 10 / 2026, page 129 / 641 121 / 159 which are linked to glycerol by an ether-type bond (phospholipid ether lipids (PLELs)). This is one of the most widely used non-genetic criteria for distinguishing the three domains. In this context, phospholipids derived from microbial cell membranes, characterized by different acyl chains, are excellent signature molecules, as this structural diversity can be linked to a specific microbial taxon.

[00230] As provided in this document, in order to determine whether a strain of an organism is active, the expression level of one or more of the second unique markers is measured, which may be the same as or different from the first marker (Fig. 31, 1004; Fig. 32, 2004). The first unique markers are described above. The second unique marker is a marker of microorganism activity. For example, in one embodiment, the mRNA or protein expression of any of the first markers described above is considered as a second unique marker for the purposes of this invention.

[00231] In one embodiment, if the expression level of the second marker is above a threshold level (e.g., a control level) or at a threshold level, the microorganism is considered active (Fig. 31, 1005; Fig. 32, 2005). Activity is determined in one embodiment if the expression level of the second marker is altered by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, or at least about 30% compared to a threshold level, which in some embodiments is a control level.

[00232] Second unique markers are measured, in one modality, at the protein, RNA, or metabolite level. A second unique marker is the same as or different from the first unique marker.

[00233] As foreseen above, several unique first markers and unique second markers can be detected, according to the methods described in this document. Furthermore, the detection and quantification of a unique first marker is performed according to methods known to those skilled in the art (Fig. 31, 1003-1004, Fig. 32, 2003-2004).

[00234] Nucleic acid sequencing (e.g., gDNA, cDNA, rRNA, mRNA) in one modality is used to determine the absolute abundance Petition 870260102095, dated 02 / 10 / 2026, p. 130 / 641 122 / 159 of a first unique marker and / or a second unique marker. Sequencing platforms include, but are not limited to, Sanger and high-throughput sequencing methods, provided by Roche / 454 Life Sciences, Illumina / Solexa, Pacific Biosciences, Ion Torrent, and Nanopore. Sequencing may be amplicon sequencing of specific DNA or RNA sequences or shotgun sequencing of the complete metagenome / transcriptome.

[00235] Traditional Sanger sequencing (Sanger et al. (1977) DNA sequencing with chain termination inhibitors. Proc Natl. Acad. Sci. USA, 74, pp. 5463-5467, incorporated herein by reference in its entirety) is based on the selective incorporation of chain termination dideoxynucleotides by DNA polymerase during DNA replication in vitro and is available for use with the methods described in this document.

[00236] In another embodiment, the sample, or a portion thereof, is subjected to nucleic acid extraction, amplification of the DNA of interest (such as the rRNA gene) with appropriate primers, and construction of clone libraries using sequencing vectors. The selected clones are then sequenced by Sanger sequencing and the nucleotide sequence of the DNA of interest is recovered, allowing the calculation of the number of unique strains of microorganisms in a sample.

[00237] 454 Roche pyrosequencing / 454 Life Sciences produces long reads and can be leveraged in the methods described in this document (Margulies et al. (2005) Nature, 437, pp. 376-380; U.S. Patents Nos. 6,274,320; 6,258,568; 6,210,891, each of which is incorporated herein in its entirety for all purposes). The nucleic acid to be sequenced (e.g., amplicons or nebulized genomic / metagenomic DNA) has specific adapters attached at each end by PCR or ligation. The adapter-equipped DNA is fixed in small beads (ideally, one bead will have one DNA fragment) which are suspended in an oil-in-water emulsion. An emulsion PCR step is then performed to make multiple copies of each DNA fragment, resulting in a series of beads where each bead contains multiple cloned copies of the same DNA fragment.Each bead is then placed in a well of a fiber optic chip that also contains enzymes necessary for the sequencing reactions. Petition 870260102095, dated 02 / 10 / 2026, page 131 / 641 123 / 159 synthesis. The addition of bases (such as A, C, G, or T) triggers the release of pyrophosphate, which produces flashes of light that are recorded to infer the sequence of DNA fragments in each well. Approximately 1 million reads per run with reads up to 1,000 bases in length can be obtained. Paired-end sequencing can be performed, which produces pairs of reads, each starting at one end of a given DNA fragment. A molecular barcode can be created and placed between the adapter sequence and the sequence of interest in multiplex reactions, allowing each sequence to be bioinformatically assigned to a sample.

[00238] Illumina / Solexa sequencing produces average read lengths of about 25 base pairs (bp) to about 300 bp (Bennett et al. (2005) Pharmacogenomics, 6:373-382; Lange et al. (2014). BMC Genomics 15, p. 63; Fadrosh et al. (2014) Microbiome 2, p. 6; Caporaso et al. (2012) ISME J, 6, p. 162-1624; Bentley et al. (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature, 456:53-59). This sequencing technology is also a synthesis sequencing, but it uses reversible dye terminators and a flow cell with an attached oligo field. The DNA fragments to be sequenced have specific adapters at each end and are washed over a flow cell filled with specific oligonucleotides that hybridize the fragment ends. Each fragment is then replicated to make a cluster of identical fragments.Reversible dye-terminating nucleotides are then washed over the flow cell and allowed the necessary time to couple. Excess nucleotides are washed away, the flow cell is visualized, and the reversible terminators can be removed so the process can be repeated and nucleotides can continue to be added in subsequent cycles. Paired-end reads of 300 bases in length can be achieved. An Illumina platform can produce 4 billion paired-end fragments, with 125 bases for each read in a single run. Barcodes can also be used for sample multiplexing, but indexing primers are used instead.

[00239] The SOLiD process (ligation sequencing and oligonucleotide detection, Life Technologies) is a ligation sequencing approach and can be used with the methods described in this document to detect Petition 870260102095, dated 02 / 10 / 2026, p. 132 / 641 124 / 159 the presence and abundance of a first marker and / or a second marker. (Fig. 31, 1003-1004; Fig. 32, 2003-2004) (Peckham et al. SOLID™ Sequencing and 2-Base Encoding. San Diego, CA: American Society of Human Genetics, 2007; Mitra et al. (2013) Analysis of the intestinal microbiota using SOLID 16S rRNA gene sequencing and SOLID shotgun sequencing. BMC Genomics, 14(Suppl 5): S16; Mardis (2008) Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet, 9:387-402; each incorporated herein by reference in its entirety). A library of DNA fragments is prepared from the sample to be sequenced and is used to prepare populations of clonal beads, where only one species of the fragment will be present on the surface of each magnetic bead. The fragments attached to the magnetic beads will have a universal P1 adapter sequence so that the initial sequence of each fragment is known and identical.The primers hybridize with the P1 adapter sequence in the library template. A series of four fluorescently labeled di-base probes compete for binding to the sequencing primer. The specificity of the di-base probe is obtained by interrogating each 1a and 2a base in each binding reaction. Multiple cycles of binding, detection, and cleavage are performed, with the number of cycles determining the eventual read length. The SOLiD platform can produce up to 3 billion reads per run with reads of 75 bases in length. Paired-end sequencing is available and can be used here, but with the second read in the pair being only 35 bases long. Sample multiplexing is possible through a system similar to that used by Illumina, with a separate indexing run.

[00240] The Ion Torrent system, like the 454 sequencing system, is suitable for use with the methods described in this document to detect the presence and abundance of a first marker and / or a second marker (Fig. 31, 2003-2004; Fig. 32, 2003-2004). It uses a microwell plate containing microgranules to which DNA fragments are attached. It differs from all other systems, however, in the way base incorporation is detected. When a base is added to a growing DNA strand, a proton is released, which slightly alters the surrounding pH. pH-sensitive microdetectors are associated with the wells in the plate and record when these changes occur. The different bases (A, C, G, T) are washed sequentially through the wells. Petition 870260102095, dated 02 / 10 / 2026, page 133 / 641 125 / 159 allowing inference of the sequence of each well. The Ion Proton platform can produce up to 50 million reads per run with read lengths of 200 bases. The Personal Genome Machine platform has longer reads of 400 bases. Bidirectional sequencing is available. Multiplexing is possible through standard inline molecular barcode sequencing.

[00241] The Pacific Biosciences SMRT (PacBio) sequencing system utilizes a single-molecule, real-time sequencing approach and, in one modality, is used with the methods described in this document to detect the presence and abundance of a first marker and / or a second marker (Fig. 31, 1003-1004; Fig. 32, 2003-2004). The PacBio sequencing system does not involve any amplification steps, differentiating it from other major next-generation sequencing systems. In one modality, sequencing is performed on a chip containing multiple zero-mode waveguide (ZMW) detectors. DNA polymerases are ligated to the ZMW detectors, and the incorporation of phospholinked dye-labeled nucleotides is visualized in real time as the DNA strands are synthesized. The PacBio system produces very long read lengths (on average, about 4,600 bases) and a very high number of reads per run (about 47,000).The typical paired-end approach is not used with PacBio, as reads are typically long enough that fragments, via CCS, can be covered multiple times without needing to sequence each end independently. Multiplexing with PacBio does not involve independent reading, but follows the standard inline barcode model.

[00242] In one embodiment, where the first unique marker is in the ITS genomic region, an automated ribosomal intergenic spacer analysis (ARISA) is used to determine the number and identity of microorganism strains in a sample (Fig. 31, 2003, Fig. 32, 2003) (Ranjard et al. (2003). Environmental Microbiology 5, pp. 1111-1120, incorporated by reference in its entirety for all purposes). The ITS region has significant heterogeneity in nucleotide length and sequence. The use of a fluorescently labeled forward primer and an automated DNA sequencer enables high separation resolution and high throughput. The inclusion of an internal standard in each sample provides precision in sizing. Petition 870260102095, dated 02 / 10 / 2026, page 134 / 641 126 / 159 general fragments.

[00243] In another embodiment, fragment length polymorphism (RFLP) of PCR-amplified rDNA fragments, also known as restriction analysis of amplified ribosomal DNA (ARDRA), is used to characterize the first unique markers and their abundance in the samples (Fig. 31, 1003, Fig. 32, 2003) (Massol-Deya et al. (1995). Mol. Microb. Ecol. Manual. 3.3.2, pp. 1-18, incorporated by reference in its entirety for all purposes). The rDNA fragments are generated by PCR using general primers, digested with restriction enzymes, subjected to electrophoresis on agarose or acrylamide gels, and stained with ethidium bromide or silver nitrate.

[00244] One printing technique used to detect the presence and abundance of a single first marker is single-strand conformation polymorphism (SSCP) (Lee et al. (1996). Appl Environ Microbiol 62, pp. 3112-3120; Scheinert et al. (1996). J. Microbiol. Methods 26, pp. 103-117; Schwieger & Tebbe (1998). Appl. In this technique, DNA fragments, such as PCR products obtained with specific primers for the 16S rRNA gene, are denatured and directly subjected to electrophoresis on a non-denaturing gel. Separation is based on differences in size and the folded conformation of single-stranded DNA, which influences electrophoretic mobility.Recanalization of DNA strands during electrophoresis can be avoided by a number of strategies, including the use of a phosphorylated primer in PCR, followed by specific digestion of the phosphorylated strands with lambda exonuclease, and the use of a biotinylated primer to perform magnetic separation of a single strand after denaturation. To assess the identity of the predominant populations in a given bio-set, in one modality, the bands are excised and sequenced, or SSCP patterns can be hybridized with specific probes. Electrophoretic conditions, such as the gel matrix, temperature, and the addition of glycerol to the gel, can influence the separation.

[00245] In addition to sequencing-based methods, other methods for quantifying the expression (e.g., gene and protein expression) of a second marker are usable with the methods provided here to determine the expression level of one or more of the second markers (Fig. 31, Petition 870260102095, dated 02 / 10 / 2026, p. 135 / 641 127 / 159 1004; Fig. 32, 2004). For example, quantitative RT-PCR, microarray analysis, linear amplification techniques, such as nucleic acid sequence-based amplification (NASBA), are all usable with the methods described in this document and can be performed according to methods known to those skilled in the art.

[00246] In another embodiment, the sample, or a portion thereof, is subjected to a quantitative polymerase chain reaction (PCR) to detect the presence and abundance of a first and / or second marker (Fig. 31, 1003-1004; Fig. 32, 2003-2004). The specific activity of microorganism strains is measured by reverse transcription of ribosomal and / or messenger RNA (rRNA and mRNA) into complementary DNA (cDNA), followed by PCR (RT-PCR).

[00247] In another embodiment, the sample, or a portion thereof, is subjected to PCR-based imprinting techniques to detect the presence and abundance of a first and / or second marker (Fig. 31, 1003-1004; Fig. 32, 2003-2004). The PCR products can be separated by electrophoresis based on nucleotide composition. Sequence variation among different DNA molecules influences fusion behavior, and therefore molecules with different sequences stop migrating at different positions in the gel. Thus, electrophoretic profiles can be defined by the position and relative intensity of different bands or peaks and can be translated into numerical data for the calculation of diversity indices. The bands can also be removed from the gel and subsequently sequenced to reveal the phylogenetic affiliation of community members.Electrophoresis methods include, but are not limited to: denaturing gradient gel electrophoresis (DGGE), temperature gradient gel electrophoresis (TGGE), single-strand polymorphism (SSCP), restriction fragment length polymorphism (RFLP) analysis or amplified ribosomal DNA restriction analysis (ARDRA), terminal restriction fragment length polymorphism (T-RFLP) analysis, automated ribosomal intergenic spacer analysis (ARISA), randomly amplified polymorphic DNA (RAPD), DNA amplification fingerprinting (DAF), and Bb-PEG electrophoresis.

[00248] In another embodiment, the sample, or a portion thereof, is subjected to a chip-based platform, such as microarrays or microfluidics, to determine the Petition 870260102095, dated 02 / 10 / 2026, page 136 / 641 128 / 159 abundance of a first unique marker and / or the presence / abundance of a second unique marker (Fig. 31, 1003-1004, Fig. 32, 2003-2004). PCR products are amplified from all DNA in the sample and hybridized directly with known molecular probes fixed in microarrays. After the fluorescence-labeled PCR fragments are hybridized with the probes, positive signals are classified using confocal laser scanning microscopy. With the microarray technique, samples can be rapidly evaluated for replication, which is a significant advantage in microbial community analyses. In general, the hybridization signal intensity in microarrays is directly proportional to the abundance of the target organism. The universal high-density 16S microarray (PhyloChip) contains approximately 30,000 16S rRNA gene probes targeting various cultured microbial species and candidate strains.These probes target all 121 demarcated prokaryotic orders and allow the simultaneous detection of 8,741 bacterial and archaeal taxa. Another microarray in use for profiling microbial communities is the functional gene array (FGA). Unlike PhyloChips, FGAs are primarily designed to detect specific metabolic groups of bacteria. Thus, the FGA not only reveals community structure but also sheds light on the metabolic potential of the community in situ. The FGA contains probes of genes with known biological functions, therefore they are useful for linking microbial community composition to ecosystem functions. An FGA called GeoChip contains >24,000 probes of all known metabolic genes involved in various biogeochemical, ecological, and environmental processes, such as ammonia oxidation, methane oxidation, and nitrogen fixation.

[00249] A protein expression assay, in one embodiment, is used with the methods described in this document in order to determine the expression level of one or more of the second markers (Fig. 31, 1004; Fig. 32, 2004). For example, in one embodiment, mass spectrometry or an immunoassay, such as an enzyme-linked immunosorbent assay (ELISA), is used to quantify the expression level of one or more of the second markers, where one or more of the single second markers are a protein.

[00250] In one embodiment, the sample, or a portion thereof, is subjected to the incorporation of bromodeoxyuridine (BrdU) to determine the level of a second Petition 870260102095, dated 02 / 10 / 2026, p. 137 / 641 129 / 159 single marker (Fig. 31, 2004; Fig. 32, 2004). Brdll, a synthetic nucleoside analog of thymidine, can be incorporated into the newly synthesized DNA of replicating cells. Specific antibodies to BRdU can then be used for detection of the base analog. Thus, Brdll incorporation identifies cells that are actively replicating their DNA, a measure of a microorganism's activity according to one embodiment of the methods described herein. BrdU incorporation can be used in combination with FISH to provide the identity and activity of target cells.

[00251] In one embodiment, the sample, or a portion thereof, is subjected to microautoradiography (MAR) combined with FISH to determine the level of a second unique marker (Fig. 31, 1004; Fig. 32, 2004). MAR-FISH is based on the incorporation of radioactive substrate into cells, detection of active cells by autoradiography, and identification of cells by FISH. Detection and identification of active cells at single-cell resolution is performed with a microscope. MAR-FISH provides information on total cells, probe target cells, and the percentage of cells incorporating a given radiolabeled substance. The method provides an assessment of the in situ function of target microorganisms and is an effective approach to studying the in vivo physiology of microorganisms. A technique developed for quantification of cell-specific substrate uptake in combination with MAR-FISH is known as quantitative MAR (QMAR).

[00252] In one embodiment, the sample, or a portion thereof, is subjected to stable isotope Raman spectroscopy combined with FISH (Raman-FISH) to determine the level of a second unique marker (Fig. 31, 1004; Fig. 32, 2004). This technique combines stable isotope probing, Raman spectroscopy, and FISH to link metabolic processes with particular organisms. The proportion of stable isotope incorporation by cells affects light scattering, resulting in measurable peak shifts in the labeled cellular components, including protein and mRNA components.Raman spectroscopy can be used to identify whether a cell synthesizes compounds, including but not limited to: oil (such as alkanes), lipids (such as triacylglycerols (TAG)), specific proteins (such as heme proteins, metalloproteins), cytochrome (such as P450, cytochrome c), chlorophyll, chromophores (such as pigments for light-harvested carotenoids and rhodopsins), organic polymers (such as polyhydroxyalkanoates (PHA), poly. Petition 870260102095, dated 02 / 10 / 2026, page 138 / 641 130 / 159 hydroxybutyrate (PHB)), hopanoids, steroids, starch, sulfide, sulfate and secondary metabolites (such as vitamin B12).

[00253] In one embodiment, the sample, or a portion thereof, is subjected to stable isotope probing (SIP) in DNA / RNA in order to determine the level of a second unique marker (Fig. 31, 1004; Fig. 32, 2004). SIP allows the determination of microbial diversity associated with specific metabolic pathways and has generally been applied to the study of microorganisms involved in the utilization of carbon and nitrogen compounds. The substrate of interest is labeled with stable isotopes (such as 13C or 15N) and added to the sample. Only microorganisms capable of metabolizing the substrate will incorporate it into their cells. Subsequently, 13C-DNA and 15N-DNA can be isolated by density gradient centrifugation and used for metagenomic analysis. RNA-based SIP can be a responsive biomarker for use in SIP studies, since RNA itself is a reflection of cellular activity.

[00254] In one embodiment, the sample, or a portion thereof, is subjected to an isotope array to determine the level of a second unique marker (Fig. 31, 1004; Fig. 32, 2004). Isotope arrays allow for functional and phylogenetic screening of active microbial communities with high throughput. The technique utilizes a combination of SIP to monitor substrate uptake profiles and microarray technology to determine taxonomic identities of active microbial communities. Samples are incubated with 14C-labeled substrate, which, during the course of growth, is incorporated into the microbial biomass. 14C-labeled rRNA is separated from unlabeled rRNA and then labeled with fluorochromes. The fluorescently labeled rRNA is hybridized to a phylogenetic microarray, followed by screening for radioactive and fluorescent signals.This technique thus allows for the simultaneous study of the composition of the microbial community and the specific consumption of substrates by metabolically active microorganisms in complex microbial communities.

[00255] In one embodiment, the sample, or a portion thereof, is subjected to a metabolomic assay to determine the level of a second unique marker (Fig. 31, 1004; Fig. 32, 2004). Metabolomics studies the metabolome, which represents the collection of all metabolites, the end products of cellular processes, in a biological cell, tissue, organ, or organism. This methodology can be used Petition 870260102095, dated 02 / 10 / 2026, page 139 / 641 131 / 159 to monitor the presence of microorganisms and / or microorganism-mediated processes, as it allows associating specific metabolic profiles with different microorganisms. Profiles of intracellular and extracellular metabolites associated with microbial activity can be obtained using techniques such as gas chromatography-mass spectrometry (GC-MS). The complex mixture of a metabolomic sample can be separated by techniques such as gas chromatography, high-performance liquid chromatography, and capillary electrophoresis. Metabolite detection can be by mass spectrometry, nuclear magnetic resonance (NMR), spectroscopy, ion mobility spectrometry, electrochemical detection (linked to HPLC), and radiolabeling (when combined with thin-layer chromatography).

[00256] According to the embodiments described in this document, the presence and respective number of one or more strains of microorganisms in a sample are determined (Fig. 31, 1006; Fig. 32, 2006). For example, strain identity information obtained from evaluating the number and presence of first markers is investigated to determine how many occurrences of a unique first marker are present, thus representing a unique strain of the microorganism (e.g., counting the number of sequence reads in a sequencing assay). This value can be represented in one embodiment as a percentage of the total sequence reads of the first marker to give a percentage of the unique strains of the microorganism of a specific microorganism type. In another embodiment, this percentage is multiplied by the number of microorganism types (obtained in step 1002 or 2002, see Fig. 31 and Fig. 32, 2006).32) to obtain the absolute abundance of one or more strains of microorganisms in a sample and in a given volume.

[00257] One or more of the microorganism strains are considered active, as described above, if the level of the second expression of the single marker is at or above a threshold level, for example, at least about 5%, at least about 10%, at least about 20%, or at least about 30% above a control level.

[00258] In another aspect of the invention, a method for determining the absolute abundance of one or more strains of microorganisms is determined in a plurality of samples (Fig. 32, see, in particular, 2007). For a strain of Petition 870260102095, dated 02 / 10 / 2026, p. 140 / 641 132 / 159 For a microorganism to be classified as active, it only needs to be active in one of the samples. Samples can be taken over several points in time from the same source or can be from different environmental sources (e.g., from different animals).

[00259] The absolute abundance values ​​relative to the samples are used in one embodiment to relate one or more of the active microorganism strains to an environmental parameter (Fig. 32, 2008). In one embodiment, the environmental parameter is the presence of a second active microorganism strain. The relationship of one or more active microorganism strains to the environmental parameter, in one embodiment, is performed by determining the co-occurrence of the strain and the parameter by correlation or by network analysis.

[00260] In one embodiment, the determination of the co-occurrence of one or more strains of active microorganisms with an environmental parameter comprises a network and / or cluster analysis method to measure the connectivity of strains or of a strain with an environmental parameter in a network, where the network is a collection of one or more samples that share a common or similar environmental parameter. In another embodiment, the network and / or cluster analysis method can be applied to determine the co-occurrence of two or more strains of active microorganisms in a sample (Fig. 32, 2008). In another embodiment, network analysis comprises nanoparametric approaches, which include mutual information to establish connectivity between variables. In another embodiment, network analysis comprises linkage analysis, modularity analysis, robustness measures, interdependence measures, connectivity measures, transitivity measures, centrality measures, or a combination thereof (Fig.32, 2009). In another modality, the cluster analysis method comprises the construction of a connectivity model, subspace model, distribution model, density model or a centroid model and / or the use of community detection algorithms, such as the Louvain, Bron-Kerbosch, Girvan-Newman and Clauset-Newman-Moore, Pons-Latapy and Wakita-Tsurumi algorithms (Fig. 32, 2010).

[00261] In one embodiment, the cluster analysis method is a heuristic method based on modularity optimization. In another embodiment, the cluster analysis method is the Louvain method. See, for example, the method described by Blondel et al. (2008) Rapid deployment of communities into large networks. Petition 870260102095, dated 02 / 10 / 2026, page 141 / 641 133 / 159 Journal of Statistical Mechanics: Theory and Experiment, Volume 2008, October 2008, incorporated herein by reference in its entirety for all purposes.

[00262] In another modality, network analysis comprises predictive network modeling through mining and prediction, collective classification, link-based clustering, relational similarity, or a combination thereof. In another modality, network analysis comprises population differential equation modeling. In another modality, network analysis comprises Lotka-Volterra modeling.

[00263] In one embodiment, the relationship of one or more active microorganism strains to an environmental parameter (e.g., determining co-occurrence) in the sample comprises the creation of matrices filled with associations that denote associations of environmental parameter and microorganism strain.

[00264] In one embodiment, the various sample data obtained in step 2007 (e.g., from two or more samples that may be collected at two or more time points, where each time point corresponds to an individual sample) are compiled. In another embodiment, the number of cells of each or more of these microorganism strains in each sample is stored in an association matrix (which may be, in some embodiments, an abundance matrix). In one embodiment, the association matrix is ​​used to identify associations between active microorganism strains in a specific time point sample using rule mining approaches weighted with association data (e.g., abundance). Filters are applied, in one embodiment, to remove insignificant rules.

[00265] In one embodiment, the absolute abundance of one or more or two or more strains of active microorganisms is related to one or more environmental parameters (Fig. 32, 2008), for example, by co-occurrence determination. The environmental parameters are chosen by the user depending on the sample(s) to be analyzed and are not restricted by the methods described in this document. The environmental parameter may be a parameter of the sample itself, for example, pH, temperature, amount of protein in the sample. Alternatively, the environmental parameter is a parameter that affects a change in the identity of a Petition 870260102095, dated 02 / 10 / 2026, page 142 / 641 134 / 159 microbial community (i.e., where the “identity” of a microbial community is characterized by the type of microorganism strains and / or number of specific microorganism strains in a community) or is affected by a change in the identity of a microbial community. In one embodiment, the environmental parameter is the presence, activity, and / or abundance of a second microorganism strain in the microbial community, present in the same sample.

[00266] In some modalities described in this document, an environmental parameter is referred to as a metadata parameter.

[00267] Other examples of metadata parameters include, but are not limited to, genetic information of the host from which the sample was obtained (e.g., DNA mutation information), sample pH, sample temperature, expression of a particular protein or mRNA, nutrient conditions (e.g., level and / or identity of one or more nutrients in the surrounding environment / ecosystem), susceptibility or resistance to disease, disease onset or progression, sample susceptibility or resistance to toxins, efficacy of xenobiotic compounds (pharmaceutical drugs), biosynthesis of natural products, or a combination thereof.

[00268] For example, according to one embodiment, changes in the microorganism strain number are calculated in several samples, according to the method in Fig. 32 (i.e., in 2001-2007). Changes in the strain number of one or more active strains over time are compiled (e.g., one or more strains that were initially identified as active according to the 2006 step) and the directionality of the change is observed (i.e., negative values ​​denoting decreases and positive values ​​denoting increases). The number of cells over time is represented as a network, with microorganism strains representing nodes and weighted abundance rules representing edges. Markov chains and random walks are leveraged to determine connectivity between nodes and to define clusters. The clusters in one embodiment are filtered using metadata to identify the clusters associated with the desired metadata (Fig. 32, 2008).

[00269] In another modality, strains of microorganisms are classified according to the importance of the integration of changes in the number of cells over time. Petition 870260102095, dated 02 / 10 / 2026, page 143 / 641 135 / 159 of the time and strains present in target clusters, with the greatest changes in the number of cells in the higher classifications.

[00270] A network and / or cluster analysis method, in one embodiment, is used to measure the connectivity of one or more networks, wherein a network is a collection of two or more samples that share a common or similar environmental parameter. In one embodiment, network analysis comprises linkage analysis, modularity analysis, robustness measures, interdependence measures, connectivity measures, transitivity measures, centrality measures, or a combination thereof. In another embodiment, network analysis comprises predictive network modeling through link mining and prediction, social network theory, collective classification, link-based clustering, relational similarity, or a combination thereof. In another embodiment, network analysis comprises population differential equation modeling. In yet another embodiment, network analysis comprises Lotka-Volterra modeling.

[00271] The cluster analysis method comprises the construction of a connectivity model, a subspace model, a distribution model, a density model, or a centroid model.

[00272] Network and cluster-based analysis, for example, to perform step 2008 of Fig. 32, can be performed using a module. As used in this document, a module can be, for example, any assembly, any instructions and / or any set of operationally coupled electrical components, and may include, for example, memory, a processor, electrical traces, optical connectors, software (running on hardware) and / or similar.

[00273] In some embodiments, a network and / or cluster analysis method is used to measure the connectivity of one or more networks, where the network is a collection of two or more samples that share a common or similar environmental parameter. In one embodiment, network analysis comprises link analysis, modularity analysis, robustness measures, interdependence measures, connectivity measures, transitivity measures, centrality measures, or a combination thereof. In another embodiment, network analysis comprises predictive network modeling through link mining and prediction. Petition 870260102095, dated 02 / 10 / 2026, page 144 / 641 136 / 159 social network theory, collective classification, link-based clustering, relational similarity, or a combination thereof. In another embodiment, network analysis comprises mutual information, calculations of the maximum information coefficient (MIC), or other non-parametric methods between variables to establish connectivity. In another embodiment, network analysis comprises population differential equation modeling. In yet another embodiment, network analysis comprises Lotka-Volterra modeling.

[00274] The environmental parameter can be a parameter of the sample itself, for example, pH, temperature, amount of protein in the sample. Alternatively, the environmental parameter is a parameter that affects a change in the identity of a microbial community (i.e., where the “identity” of a microbial community is characterized by the type of microorganism strains and / or number of specific microorganism strains in a community) or is affected by a change in the identity of a microbial community. For example, in some embodiments, an environmental parameter is an animal's food intake or the number of eggs produced. In some embodiments, the environmental parameter is the presence, activity, and / or abundance of a second microorganism strain in the microbial community, present in the same sample. In some embodiments, an environmental parameter is referred to as a metadata parameter.

[00275] Other examples of metadata parameters include, but are not limited to, genetic information of the host from which the sample was obtained (e.g., DNA mutation information), sample pH, sample temperature, expression of a particular protein or mRNA, nutrient conditions (e.g., level and / or identity of one or more nutrients in the surrounding environment / ecosystem), susceptibility or resistance to disease, disease onset or progression, sample susceptibility or resistance to toxins, efficacy of xenobiotic compounds (pharmaceutical drugs), biosynthesis of natural products, or a combination thereof.

[00276] The term maximum information coefficient or MIC refers to a type of non-parametric analysis that identifies a score between active microbial strains of the present disclosure and at least one measured metadata (e.g., weight gain). The results of the non-parametric analysis are pooled to create a list of all relationships and their corresponding MIC scores. Petition 870260102095, dated 02 / 10 / 2026, page 145 / 641 137 / 159 If the relationship has a score below a certain threshold, the relationship will be considered / identified as irrelevant. If the relationship is above a certain threshold, the relationship will be considered / identified as relevant and will be subject to network analysis. The methods for determining MIC scores are further described in U.S. Patent No. 9,540,676, which is incorporated by reference in its entirety herein.

[00277] This code snippet shows an example methodology for MIC analysis, according to one modality: Total list of read relations as links threshold = 0.8 for i in range(len(links)): if links >= threshold multiplier[i] = 1 else multiplier[i] = 0 end if links_temp = multiplier*links finaljinks = links_temp[links_temp != 0] savetxt(output_file,final_links) output_file.close()

[00278] With regard to MIC scores, a cutoff point based on this score is used to define microorganisms as useful and not useful with respect to improving specific traits. The point where the data points on the curve move the transition from the logarithmic scale to the linear scale (relative to the slope) is the inflection point. Organisms with MIC scores below the inflection point are generally not useful, while organisms with MIC scores above the inflection point are generally useful, as it relates to the specific trait being evaluated for the MIC score.

[00279] In some forms, the compositions of this publication Petition 870260102095, dated 02 / 10 / 2026, page 146 / 641 138 / 159 comprise one or more bacteria that have a MIC score of at least about 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.7, 0.75, 0.8, 0.85, 0.9, or 0.95. In some embodiments, the isolated bacteria selected for inclusion in the microbial compositions described in this document comprise a MIC score of at least 0.2.

[00280] Based on the network analysis results, active strains are selected for the preparation of products (e.g., assemblies, aggregates, and / or other synthetic groupings) containing the selected strains. The network analysis output can also be used to inform the selection of strains for further product composition testing.The limits can be, depending on the implementation and application: (1) determined empirically (e.g., based on distribution levels, defining a cutoff value at a number that removes a specific or significant portion of low-level readings); (2) any non-zero value; (3) percent / percent basis; (4) only strains whose normalized readings of the second marker (i.e., activity) are greater than the normalized readings of the first marker (cell count); (5) Iog2 fold change of the change between activity and quantity or cell count; (6) the readings of the second normalized marker (activity) are greater than the average second marker (activity) for the entire sample (and / or set of samples); and / or any threshold of the magnitude described above, plus a statistical threshold (i.e., by significance test).The following example provides details of the thresholding regarding the distributions of RNA-based second marker measurements relative to DNA-based first marker measurements, according to one embodiment. Microbial culture techniques

[00281] The isolation, identification, and culture of the microbes in this disclosure can be carried out using standard microbiological techniques. Examples of such techniques can be found in Gerhardt, P. (ed.) Methods for General and Molecular Microbiology. American Society for Microbiology, Washington, DC (1994) and Lennette, EH (ed.) Handbook of Clinical Microbiology, Third Edition. American Society for Microbiology, Washington, DC (1980), each of which is incorporated by reference. Petition 870260102095, dated 02 / 10 / 2026, p. 147 / 641 139 / 159

[00282] Isolation can be performed by passing the sample through a solid medium (e.g., nutrient agar plates) to obtain a single colony, which is characterized by the phenotypic characteristics described above (e.g., Gram-positive / negative, capable of forming spores aerobically / anaerobically, cell morphology, carbon source metabolism, acid / base production, enzymatic secretion, metabolic secretions, etc.) and reduce the likelihood of dealing with a contaminated culture.

[00283] For example, for disclosure microbes, biologically pure isolates can be obtained through repeated subculture of biological samples, each subculture followed by passage in solid media to obtain individual colonies or colony-forming units. Methods of preparation, thawing, and cultivation of lyophilized bacteria are known in the art, for example: Gherna, RL and CA Reddy. 2007. Culture Preservation, p. 1019-1033. In CA Reddy, TJ Beveridge, JA Breznak, GA Marzluf, TM Schmidt and LR Snyder, eds. American Society for Microbiology, Washington, DC, 1033 pages; incorporated by reference herein. Thus, lyophilized liquid formulations and long-term stored cultures at -70°C in glycerol-containing solutions are contemplated for use in providing formulations of the present disclosure.

[00284] The microbes of the disclosure can be propagated in a liquid medium under aerobic conditions or, alternatively, under anaerobic conditions. The medium for the growth of the bacterial strains of the present disclosure includes a carbon source, a nitrogen source and inorganic salts, as well as specially necessary substances such as vitamins, amino acids, nucleic acids and the like.Examples of suitable carbon sources that can be used for microbial growth include, but are not limited to, starch, peptone, yeast extract, amino acids, sugars such as glucose, arabinose, mannose, glucosamine, maltose and the like; salts of organic acids such as acetic acid, fumaric acid, adipic acid, propionic acid, citric acid, gluconic acid, malic acid, pyruvic acid, malonic acid and the like; alcohols such as ethanol and glycerol and the like; oil or fat such as soybean oil, rice bran oil, olive oil, corn oil, sesame oil. The amount of carbon source added varies according to the type of carbon source and is normally between 1 and 100 g / L. Preferably, glucose, starch and / or peptone are contained in the medium as a source. Petition 870260102095, dated 02 / 10 / 2026, pp. 148 / 641 140 / 159 main carbon, at a concentration of 0.1-5% (w / v).

[00285] Examples of suitable nitrogen sources that can be used for the growth of the bacterial strains of this disclosure include, but are not limited to, amino acids, yeast extract, tryptone, beef extract, peptone, potassium nitrate, ammonium nitrate, ammonium chloride, ammonium sulfate, ammonium phosphate, ammonia, or combinations thereof. The amount of nitrogen source varies according to the type of nitrogen source, typically between 0.1 g / L and 30 g / L.

[00286] Inorganic salts, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate, magnesium chloride, ferric sulfate, ferrous sulfate, ferric chloride, ferrous chloride, manganous sulfate, manganous chloride, zinc sulfate, zinc chloride, cupric sulfate, calcium chloride, sodium chloride, calcium carbonate and sodium carbonate may be used alone or in combination. The amount of inorganic acid varies according to the type of inorganic salt, typically between 0.001 g / L and 10 g / L. Examples of substances especially needed include, but are not limited to, vitamins, nucleic acids, yeast extract, peptone, meat extract, malt extract, dry yeast and combinations thereof.

[00287] Cultivation can be carried out at a temperature that allows the growth of microbial strains, essentially between 20°C and 46°C. In some cases, a temperature range is 30°C-39°C. For optimal growth, in some modalities, the medium can be adjusted to pH 6.0-7.4. It will be appreciated that commercially available media can also be used to cultivate microbial strains, such as Nutrient Broth or Nutrient Agar available from Difco, Detroit, Ml. It will be understood that the cultivation time may differ depending on the type of culture medium used and the concentration of sugar as the main carbon source.

[00288] In some respects, cultivation lasts between 8-96 hours. The microbial cells thus obtained are isolated using methods that are well known in the art. Examples include, but are not limited to, membrane filtration and centrifugal separation. The pH can be adjusted using sodium hydroxide and the like, and the culture can be dried using a freeze dryer, until Petition 870260102095, dated 02 / 10 / 2026, page 149 / 641 141 / 159 water content becomes equal to 4% or less. Microbial cocultures can be obtained by propagating each strain as described above. In some respects, multi-strain microbial cultures can be obtained by propagating two or more of the strains described above. It will be appreciated that microbial strains can be grown together when compatible culture conditions can be employed. Methods of Use

[00289] In some embodiments, the present disclosure provides a method for treating and / or preventing colic in a horse, comprising administering a microbial composition described in this document to a horse in need in an amount effective to prevent and / or treat colic in horses that received the microbial composition compared to a horse to which the microbial composition was not administered.

[00290] In some embodiments, the microbial composition is administered to the horse daily for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 days or more. In some embodiments, the microbial composition is administered to the horse daily for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 weeks or more. In some embodiments, the microbial composition is administered to the horse daily for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 days or more.

[00291] In some embodiments, the microbial compositions described in this document are administered by fecal microbiota transplantation via nasogastric intubation, fecal enema, direct injection of microbial suspension into the intestines or colon during surgery, as a liquid formulation or bolus injection, as small pills administered with food, as a powder sprinkled on feed, or as a pellet in the feed. In some embodiments, the microbial compositions are administered with one or more additional therapeutic agents or interventions. For example, in some embodiments, the microbial compositions are administered with an antibiotic, a proton pump inhibitor, and / or food. In some embodiments, the microbial compositions are administered after the administration of an antibiotic, a proton pump inhibitor, and / or food. In such embodiments, the administration of antibiotics, proton pump inhibitors Petition 870260102095, dated 02 / 10 / 2026, p. 150 / 641 142 / 159 with or immediately before the compositions described in this document increases the pH of the equine stomach, thus allowing the microbes present in the composition to persist for long periods of time after administration. In some modalities, the pH of the stomach is increased by at least 0.2, at least 0.4, at least 0.6, at least 0.8, at least 1, at least 1.2, at least 1.4, at least 1.6, at least 1.8, at least 2, at least 2.2, at least 2.4, at least 2.6, at least 2.8, at least 3, at least 3.2, at least 3.4, at least 3.6, at least 3.8, at least 4, at least 4.2, at least 4.4, at least 4.6, at least 4.8, at least 5, at least 5.2, at least 5.4, at least 5.6, at least 5.8, at least 6, at least 6.2, at least 6.4, at least 6.6, at least 6.8, or at least 7. In some modalities, microbial compositions are administered before, during, or after a surgical procedure.

[00292] In some embodiments, the compositions of this disclosure are administered to competitively exclude microbial pathogens from causing a disease state in horses. In some embodiments, administration of the compositions described herein prevents pathogenic microbes from outcompeting non-pathogenic microbes present in the composition in the horse's stomach and / or gastrointestinal tract. In some embodiments, the compositions of this disclosure competitively bind glycocalyx / extracellular matrix molecules of intestinal cell walls to prevent or competitively inhibit pathogens from adhering to lectins and other molecules such as collagens (particularly types III, IV, and V), gelatin, fibrinogen, laminin, and vitronectin. Pathogen adhesion to these molecules is believed to contribute to the virulence of the pathogens.

[00293] In some embodiments, the administration of compositions of the present disclosure results in a decrease in the binding of pathogenic microbes to the glycocalyx / extracellular matrix of equine gastrointestinal tract cells. In some embodiments, the compositions of the present disclosure result in the binding of the administered microbes to the glycocalyx / extracellular matrix, preventing pathogenic microbes from adhering to the glycocalyx / extracellular matrix and preventing pathogenic diseases. In some embodiments, the compositions of the present disclosure result in the chemical modification of the glycocalyx / extracellular matrix molecules by the administered microbial composition, preventing the adhesion of pathogenic microbes. Petition 870260102095, dated 02 / 10 / 2026, page 151 / 641 143 / 159 to the glycocalyx / extracellular matrix and preventing pathogenic diseases. In some modalities, the molecules bound to or chemically modified by the administered microbes are selected from lectins, collagens, gelatins, fibrinogens, laminins, and vitronectins.

[00294] In some embodiments, administration of microbial compositions of the present disclosure to equines stimulates the production of B cells. In some embodiments, administration of microbial compositions of the present disclosure to equines results in an increase in one or more types of B cells by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.

[00295] In some embodiments, administration of microbial compositions of the present disclosure to horses activates B cells. In some embodiments, administration of microbial compositions of the present disclosure to horses results in an increase in the activation of one or more types of B cells by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.

[00296] In some embodiments, B cells are selected from regulatory B cells, B-1 cells, B-2 cells, marginal zone B cells, follicular B cells, memory B cells, plasma cells and plasma blasts.

[00297] In some embodiments, administration of microbial compositions of the present disclosure to equines stimulates the production of T cells. In some embodiments, administration of microbial compositions of the present disclosure to equines results in an increase in one or more types of T cells by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least Petition 870260102095, dated 02 / 10 / 2026, page 152 / 641 144 / 159 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.

[00298] In some embodiments, administration of microbial compositions of the present disclosure to horses activates T cells. In some embodiments, administration of microbial compositions of the present disclosure to horses results in an increase in the activation of one or more types of T cells by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.

[00299] In some modalities, T cells are selected from γδ (gamma delta) T cells, αβ (alpha beta) T cells, natural killer T cells, regulatory T cells, memory T cells, cytotoxic T cells, helper T cells, and effector T cells.

[00300] In some embodiments, administration of microbial compositions of the present disclosure to equines activates antigen-presenting cells. In some embodiments, administration of microbial compositions of the present disclosure to horses results in an increase in the activation of one or more types of antigen-presenting cells by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%. In some modalities, antigen-presenting cells are selected from dendritic cells, macrophages, B cells, or innate lymphoid cells.

[00301] In some modalities, the administration of microbial compositions Petition 870260102095, dated 02 / 10 / 2026, page 153 / 641 145 / 159 of this disclosure to horses results in an increase in the number of isolated lymphoid follicles (ILFs). In some embodiments, administration of microbial compositions of the present disclosure to equines results in an increase in isolated lymphoid follicles by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.

[00302] In some embodiments, administration of microbial compositions of the present disclosure results in modulation of the gene expression of mucins, tight-junction polypeptides, and cytokines. In some embodiments, modulation of the gene expression of mucins, tight-junction polypeptides, and cytokines results in an increase in the gene expression of said molecules. In some embodiments, modulation of the gene expression of mucins, tight-junction polypeptides, and cytokines results in a decrease in the gene expression of said molecules.

[00303] In some embodiments, administration of the microbial compositions of the present disclosure results in a decrease in mucin expression. In some embodiments, the mucins are selected from MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC6, MUC13, and MUC16.

[00304] In some embodiments, administration of the microbial compositions of the present disclosure results in a decrease in cytokine expression. In some embodiments, the cytokines are selected from granulocyte-macrophage stimulating factor (GM-CSF), IL-1RA, IL-1a, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-11, IL-12, IL-13, IL-17A, IL-17D, IL-17E, IL-17F, IL-18, IL-22, IL-23, tumor necrosis factor (TNF), interferon beta (IFN-β), IFN-γ and IFN-λ.

[00305] In some embodiments, administration of microbial compositions of the present disclosure results in a decrease in intestinal inflammation in horses, as measured by serum levels of inflammatory markers. In some embodiments, the inflammatory markers are selected from a1 Petition 870260102095, dated 02 / 10 / 2026, page 154 / 641 146 / 159 acid glycoprotein (AGP), IL-8, IL-1β, IL-17A, IL-17F, transforming growth factor (TGF-P4), fatty acid-binding protein (FABP2), C-reactive protein, haptoglobin, ceruloplasmin, hemopexin, and serum amyloid A.

[00306] In some embodiments, the methods provided in this document prevent or reduce one or more symptoms of colic in a horse. For example, in some embodiments, the methods prevent or reduce one or more selected symptoms of abdominal pain, stomach irritation, rolling, stomach kicks, GI organ distension, and decreased feeding. In some embodiments, the methods provided in this document reduce the frequency with which colic occurs in a horse. For example, in some embodiments, the methods provided in this document decrease the frequency of colic episodes in a horse administered with the compositions described in this document compared to the frequency of colic episodes observed in a horse that did not receive the compositions described in this document. Other Numbered Modes

[00307] Other numbered versions of this disclosure are provided as follows:

[00308] Modality 1. A microbial composition comprising: one or more bacteria with a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from SEQ ID NOs: 1-574; and a carrier suitable for equine administration.

[00309] Modality 2. The microbial composition of Modality 1 comprises one or more bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475.

[00310] Modality 3. The microbial composition of Modality 1 comprises one or more bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426 and SEQ ID NO: 475.

[00311] Mode 4. The microbial composition of Mode 1, Petition 870260102095, dated 02 / 10 / 2026, p. 155 / 641 147 / 159 comprises one or more bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO: 476.

[00312] Modality 5. The microbial composition of Modality 1 comprises one or more bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433 and SEQ ID NO: 476.

[00313] Modality 6. The microbial composition of Modality 1 comprises two, three, four, five or more bacteria with a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from SEQ ID NOs: 1-574.

[00314] Modality 7. The microbial composition of Modality 1 comprises two, three, four, or five bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475.

[00315] Modality 8. The microbial composition of Modality 1 comprises two, three, four, or five bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO: 475.

[00316] Modality 9. The microbial composition of Modality 1 comprises two, three, four, or five bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO: 476.

[00317] Modality 10. The microbial composition of Modality 1 comprises two, three, four, or five bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: Petition 870260102095, dated 02 / 10 / 2026, p. 156 / 641 148 / 159 320, SEQ ID NO: 433 and / or SEQ ID NO: 476.

[00318] Modality 11. The microbial composition comprising: one or more bacteria selected from Clostridium spp.; Streptococcus spp.; Escherichia spp.; and Atlantibacter spp.; and a suitable carrier for equine administration.

[00319] Modality 12. The microbial composition comprising: one or more bacteria selected from a Clostridium butyricum bacterium; a Streptococcus equinis bacterium; an Escherichia coli bacterium; a Clostridium maximum bacterium; and an Atlantibacter hermannii bacterium; and a suitable carrier for equine administration.

[00320] Modality 13. The microbial composition of Modality 12, wherein: the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID NOs: 5-13; the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID NOs: 143-150; the bacterium Escherichia coli comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID NOs: 321-328; The bacterium Clostridium maximum comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID Nos: 430-437; and / or the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to one of the SEQ ID Nos: 480-486.

[00321] Modality 14. The microbial composition of Modality 12, wherein: the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 5-13; the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 143-150; the bacterium Escherichia coli comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 321-328; the bacterium Clostridium maximum comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 430-437; and / or the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 480-486. Petition 870260102095, dated 02 / 10 / 2026, p. 157 / 641 149 / 159

[00322] Embodiment 15. The microbial composition of any of Embodiments 12-14, wherein: the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 5 or SEQ ID NO: 11; the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 141 or SEQ ID NO: 142; the bacterium Escherichia coli comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 319 or SEQ ID NO: 320; The bacterium Clostridium maximum comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 426 or SEQ ID NO: 433; and / or the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 475 or SEQ ID NO: 476.

[00323] Embodiment 16. The microbial composition of any of Embodiments 12-14, wherein: the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 5 or SEQ ID NO: 11; the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 141 or SEQ ID NO: 142; the bacterium Escherichia coli comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 319 or SEQ ID NO: 320; the bacterium Clostridium maximum comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 426 or SEQ ID NO: 433; and / or the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 475 or SEQ ID NO: 476.

[00324] Modality 17. The microbial composition, according to any of the Modalities 1-16, in which one or more bacteria have a MIC count of at least about 0.2.

[00325] Modality 18. The microbial composition, according to either of Modalities 1-17, where the equine is either a domesticated equine or a wild equine.

[00326] Modality 19. The microbial composition, according to any of the Modalities 1-18, in which the equine is selected from among a horse, a zebra, a mule and a donkey. Petition 870260102095, dated 02 / 10 / 2026, p. 158 / 641 150 / 159

[00327] Modality 20. The microbial composition, according to any of the Modalities 1-19, wherein the carrier comprises a solidifying agent and a sweetening agent.

[00328] Modality 21. Microbial composition, according to Modality 20, wherein the solidifying agent is selected from xanthan gum, agar and gelatin.

[00329] Modality 22. The microbial composition, according to Modality 20, wherein the sweetening agent is selected from corn syrup, molasses, cane molasses, brewer's yeast and honey.

[00330] Modality 23. The microbial composition, according to any of the Modalities 1-22, wherein the composition is formulated as a gel, a liquid, a powder, a tablet, a capsule, a pill, a food additive, a food ingredient, a food supplement, a water additive, a heat-stabilized additive, a moisture-stabilized additive, a pelleted food additive, a pre-pelleted applied food additive, a post-pelleted applied food additive or a spray additive.

[00331] Modality 24. The microbial composition, according to any of the Modalities 1-23, wherein the composition is formulated for administration by injection, direct application to the target organ, bolus administration, oral administration (as part of or in conjunction with food), fecal enema, fecal microbiota transplantation via nasogastric intubation.

[00332] Modality 25. The microbial composition, according to any of Modalities 1-24, comprising one or more bacteria in an amount effective to treat one or more symptoms of colic in a horse or to reduce the frequency of colic episodes.

[00333] Modality 26. A method for preventing and / or treating colic in a horse, comprising administering the microbial composition according to any of the Modalities 1-25, to a horse in need, in an amount effective to prevent and / or treat colic in horses administered with the microbial composition, compared to a horse that did not receive the microbial composition.

[00334] Modality 27. The method, according to Modality 26, in which Petition 870260102095, dated 02 / 10 / 2026, p. 159 / 641 151 / 159 the equine is a domesticated equine or a wild equine.

[00335] Modality 28. The method of Modality 26 or Modality 27, in which the equine is selected from a horse, a zebra, a mule, and a donkey.

[00336] Modality 29. The method, according to any of the Modalities 26-28, in which the microbial composition is administered daily for at least 1, 2, 3, 4, 5, 6, 7 days or more.

[00337] Modality 30. The method, according to any of Modalities 26-28, in which the microbial composition is administered daily for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks or more.

[00338] Modality 31. The method, according to any of the Modalities 26-28, in which the microbial composition is administered daily for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, or more.

[00339] Modality 32. The method, according to any of the Modalities 26-31, in which the microbial composition is administered to the equine with an antibiotic, a proton pump inhibitor and / or feed.

[00340] Modality 33. The Method, according to any of the Modalities 26-31, in which the microbial composition is administered to the equine after the administration of an antibiotic, a proton pump inhibitor and / or food.

[00341] Modality 34. The method, according to any of the Modalities 26-33, in which the administration of the microbial composition reduces one or more colic symptoms selected from abdominal pain, stomach irritation, rolling, kicking in the stomach area, distension of the GI organs and decreased food intake.

[00342] Modality 35. The method, according to any of the Modalities 26-33, in which administration of the microbial composition reduces the frequency of colic episodes in a horse administered with the microbial composition, compared with a horse that did not receive the composition. Petition 870260102095, dated 02 / 10 / 2026, page 160 / 641 152 / 159 microbial. Examples

[00343] This disclosure is further illustrated by reference to the following Experimental Data and Examples. However, it should be noted that these Examples and Experimental Data, like the embodiments described above, are illustrative and should not be interpreted as restricting the scope of the disclosure in any way. Example 1: Formulation of microbial compositions for administration to horses.

[00344] An equine microbial composition (comprising AscusEQ_4F (SEQ ID NO: 11), AscusEQ_61A (SEQ ID NO: 320), AscusEQ_140A (SEQ ID NO: 142), AscusEQ_414G (SEQ ID NO: 433) and AscusEQ_109A (SEQ ID NO: 476), referred to as Ascus Equine) was formulated for administration to horses. Briefly, the equine product is administered as a sweet paste administered orally. The dose, therefore, needs high viscosity to delay oxygen permeation during administration and to provide time for the equine patient to consume most of the dose without loss of composition. Encapsulation of microbes with sodium alginate was used to aid distribution to the large intestine, protecting the cells against variable / low pH in the equine gastric contents.

[00345] Solidification and sweetening: gelatin and xanthan gum tested for solidification viscosity at the following concentrations: (k) Gelatin 0.1% - 1.4% (l) Xanthan gum 0.2% - 2.0% (m) Agar 0.25% - 2.5%.

[00346] Xanthan gum concentrations above 1.4% gelled adequately. Agar concentrations of 1% were ideal. Other potential food-grade thickening agents suitable for use during the solidification process include: starches, algin, guar gum, collagen, pectin, and carboxymethylcellulose. The solidified mixture is sweetened with corn syrup, molasses, cane molasses, brewer's yeast, and / or honey to make it palatable to the ...

Claims

1 / 8 CLAIMS 1. Microbial composition, characterized in that it comprises: a. one or more bacteria with a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from SEQ ID NOs: 1-574; and b. a vehicle suitable for equine administration.

2. Microbial composition, according to claim 1, characterized in that it comprises one or more bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426, and SEQ ID NO:

475.

3. Microbial composition, according to claim 1, characterized in that it comprises one or more bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426 and SEQ ID NO:

475.

4. Microbial composition, according to claim 1, characterized in that it comprises one or more bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98%, or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433, and SEQ ID NO:

476.

5. Microbial composition, according to claim 1, characterized in that it comprises one or more bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433 and SEQ ID NO:

476.

6. Microbial composition, according to claim 1, characterized in that it comprises two, three, four, five or more bacteria Petition 870260102095, dated 10 / 02 / 2026, page 169 / 641 2 / 8 with a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from SEQ ID Nos: 1-574.

7. Microbial composition, according to claim 1, characterized in that it comprises two, three, four or five bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98% or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426 and SEQ ID NO:

475.

8. Microbial composition, according to claim 1, characterized in that it comprises two, three, four or five bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 141, SEQ ID NO: 319, SEQ ID NO: 426 and SEQ ID NO:

475.

9. Microbial composition, according to claim 1, characterized in that it comprises two, three, four or five bacteria with a 16S nucleic acid sequence that is at least 97%, at least 98% or at least 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433 and SEQ ID NO:

476.

10. Microbial composition, according to claim 1, characterized in that it comprises two, three, four or five bacteria with a 16S nucleic acid sequence comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 142, SEQ ID NO: 320, SEQ ID NO: 433 and SEQ ID NO:

476.

11. Microbial composition, characterized in that it comprises: a. one or more bacteria selected from i. a Clostridium spp. bacterium; ii. a Streptococcus spp. bacterium; iii. an Escherichia spp. bacterium; iv. a Clostridium spp. bacterium; and v. an Atlantibacter spp. bacterium; and b. a vehicle suitable for equine administration.

12. Microbial composition, characterized in that it comprises: a. one or more bacteria selected from i. a Clostridium butyricum bacterium; ii. a Streptococcus equinis bacterium; iii. an Escherichia coli bacterium; iv. a Clostridium maximum bacterium; and v. an Atlantibacter hermannii bacterium; and b. a vehicle suitable for equine administration.

13. Microbial composition, according to claim 12, characterized in that: a. the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence that is at least 97%, 98% or 99% identical to one of the SEQ ID NOs: 5-13; b. the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence that is at least 97%, 98% or 99% identical to one of the SEQ ID NOs: 143-150; c. the bacterium Escherichia coli comprises a 16S nucleic acid sequence that is at least 97%, 98% or 99% identical to one of the SEQ ID NOs: 321-328; d. the bacterium Clostridium maximum comprises a 16S nucleic acid sequence that is at least 97%, 98% or 99% identical to one of the SEQ IDs Nos: 430-437; and / or the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence that is at least 97%, 98% or 99% identical to one of the SEQ IDs Petition 870260102095, dated 02 / 10 / 2026, p. 171 / 641 4 / 8 Nos: 480-486.

14. Microbial composition, according to claim 12, characterized in that: a. the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 5-13; b. the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 143-150; c. the bacterium Escherichia coli comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 321-328; d. the bacterium Clostridium maximum comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 430-437; and / or e. the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence comprising or consisting of one of the SEQ ID NOs: 480-486.

15. Microbial composition, according to any one of claims 12 to 14, characterized in that: a. the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence that is at least 97%, 98% or 99% identical to SEQ ID NO: 5 or SEQ ID NO: 11; b. the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence that is at least 97%, 98% or 99% identical to SEQ ID NO: 141 or SEQ ID NO: 142; c. the bacterium Escherichia coli comprises a 16S nucleic acid sequence that is at least 97%, 98% or 99% identical to SEQ ID NO: 319 or SEQ ID NO: 320; d. the bacterium Clostridium maximum comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 426 or SEQ ID NO: 433; and / or Petition 870260102095, dated 02 / 10 / 2026, page 172 / 641 5 / 8 and the bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence that is at least 97%, 98%, or 99% identical to SEQ ID NO: 475 or SEQ ID NO:

476.

16. Microbial composition, according to any one of claims 12 to 14, characterized in that: a. the bacterium Clostridium butyricum comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 5 or SEQ ID NO: 11; b. the bacterium Streptococcus equinis comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 141 or SEQ ID NO: 142; c. the bacterium Escherichia coli comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 319 or SEQ ID NO: 320; d. the bacterium Clostridium maximum comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 426 or SEQ ID NO: 433; and / or e. The bacterium Atlantibacter hermannii comprises a 16S nucleic acid sequence comprising or consisting of SEQ ID NO: 475 or SEQ ID NO:

476.

17. Microbial composition, according to any one of claims 1 to 16, characterized in that one or more bacteria have a MIC count of at least about 0.

2.

18. Microbial composition, according to any one of claims 1 to 17, characterized in that the equine is either a domesticated equine or a wild equine.

19. Microbial composition, according to any one of claims 1 to 18, characterized in that the equine is selected from among a horse, a zebra, a mule and a donkey.

20. Microbial composition, according to any one of claims 1 to 19, characterized in that the vehicle comprises a solidifying agent and a sweetening agent. Petition 870260102095, dated 02 / 10 / 2026, p. 173 / 641 6 / 8 21. Microbial composition, according to claim 20, characterized in that the solidifying agent is selected from xanthan gum, agar and gelatin.

22. Microbial composition, according to claim 20, characterized in that the sweetening agent is selected from corn syrup, molasses, cane molasses, brewer's yeast and honey.

23. Microbial composition, according to any one of claims 1 to 22, characterized in that the composition is formulated as a gel, a liquid, a powder, a tablet, a capsule, a pill, a food additive, a food ingredient, a food supplement, a water additive, a heat-stabilized additive, a moisture-stabilized additive, a pelleted food additive, a pre-pelleted applied food additive, a post-pelleted applied food additive, or a spray additive.

24. Microbial composition, according to any one of claims 1 to 23, characterized in that the composition is formulated for administration by injection, direct application to the target organ, bolus administration, oral administration (such as in conjunction with or as part of food), fecal enema, fecal microbiota transplantation via nasogastric intubation.

25. Microbial composition, according to any one of claims 1 to 24, characterized in that it comprises one or more bacteria in an amount effective for treating one or more symptoms of colic in a horse or for reducing the frequency of colic episodes.

26. Use of the microbial composition, as defined in any one of claims 1 to 25, characterized in that it is in the manufacture of a medicament or product for preventing and / or treating colic in an equine.

27. Use according to claim 26, characterized in that the equine is either a domesticated equine or a wild equine.

28. Use according to claim 26 or 27, characterized in that the equine is selected from among a horse, a zebra, a mule and a donkey.

29. Use, according to any of claims 26 to 28, Petition 870260102095, dated 10 / 02 / 2026, page 174 / 641 7 / 8 characterized in that the microbial composition is to be administered daily for at least 1, 2, 3, 4, 5, 6, 7 days or more.

30. Use, according to any of claims 26 to 28, characterized in that the microbial composition is to be administered daily for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks or more.

31. Use, according to any of claims 26 to 28, characterized in that the microbial composition is to be administered daily for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, or more.

32. Use, according to any one of claims 26 to 31, characterized in that the microbial composition is to be administered to the equine with an antibiotic, a proton pump inhibitor and / or feed.

33. Use, according to any one of claims 26 to 31, characterized in that the microbial composition is to be administered to the equine after the administration of an antibiotic, a proton pump inhibitor and / or food.

34. Use, according to any of claims 26 to 33, characterized in that administration of the microbial composition reduces one or more colic symptoms selected from abdominal pain, stomach irritation, rolling, kicking in the stomach, distension of the GI organs and decreased food intake.

35. Use, according to any of claims 26 to 33, characterized in that administration of the microbial composition reduces the frequency of colic episodes in a horse administered with the microbial composition, compared with a horse that did not receive the microbial composition.

36. Use of the microbial composition, as defined in any one of claims 1 to 25, characterized in that it is in the manufacture of a medicament or product to reduce intestinal inflammation in an equine. Petition 870260102095, dated 10 / 02 / 2026, p. 175 / 641 8 / 8 37. Microbial composition, according to any one of claims 1 to 25, characterized in that the microbial composition is a paste formulated for oral administration to an equine. Petition 870260102095, dated 02 / 10 / 2026, p. 176 / 641